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Abstract 
 
Cardiovascular diseases including coronary artery disease are the major cause of 
death worldwide. Saphenous vein (SV) bypass grafting is widely used to revascularise 
atherosclerotic coronary arteries, although failure rates are problematic. Adverse 
remodelling and intimal hyperplasia (IH) underlie graft failure primarily driven by 
aberrant smooth muscle cell (SMC) function.    
 Whilst altered SMC function is pivotal to the adaptation of SV grafts, in the longer 
term excessive cell proliferation and migration lead to intimal hyperplasia that 
compromises patency rates. Whilst there are no pharmacological agents to effectively 
prevent IH, accumulating evidence has implicated microRNAs (miRs), short non-
coding RNAs that negatively regulate gene expression, in SMC phenotypic changes 
and vascular remodelling. In particular, miR-21 is highly expressed in the 
cardiovascular system and is reportedly dysregulated in pathological conditions. This 
thesis confirmed a distinct phenotype in SV-SMC from T2DM patients, relative to 
those from patients without diabetes (ND), although this was not associated with 
differential miR-21 expression.  
Artificial overexpression of miR-21 in ND SV-SMC increased total cell area and cell 
proliferation and its knockdown was able to reverse the increase in cell area. In 
addition, treating SV-SMC with PDGF-BB, commonly associated with vascular 
remodelling, led to increased miR-21 expression through activation of both ERK and 
Akt; inhibition of either pathway abrogated miR-21 expression. Exploring the 
downstream target genes of miR-21 using a vascular remodelling specific array and 
follow-up RT-PCR yielded two genes affected by miR-21 overexpression; increased 
MMP-1 mRNA and decreased IL-1A mRNA. Surprisingly, SV-SMC migration in cells 
overexpressing miR-21 did not, however, modulate migration through collagen-1 or -
3 coated membranes. Potential downstream target genes of miR-21 mediating 
functional changes related to SMC proliferation and migration were tested. Whilst 
there were no clear effects on “classical” targets (PDCD4, PTEN and Spry), a 
significant downregulation of RECK mRNA and protein in miR-21 overexpressing SV-
SMC was apparent. Further studies are required to explore in detail how RECK is 
involved in miR-21 mediated cellular functions and whether targeting miR-21 in SV-
SMC would provide a promising therapeutic strategy to improve outcomes in patients 
following SV grafting. 
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Chapter 1 
INTRODUCTION
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Chapter 1 
      Introduction 
 
1.1.  Coronary heart disease 
According to the World Health Organisation, cardiovascular disease (CVD) is the 
number one cause of death globally. Although the survival rate of patients with 
coronary artery disease (CAD) has been progressively improving, approximately 17.5 
million people died from CVD in 2012, 7.4 million of the death cases resulted from 
CAD and 6.7 million were due to stroke. CVD accounts for 31% of universal deaths 
and is expected to rise to more than 23.6 million by 2030 (Laslett et al., 2012). In 
addition to its mortality burden, the non-fatal cases following myocardial infarction and 
stroke result in significant morbidity with ensuing social and economic consequences. 
Therefore, CAD has become a universal public health problem which deserves more 
attention. Risk factors can be classified into modifiable biological factors such as 
hypertension, diabetes, elevated plasma low-density lipoprotein (LDL) and 
triglycerides, smoking, physical inactivity, and obesity. Whereas, the non-modifiable 
risk factors are age, ethnicity and family history of early heart disease or stroke 
(Thayer et al., 2010, Saran et al., 2010).  
 
  
The myocardium is supplied by two main arteries; the right coronary artery (RCA) 
and left coronary artery (LCA). RCA branches into the right marginal artery and 
posterior descending artery while the LCA branches into circumflex and left anterior 
descending artery (Figure 1.1). The right and left coronary arteries originate from the 
aorta and provide a source of blood supply to the most vital muscle structure of the 
body, the heart. The RCA supplies the SA and AV nodes, the myocardium and 
external wall of the right atrium and right ventricle. Both the RCA and circumflex 
branch of the LCA supply the atria via small branches. The LCA typically supplies the 
interventricular septum, the anterior wall of the right ventricle and the external wall of 
the left ventricle (Moore et al., 2013). The coronary circulation is the network that 
supplies oxygenated blood to the heart and collects deoxygenated blood from the 
heart muscle (Kern et al., 2006). Obstruction and interruption of the coronary 
circulation by atherosclerotic plaque in one or more of the coronary arteries retards 
the supply of oxygen and other essential nutrients to the myocardium (Figure 1.1). As 
this plaque lesion progresses, unstable coronary syndromes, myocardial infarction 
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and stroke may then occur, which thus result in high mortality rates (Marieb and 
Hoehn, 2007). 
Angiography is the diagnostic procedure utilised to detect whether a plaque is 
blocking a coronary artery and the extent of coronary lesion. A small catheter is 
inserted into the patient’s wrist radial artery or groin femoral artery and when it 
reaches the heart a dye is injected into the coronary circulation. This is accompanied 
by a special X-ray to image the atherosclerotic lesion of the coronary arteries. 
Angiographic images shown in Figure 1.2 demonstrate the normal architecture of 
coronary arteries from patients without CAD (A), and patients with CAD in the 
presence (C) and absence of diabetes (B).  
 
 
Figure 1.1: Schematic diagram of coronary artery and common sites of 
coronary artery occlusion. 
Sites 1-3 account for 85% of all occlusions. 1- Anterior interventricular branch of LCA 
(40-50%), 2- RCA (30-40%), 3- Circumflex branch of the LCA. The remaining 4-6 
account for 15% of total occlusions. 4- Left coronary artery, 5- Posterior 
interventricular branch, 6- Posterior descending artery. Adapted from Moore et al. 
(2013).  
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Figure 1.2: Angiographic images of coronary artery disease. 
A- The coronary arteries of the patient without CAD have a smooth outline with no 
angiographic filling defects within the vessel lumen to indicate atherosclerosis or 
stenosis. B- A discrete, focal stenosis of the left anterior descending branch of the 
LCA in non-diabetic patient. C- The RCA of patient with type 2 diabetes (T2DM) has 
diffuse narrowing in the proximal and mid segments of its posterior descending 
branch. The vessels of T2DM patient appear smaller, consistent with diffuse 
atherosclerosis with multiple stenosis. There is a long stenosis affecting the proximal 
segment of the first diagonal branch with a further stenosis in the mid segment of the 
left anterior descending branch of the LCA. Images kindly provided by Dr Stephen 
Wheatcroft, Leeds General Infirmary, UK.  
A- Normal      RCA LCA
B- Non-diabetic                              Focal stenosis of LCA
C-T2DM      RCA stenosis LCA stenosis
Proximal mid 
posterior descending
Diagonal 
branch
Left anterior 
descending
Left anterior 
descending
5 
 
1.2. Blood vessel wall 
The blood vessel walls of both arteries and veins consists of three main layers: the 
intima, media, and adventitia (Figure 1.3). 
 
 Basement membrane endothelium (intima) 
The intimal layer underlying the lumen is a continuous monolayer of endothelial 
cells (EC). A proteoglycan-rich layer lies directly beneath the endothelial layer 
together with, few vascular smooth muscle cells (SMC), and macrophages (Newby 
and Zaltsman, 2000). This layer acts as a barrier between the blood and vessel wall, 
controls the transport of ions and fluids across the vascular space and also controls 
homeostasis and vascular tone (Stevens et al., 2000). The basement membrane or 
the extracellular matrix (ECM) is comprised of type IV collagen, which provides the 
structural support to form a fibrillar network of basal lamina, and also can modulate 
the adhesion, proliferation, migration, and survival of EC (Sell et al., 2009). Additional 
components include laminin, elastin, and heparan sulphate proteoglycans (Califano 
and Reinhart-King, 2013).  
 
 Vascular smooth muscle cells (media) 
 Underlying the intima is the media which contains mainly vascular SMC and these 
compose the majority of blood vessel wall (Califano and Reinhart-King, 2013). 
Vascular SMC in the medial layer are tightly packed into their interstitial matrix, which 
comprises type I and III collagen, fibronectin, and proteoglycans. Collagen I followed 
by collagen III constitute the major structural components of the ECM structure 
comprising 80% and 11% respectively (Newby and Zaltsman, 2000). The principal 
role of vascular SMC is to maintain prominent plasticity and to regulate blood pressure 
and blood flow distribution. The presence of the well-defined organisation of the 
vascular SMC and ECM in the media provide the structural foundation of the 
physiological property of the blood vessels. This will allow the differentiation of SMC 
that constitutes a critical part of vascular development to perform biosynthesis, 
proliferation, and contraction of the vasculature (Kawai-Kowase and Owens, 2007). 
On the other hand, in response to pathophysiological stimuli such as cytokines and 
growth factors in the circulation, disorganisation of the media structure together with 
other secreted mediators, provoke SMC and ECM to proliferate and migrate into the 
intima, thus initiating the development of atherosclerosis and restenosis (Alexander 
and Owens, 2012).  
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Figure 1.3: Normal blood vessel structure. 
Normal blood vessel is composed of 3 layers. The innermost is the intima which is 
composed of endothelial cells (EC), lying on the basement membrane. The middle 
layer is the media which mainly contains smooth muscle cells (SMC). The outermost 
layer is the adventitia which contains fibroblasts, mast cells, and the vasa vasorum. 
 
 Adventitia 
The adventitia is the outermost connective tissue surrounding the vessel and 
normally contains collagen, vasa vasorum (comprising arterioles, capillaries, and 
veins), nerve endings, fat, quiescent inflammatory cells and fibroblasts (Manon-
Jensen et al., 2016). The main functions of the adventitia are to support the outer 
layer of the blood vessel, molecular exchange, storage and secretion of key regulators 
for the vessel wall function (Chen, 2011). The activated adventitia cells also generate 
reactive oxygen species (ROS), cytokines, growth factors and matrix 
metalloproteinases (MMPs) that collectively activate the medial cells for phenotypic 
modulation (Gareri et al., 2016). In severe arterial injury, stretching of the adventitia 
is accompanied by increased adventitial thickness, myofibroblast proliferation and 
collagen formation (Shi et al., 1996). The adventitial fibrotic response to vascular 
intervention plays a crucial role in restenosis by either circumferential compression of 
the vessel wall or by inhibiting external elastic lamina expansion (Lafont et al., 1995).   
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1.3. Atherosclerosis 
Despite the continued advances in therapeutic treatment, atherosclerosis remains 
the leading cause of CVD and death around the world (Libby et al., 2011). 
Atherosclerosis is a chronic, progressive inflammatory disorder and interactions of 
different vascular cell types that are the underlying cause of angina, CAD and stroke 
(Libby, 2002). When coronary atherosclerosis progresses, the collateral vessels 
expand as a compensatory mechanism to the reduction of the perfusion rate in the 
resting state (Baykan et al., 2015). However, when there is increased activity, the 
myocardium requires an additional blood supply to cover the high oxygen demand. 
The insufficiency of blood supply to the heart (ischaemia) may then lead to myocardial 
infarction. 
 
 
The endothelial layer is an interface between the blood stream and blood vessel 
wall. It normally promotes vasodilatation and protective antithrombotic properties by 
secreting prostacyclin, nitric oxide (NO) and adenosine (Holt et al., 1993). Disturbance 
of blood flow by a reduction in shear stress or endothelial injury permits white blood 
cell (leukocyte) adhesion onto the endothelial layer and provokes proatherogenic 
responses (Chatzizisis et al., 2007). Leukocyte adhesion can also be activated by the 
cell surface receptors, integrins (Luo et al., 2007). Subsequently, this can trigger the 
sub-endothelial layer to retain LDL cholesterol in focal areas of arteries through 
electrostatic binding to proteoglycan in the intima (Tabas et al., 2015). The 
subendothelial accumulation of LDL particles become oxidised and modified by 
enzymes into proinflammatory particles which lead to activation of EC and chronic 
inflammation (Insull Jr, 2009). Once resident in the arterial intima, leukocytes and T-
lymphocytes communicate and recruit several cell types and mediators including EC, 
monocyte-derived macrophages, mitogens, chemoattractants, and chemokines 
(Figure 1.4A). Since the antithrombotic property of the lumen is lost by the disturbed 
inner endothelial layer of the lumen wall together with proteoglycan, this will further 
facilitate platelet adhesion.  
 
 
Additionally, both activated macrophages and SMC promote the secretion of 
enzymes such as MMPs which degrade ECM components (George et al., 2000). 
Upon the influence of mechanical stress, growth factors and MMP secretion, vascular 
SMC become phenotypically modulated and thus proliferate and migrate into the 
damaged intimal layer (Zemskov et al., 2012, Owens et al., 2004). Accordingly, this 
results in the formation of necrotic lesions, apoptosis and narrowing of the interior 
lumen (Figure 1.4B).   
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Figure 1.4: Stages of atherosclerosis development. 
A- Initial step of atherosclerosis begins by adhesion of leukocytes to the endothelial 
cell (EC) monolayer, maturation of monocytes into macrophages yielding foam cells 
and activated EC layer. B- Lesion progression involves migration and proliferation of 
SMC, platelet adhesion and synthesis of ECM macromolecules. C- Thrombosis, 
disruption of atherosclerotic plaque and blood coagulation all can impede blood flow.  
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Vascular inflammation is orchestrated by a cascade of inflammatory and growth 
mediators. For example, ROS generation and secretion of inflammatory molecules by 
activated macrophages such as cytokines including interleukins (IL-1, IL-6 and IL-8), 
tumour necrosis factor alpha (TNF-α), and interferons (McDonald et al., 2012). 
Important signalling proteins and growth factors such as platelet–derived growth 
factor (PDGF) and transforming growth factor-β (TGF-β) are also attracted to the 
atherosclerotic lesion in response to injury and contribute to ECM modulation 
(Hansson et al., 2015, Usman et al., 2015). 
 
 
Atherosclerosis is a gradual progression from lipid particles into a complicated 
fibrotic plaque inside the inner wall of the artery. The atherosclerotic plaque consists 
of a lipid-rich core which is found in the centre of the luminal part. On the luminal side 
of the lipid core is a fibrous cap, which consists of lipid particles with macrophages, 
connective tissues and foam cells. In the initial atherosclerotic stages, the balance 
between SMC proliferation, matrix synthesis and cellular senescence in the intima 
can help in mediating plaque repair, resulting in plaque stability (Bennett et al., 2016). 
The stability of the atherosclerotic cap relies also on the thickness of fibrous cap and 
the level of cap inflammation. However, the core is highly thrombogenic and in the 
advanced lesion of atherosclerosis, the plaque can then grow large enough until it 
harmfully occludes the artery lumen and eventually reduces its blood flow (Hansson 
et al., 2015, Plutzky, 1999). The increased synthesis of SMC and a parallel increase 
in ECM production by SMC can stabilise the atherosclerotic plaque (Hao et al., 2003). 
 
As a major consequence to inflammatory mediators’ secretion, macrophages 
increase lipid content and foam cells are stabilised and SMC together with collagen 
are activated to migrate into the intimal layer inducing atherosclerotic scar. Another 
serious drawback is when the unstable fibrous plaque becomes fragile and may 
eventually rupture, causing thrombotic mass and occlusion of the artery (Figure 1.4C). 
Plaque rupture is enhanced by cap thinning stimulated by the accelerated death of 
SMC and degradation of collagen and ECM (Bennett et al., 2016, Lo and Plutzky, 
2012). This can further trigger vascular thrombosis, ischaemia, myocardial infarction, 
stroke and limb ischemia (Jamaluddin et al., 2011).  
 
 
Patients with T2DM have an increased prevalence of coronary atherosclerosis and 
account for a significant proportion of coronary interventions compared with ND 
individuals (Rong et al., 2016). T2DM patients have a 2-4 fold higher incidence of 
CVD and more dramatic rates of morbidity and mortality than patients without diabetes 
(Wang et al., 2015b). Moreover, several studies reported the high incidence of 
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restenosis in T2DM patients that reached up to 70% following coronary intervention 
(Gao et al., 2015, Kip et al., 1996). 
Whilst available drug therapies for CAD such as lipid-lowering drugs, vasodilators, 
and coagulation and platelet aggregation inhibitors are helpful in mild-moderate stable 
conditions (Yusuf et al., 2011, Antiplatelet Trialists, 1994). These pharmacological 
therapies help to control the symptoms and slow disease progression rather than 
preventing the actual cause of the disease. In severe cases and inappropriate 
treatment, this can lead to complete vessel occlusion, acute myocardial infarction, 
stroke, angina or sudden cardiac death (Busing et al., 2005). Owing to the high 
prevalence of CHD, interventional surgical treatment including percutaneous coronary 
intervention (PCI) and coronary artery bypass grafting (CABG) are widespread 
procedures to rescue the patients with acute and severe coronary occlusion (Pugh et 
al., 2001). 
 
 Percutaneous coronary intervention 
An emergency treatment for acute coronary syndrome, PCI or angioplasty involves 
non-surgical widening of the occluded coronary artery. This treatment involves 
inserting a catheter with an attached deflated balloon through the skin into radial (arm) 
or femoral (groin) artery of the patient, guided up into the obstructed coronary artery. 
The balloon is then inflated inside the artery at the site of obstruction, dilating the 
vessel. Alternatively, this can also be accompanied by a subsequent stent placement 
to provide mechanical support and keep the artery open, together with antiplatelet 
medications to prevent blood clotting (Busing et al., 2005, Dangas and Kuepper, 
2002).  
 
The most common PCI available for treating patients with symptomatic CAD are 
either bare-metal stents (commonly stainless steel) or drug-eluting stents which 
release immunosuppressive or anti-proliferative reagents (Joner et al., 2006, Celik et 
al., 2016). These procedures improve the haemodynamic flow rate and restore normal 
blood flow. PCI can also lead to blood vessel damage by the catheter and endothelial 
disruption, an important problem following endovascular treatment that can eventually 
cause vascular restenosis (Kimura et al., 2002, Moore et al., 2013). Therefore, 
thrombotic risk and atherosclerotic plaque formation accompanying stent placement 
are the major pathological outcomes. This eventually leads to atherosclerosis and 
serious occlusion, with an incidence rate of 30-40% within 3-6 months following stent 
implantation (Chen et al., 2012).  
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 Coronary artery bypass graft surgery 
Coronary artery bypass grafting remains a mainstay therapy for patients with 
multivessel occluded coronary arteries and multiple risk factors, and for patients with 
left main CAD and low ejection fraction (Yahagi et al., 2016). Reports have shown 
that 20-25% of patients undergoing CABG have diabetes (Flaherty and Davidson, 
2005). Additionally, diabetic patients are at higher risk of perioperative morbidity, poor 
outcome and lower survival rate following CABG in comparison to ND counterparts 
(Weintraub et al., 1993, Kappetein et al., 2013). The commonly used bypass conduits 
for the occluded artery in CABG surgery are the autologous internal mammary artery 
(IMA) which is re-routed to the heart circulation, or the saphenous vein (SV) as 
illustrated in Figure 1.5., a suitable piece of the graft is attached to the ascending aorta 
and to the coronary artery above the occluded segment of the artery. CABG is highly 
effective in relieving chest pain and restoring the normal blood flow into the heart. The 
bypass can be performed to one occluded artery, but it is more common to perform 
double, triple or up to quadruple bypasses of the coronary arteries. Early CABG 
surgery provides a significant increase in survival rate compared with initial medical 
therapy (Yusuf et al., 1994, Sako et al., 2014).  
 
Figure 1.5: Schematic shows SV and IMA grafts in CABG surgery. 
The IMA and SV are utilised to re-route the occluded coronary artery circulation. SV 
harvested from patient’s leg is grafted to the aorta and the thoracic IMA is attached to 
left subclavian artery (https://en.wikipedia.org/wiki/File:Blausen_0154_CABG).  
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 Comparison between IMA and SV (differential patency) 
The use of autologous IMA was first utilised as a bypass conduit for CABG over 50 
years ago. It is still the favoured graft with superior patency and stronger resistance 
to thrombosis than the SV. As it is re-routed from the arterial circulation, this has a 
higher survival advantage over the use of SV grafts (Cameron et al., 1996). However, 
most CHD cases are associated with multivessel coronary artery occlusion which 
necessitates the use of more than one graft. Thus, because of the limited number of 
arterial grafts available to cover the multivessel occlusion, the use of SV graft is both 
necessary and indispensable. 
The underlying pathological lesion of SV graft stenosis is the characteristic 
development of intimal hyperplasia (IH) following CABG. IH often starts approximately 
4-6 weeks following SV implantation (Dietrich et al., 2000) and this can be followed 
by an atherosclerotic lesion in the vein graft which starts within one year following vein 
implantation (Wang et al., 2013b). During the first year after CABG, up to 15% of SV 
grafts fail with an expected 4-5% increase each year with severe disease of the 
partially functioning graft (Nwasokwa, 1995). Therefore, in 10 years SV graft failure 
rates are close to 50% and approximately 31% of all CABG surgeries in the United 
Kingdom (UK) necessitate reintervention (Deb et al., 2012). Conversely, 80-95% of 
IMA grafts remain patent 10 years following CABG (Wilson, 2015). 
 
Compared with IMA counterparts, SV has a greater diameter but always shows a 
lower patency rate and higher mortality rate following CABG surgery (Taggart et al., 
2010). The aetiology of IH and graft failure is a complex multifactorial procedure and 
the specific mechanisms are still unclear. Initial considerable damage of the 
endothelial layer during harvesting and implantation of the SV graft almost certainly 
triggers initiation of the subsequent processes. Therefore, vasodilatory mediators (for 
example, NO and prostacyclin) are often reduced and instead there is increased 
secretion of vasoconstrictor agents such as endothelin-1 (Verrier and Boyle, 1996). 
The secretion of NO and prostacyclin is intrinsically lower in the SV, thus, the inherent 
antithrombotic property of SV is weaker than IMA, conferring greater susceptibility of 
the SV to thrombosis and occlusion (Mitra et al., 2006). Relocating the SV from the 
patient’s leg into the higher pressure and flow rate of the new coronary arterial 
circulation can also cause graft trauma, loss of intimal integrity and aggravate the 
development of IH (Bryan and Angelini, 1994, Davies and Hagen, 1995). 
 
The SV and IMA grafts have different gene expression patterns (Zhu et al., 2013) 
and react differently to the factors secreted by the graft’s surface, including platelets, 
complement, coagulation and growth factors (Jia et al., 2006). Exposure of the 
13 
 
subendothelial matrix activates leukocyte deposition, platelet adhesion, and 
inflammatory and immune cells migration (Tanaka et al., 1993). Additionally, the 
excessive production of MMPs and cytokines promotes SMC phenotypic changes into 
proliferative and migratory phenotypes towards the lesion. This leads to the 
obstructive neointimal formation of the new graft resulting in graft remodelling and re-
occlusion following CABG (Motwani and Topol, 1998, Sabik et al., 2005).  
 
Furthermore, a number of studies compared human paired cultured SMC of SV and 
IMA, SV-SMC showed a consistently higher proliferation rate, invasive capacity and 
MAPK activation compared to cells obtained from IMA (Turner et al., 2007, Yang et 
al., 1998). These inherent functional differences between SV and IMA-SMC provide 
a further explanation for higher failure rates of SV grafts, by conferring susceptibility 
to accelerated IH and subsequent re-occlusion.  
The high propensity for the failure of vein grafts is a major limitation of bypass 
surgery as it causes recurrent ischaemic events, with more than 20% of the patients 
requiring further revascularisation procedures within 6 months (Rutanen et al., 2002). 
Lastly, cardiovascular risk factors such as patient age, smoking, hyperlipidaemia, 
hypertension, and T2DM can all facilitate and aggravate graft failure. Owing to a large 
number of patients living with the risk of late vein graft failure, and the high morbidity 
and mortality rates (Wijns and Kolh, 2010), further investigation to uncover the exact 
biological mediators involved in IH is an increasing challenge to improve vein graft 
patency. 
 
1.4. Alteration of vascular SMC phenotype  
 SMC plasticity and phenotypic switching  
SMC exhibit two distinct phenotypes and they play an important physiological role 
during normal vascular development and growth (Figure 1.6). In the early stages of 
blood vessel formation, SMC are characterised by a relatively high proliferation rate 
and cellular synthesis of ECM components. Whereas in the adult blood vessel wall, 
the structure of vascular SMC remain in the mature differentiated phenotype 
(Hungerford and Little, 1999). The differentiated SMC are highly specialised cells, and 
exhibit a mainly spindle-shaped contractile phenotype with very low turnover and 
migratory actions.  
 
Vascular SMC lack terminal differentiation and exhibit remarkable plasticity 
enabling them to switch between the two different phenotypes in response to local 
environmental milieu (Figure 1.6) (Owens, 2010). This phenotypic modulation of SMC 
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results in a rhomboidal shape that is characterised by a migratory and proliferative 
phenotype, lack of selective SMC differentiation marker genes (Chaabane et al., 
2013), and increased production of ECM components (Horita et al., 2011, Zhang, 
2009). The presence of intact ECM usually maintains the contractile phenotype of 
SMC from being switched into the proliferative and migratory phenotype and reduced 
susceptibility to mitogens. The phenotypic modulation from the quiescent contractile 
into active synthetic phenotype confers a survival advantage during vascular 
development, repair and adaptation. However, this alteration in differentiation state 
can be disadvantageous and might contribute to critical pathological changes in the 
blood vessels in vascular pathologies such as atherosclerosis, aortic aneurysm 
(Ailawadi et al., 2009, Shi and Chen, 2016), and restenosis, after vascular 
interventions such as coronary angioplasty and SV bypass grafting (Owens et al., 
2004, Albinsson and Sessa, 2011). The precise mechanism underlying the high 
degree of plasticity and the precise stimulus involved in this modulation are not well 
identified. Therefore, intensive efforts are being made to identify various stimuli and 
understand the molecular mechanisms underlying phenotypic modulation in SMC.   
 
Cytoskeletal proteins contributing to cellular structure and organisation have also 
been documented as valuable tools to identify SMC differentiation (Sherwood, 2015). 
Specific marker genes for differentiated SMC are α-smooth muscle actin (ACTA2) 
which is the predominant isoform in vascular SMC (Kawasaki et al., 2008), smooth 
muscle myosin heavy chains (SM-MHC), smooth muscle myosin light chains, h1-
calponin, smoothelin, and smooth muscle α-tropomyosin (Alexander and Owens, 
2012, Gomez and Owens, 2012). Actin filaments together with other actin-binding 
proteins form a complex network at the cortical region of the cell. This network 
supports the cell, acts as tracks for movement of intracellular molecules and a barrier 
for other molecules to diffuse into the cell (Cherng et al., 2008). Furthermore, the F-
actin cytoskeleton plays an important role in the maintenance of cellular integrity, 
determining cell shape and function and driving cell movement. Actin together with 
myosin motor protein undergoes dynamic alterations to force cell movement in 
response to physiological and pathological abnormalities such as changes in shear 
stress or vascular injury (Searles et al., 2004, Pollard and Cooper, 2009). Studies 
have shown that F-actin bundling into fibres is related to SMC differentiation, and 
therefore, phenotypic modulation of vascular SMC is accompanied by changes in 
actin cytoskeleton alignment (Han et al., 2009). 
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 Role of SMC in adaptation and remodelling  
The environmental changes caused by various disease states or upon tissue injury 
result in the exposure of SMC to several factors that are involved in and facilitate 
phenotypic switching of SMC into the dedifferentiated phenotype (Figure 1.6). 
Following vascular wall damage, the controlled phenotypic modulation of SMC into 
the dedifferentiated phenotype is essential for effective adaptation to withstand 
arterial circulation, however, the imbalance and excessive SMC proliferation and 
migration signals can contribute to coronary re-occlusion in vascular pathological 
conditions (Southerland et al., 2013). 
 
 
Figure 1.6: Vascular smooth muscle cell differentiated and dedifferentiated 
phenotype.   
Differentiated SMC have spindle elongated morphology, high contractile gene 
expression (α-SMA), aligned actin fibres, lower cell area, and decreased ECM 
production and migration (Owens et al., 2004). In contrast, dedifferentiated SMC 
appear rhomboid, have low contractile gene expression, disorganised actin fibres, 
larger cell area, increased ECM and high proliferative and migratory rate (Riches et 
al., 2014). The differentiated phenotype can be protected by insulin-like growth factor 
(IGF) I and II or by insulin, whereas the dedifferentiated phenotype can be stimulated 
by platelet growth factor (PDGF), cytokines and matrix metalloproteinases (MMPs) 
(Metz et al., 2012, Hayashi et al., 1998). 
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 Intimal hyperplasia 
IH is the thickening process of the vessel intima as a result of the accumulation of 
SMC and ECM components into the intimal compartment following endothelial injury. 
Physiologically, IH occurs during the closure of the ductus arteriosus and uterus after 
birth (Newby and Zaltsman, 2000). Pathologically and upon vascular injury, IH occurs 
as a result of endothelial injury following balloon catheter denudation, angioplasty, 
autologous SV bypass grafting, vascular aneurysm, atherosclerosis and in 
hypertensive pulmonary arteries (Willis et al., 2004, Rzucidlo, 2009). Normally, most 
grafted SV develop an adaptive minor intimal thickening to resist the new stress of 
arterial haemodynamics within 4-6 weeks of CABG (Motwani and Topol, 1998). The 
dedifferentiated SMC phenotype together with the excessive secretion of ECM 
components form the bulk of extensive IH lesion that eventually lead to restenosis 
and graft failure.  
 
Effective wound repair is tightly regulated by the balance between ECM synthesis 
and degradation. However, the excessive rate of ECM production can lead to different 
pathological diseases, including atherosclerosis, neointima formation and vascular 
remodelling (Tomasek et al., 2002). Furthermore, the lack of an intact endothelial 
layer at the site of the implanted graft activates monocytes and promotes platelet 
adherence to the intima, inflammatory cells and mitogens are subsequently recruited, 
together with increased deposition of ECM components (Wan et al., 2012). The 
pathogenesis of vascular abnormalities has been postulated to be induced by 
phenotypic modulation in vascular SMC, which is accompanied by aberrant 
proliferation and migration of SMC (Figure 1.7) (Parmacek, 2009). Following injury of 
the vascular wall, the secreted collagen can in turn bind to the platelet receptors, 
enhancing platelet adhesion to the injured vascular wall (Manon-Jensen et al., 2016). 
Osteopontin is a matricellular protein which is activated in response to vascular injury 
and is stimulated by inflammatory cytokines and growth factors (Denhardt et al., 
2001). A study using murine aortic SMC showed that osteopontin was implicated in 
recruiting and enhancing SMC migration into the intima which can further trigger IH 
and vascular remodelling (Leali et al., 2007).  
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 Restenosis 
Restenosis is the generation of the neointima and development of intimal narrowing 
of the coronary artery following PCI or in grafted blood vessel after CABG as a 
compensatory vascular response to injury (Lingman et al., 2011). Restenosis occurs 
within months following PCI and this will subsequently lead to occlusion. Multiple 
factors contribute to restenosis, in particular, patients with diabetes (Bauters et al., 
2003) and hypertension (Suurküla et al., 1994) account for the high-risk group of 
negative outcome and restenosis following coronary intervention.  
 
 
   
Figure 1.7: SMC response to vascular injury. 
Following vascular injury, PDGF and MMPs are upregulated and secreted into the 
damaged endothelial layer, this will stimulate the phenotypic switching of SMC into 
the dedifferentiated phenotype which have proliferative and migratory characteristics.  
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 Mediators and inflammatory factors involved in vascular 
remodelling  
Impaired control of the differentiated state of vascular SMC is accompanied by 
increased SMC proliferation and migration towards the site of injury as a consequence 
of the secretion of various mediators involved in vascular remodelling (Ip et al., 1990) 
as illustrated in Figure 1.7 and listed in Table 1.1. These mainly include growth factors, 
inflammatory cytokines and MMPs. On the other hand, insulin and closely related 
peptide insulin-like growth factor (IGF) are known to inhibit phenotypic switching of 
SMC into the dedifferentiated phenotype (Bitto et al., 2010). 
 
 
Table 1.1 Common mediators involved during vascular remodelling and 
restenosis 
Mediators 
secreted 
Source Action 
 
Reference 
PDGF Platelets, SMC, EC SMC proliferation 
and migration 
Salabei et al. 
(2013) 
VEGF EC EC proliferation and 
migration 
Wang et al. (2004) 
TGF-β SMC, EC SMC proliferation 
 
Massagué et al. 
(2000) 
Cytokines 
 (IL1, IL6, IL8) 
Leukocytes, 
macrophages, SMC, 
EC 
Neutrophil and 
monocyte 
recruitment 
Pasi et al. (2015) 
MMPs  
(MMP- 1,2,3, 9) 
SMC, EC ECM degradation, 
SMC migration 
Amin et al. (2016) 
TIMPs SMC, EC Inhibit MMPs 
 
Visse and Nagase 
(2003) 
PDGF: Platelet-derived growth factor, VEGF: vascular endothelial growth factor, TGF- 
β: Transforming growth factor-β, IL: interleukin, MMPs: Matrix metalloproteinases, 
TIMPs: Tissue inhibitors of metalloproteinases.   
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 Growth factors 
Various types of growth factors appear to regulate SMC phenotypic modulation. 
These include vascular endothelial growth factor (VEGF) and PDGF which have been 
reported to be released from matrix stores in response to endothelial injury (Wang et 
al., 2004). 
PDGF is the most potent chemoattractant and mitogen for vascular SMC, thus, it is 
known to promote the rapid transition of SMC into synthetic and migratory phenotypes 
(Salabei et al., 2013). It has 2 disulphide-linked polypeptide chains (A and B) that form 
3 isoforms denoted PDGF-AA, PDGF-BB, and PDGF-AB. PDGF initiates its 
intracellular signalling by binding to 2 subtypes of receptors; PDGF-Rα or PDGF-Rβ 
(Adachi et al., 2004). The A chain binds to PDGF-Rα only, whilst the B chain can bind 
to both receptors. PDGF has an important physiological role in wound healing and is 
synthesised by platelets and other cell types such as macrophages, EC and SMC 
(Hassoun et al., 2009). Under pathological conditions, PDGF has been shown to 
mediate SMC proliferation and migration (from the media to intima) as in the case of 
angiogenesis, atherosclerosis, and restenosis (Clunn et al., 1997). PDGF regulates 
SMC dedifferentiation through stimulation of the mitogen-activated protein kinase 
extracellular regulated kinase 1/2 (MAPK/ERK1/2) and Phosphoinositide 3-
kinase/protein kinase B (PI3K/Akt) pathways (Gan et al., 2013). The action of PDGF 
on SV would be a challenging area of research as PDGF is a major growth factor 
associated with IH and increased SMC migration and proliferation constitute the 
cornerstone of SV graft failure (Xu et al., 2015a).  
 
 Cytokines 
Cytokines are small, soluble secreted proteins that have pro- or anti-inflammatory 
actions. They include interleukins (ILs), TGF-β, and TNF-α, all of which are associated 
with metabolic syndrome and involved in mediating SMC phenotypic changes 
(Salabei and Hill, 2013). 
 
TNF-α is found in atheromas and can be secreted by inflammatory cells and 
vascular SMC (Newby and Zaltsman, 1999). TGF-β is a powerful profibrotic agent 
released from EC and SMC in a latent form in response to inflammation. Its activation 
requires extracellular enzymes such as plasmin, urokinase and MMPs. TGF-β1 is the 
most frequently upregulated isoform in response to endothelial injury and vascular 
remodelling (Massagué et al., 2000). It has an important role in promoting SMC 
migration, increased ECM production and plaque stabilisation (Hishikawa et al., 1999, 
Ito et al., 2009). 
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IL-1 comprises two related subtypes, IL-1α and IL-1β. Both IL-1 subtypes stimulate 
IL-1R and are involved in the different immunological response, pro-inflammatory 
reactions and hematopoiesis (Pasi et al., 2015). IL-1α is an intracellular cytokine, 
constitutively available in most cell types, synthesised by monocytes and 
macrophages as an inactive proprotein (Clarke et al., 2010, Turner, 2014). IL-1α is 
released upon tissue damage or necrosis, can activate other cytokines and neutrophil 
recruitment, and controls physiological cell proliferation, growth, and apoptosis 
(Clarke et al., 2010). Furthermore, IL-1α plays an important role in ECM degradation 
by activating MMP-1, MMP-3, MMP-9 and MMP-10 expression (Turner et al., 2010). 
Subsequently, IL-1α is proteolytically processed and activated by calpain then 
secreted in response to viral infections, autoimmune diseases, tissue necrosis and 
vascular injury (Dinarello and van der Meer, 2013, Clarke et al., 2010). Unlike IL-1α 
precursor, IL-1β is inactive and needs to be cleaved by caspase-1, to release the 
active cytokine into the extracellular space (Garlanda et al., 2013). IL-1β is 
synthesised by blood monocytes, tissue macrophages and dendritic cells, and 
activated by caspase-1 in response to inflammation or immune reaction.   
 
 Matrix metalloproteinases 
Cell-matrix structure is controlled by a dynamic balance between matrix synthesis 
and breakdown and a disturbance in that balance is a major contributor to vascular 
pathological conditions (Stetler-Stevenson, 1996). MMPs play a crucial role in the 
degradation of collagen and elastin; the major components of ECM (Newby et al., 
2009) and regulate matrix turnover rate during morphogenesis, angiogenesis and 
tissue repair (Park et al., 2004). On the other hand, excessive proteolysis and an 
imbalance between MMP activation and degradation contributes to tissue destruction 
and various CVDs including, fibrosis, atherosclerosis and vascular remodelling (Amin 
et al., 2016).  
MMPs are a family of more than 25 genetically-related proteinases (Gill and Parks, 
2011). These are classified into 5 major groups according to their structure or 
substrate specificity into collagenases, gelatinases, stromelysins, matrilysins, 
membrane-bound MMP, and other unclassified subgroups. The main classes of 
MMPs are summarised in Table 1.2. 
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    Table 1.2 Types of matrix metalloproteinases (MMPs) 
Enzyme 
 
 MMP Substrate Reference 
Collagenases: Interstitial 
collagenase 1 
MMP-1 
 
Collagen type I, II and III, gelatin Visse and Nagase 
(2003)  
 Neutrophil 
collagenase 2 
MMP-8 
 
Collagen type I, III, aggrecan Kim et al. (2016) 
 Collagenase 3 MMP-13 Collagen type I,II, III, IV, X, XIV, gelatin, 
fibronectin, aggrecan 
Nagel et al. (2005) 
 Collagenase 4 MMP-18 
 
Collagen type I, III Sang and Shi (2013) 
Gelatinases: Gelatinase A MMP-2 
 
Gelatin,  
collagen IV, V, VII and X 
Halper and Kjaer (2014) 
 Gelatinase B MMP-9 
 
Gelatin, fibronectin Turner and Porter (2012) 
Stromelysins: Stromelysin 1 MMP-3 Gelatin, fibronectin, laminin, collagen type III, 
IV, V, IX, X 
Patterson et al. (2001) 
 Stromelysin 2 MMP-10 
 
Fibronectin, aggrecan, 
 collagen type I, IV, V 
Rohani et al. (2015) 
 Stromelysin 3 MMP-11 Collagen VI, laminin,  
insulin-like growth factor protein 1 
Lin et al. (2015) 
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Matrilysins: Matrilysin 1 MMP-7 Collagen type I, IV, gelatin, fibronectin, laminin, 
elastin, insulin-like growth factor protein 1 
Klein and Bischoff (2011) 
 Matrilysin 2 MMP-26 Collagen type IV, gelatin, fibronectin,  
pro-MMP-9 activation 
Gruber et al. (2012) 
Membrane-
type (MT): 
MT1  MMP-14 Collagen III, laminin, gelatin,  
Pro-enzyme MMP-2 activation 
Itoh and Seiki (2006) 
 MT2  MMP-15 Pro-enzyme MMP-2 activation Raffetto and Khalil 
(2008) 
 MT3 MMP-16 
 
Pro-enzyme MMP-2 activation Zhao et al. (2004) 
 MT4 MMP-17 
 
Gelatin, fibrin Truong et al. (2016) 
 MT5 MMP-24 
 
Pro-enzyme MMP-2 activation Wang et al. (1999) 
 MT6 MMP-25 
 
Fibronectin, type IV collagen, 
 proteoglycans 
Kang et al. (2001) 
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MMP activity is usually controlled at 3 different levels starting from gene expression, 
followed by zymogen activation and proteolytic inhibition (Raffetto and Khalil, 2008). 
MMP secretion from macrophages and vascular SMC is transcriptionally stimulated 
by different factors including PDGF, cytokines and inflammatory mediators (Kong et 
al., 2013, Sheu et al., 2004). The MMPs all share similar properties of having a Zn2+-
containing catalytic site and being generated as pro-enzymes (zymogens) that 
necessitate proteolytic activation. Activation is catalysed both at the cell surface and 
in the extracellular space. Intracellularly, activation of pro-MMPs is initiated by cellular 
endoproteases or by phosphorylation (Cha et al., 1996). At the extracellular level, 
proteolytic activation of MMPs is mediated by thrombin, fibrinolytic protease plasmin, 
serine protease tissue kallikrein, trypsin and other enzymes (Page-McCaw et al., 
2007). MMPs play key roles in cellular migration and tissue remodelling by together 
digesting all ECM components of the vascular wall (MacColl and Khalil, 2015). 
Normally their excess activation is inhibited by either α2-macroglobulin in plasma or 
by one or more of tissue inhibitors of metalloproteinases (TIMPs) (Nagase et al., 
2006). 
TIMPs are endogenous tissue inhibitors of metalloproteinases and there are four 
main types (TIMPs 1-4) which can inhibit all active forms of MMPs with variable 
preference. TIMP-1 inhibits MMP-1, MMP-3, MMP-7, and MMP-9, whereas TIMP-2 
mainly inhibits MMP-2. TIMP-3 can inhibit MMP-1, MMP-2, MMP-3, and MMP-9 (Lei 
et al., 2007), whereas TIMP-4 inhibits MT1-MMP and MMP-2 catalytic effects 
(Bourboulia and Stetler-Stevenson, 2010).  
Increasing evidence suggests that the proteolytic effects of MMPs play a crucial 
role in cellular migration, vascular formation and remodelling (Galis and Khatri, 2002). 
Normally, the ECM components interact with vascular SMC through cell-to-matrix 
contacts via integrins. SMC in the medial layer are embedded in the basement 
membrane and integrins retard SMC phenotypic modulation (Newby, 2005). Studies 
have shown that the increased secretion of MMPs digest integrins and thus facilitate 
the dedifferentiation of SMC (Newby and Zaltsman, 2000). Additionally, the balance 
between MMP synthesis, TIMPs and matrix production by SMC plays a significant 
role in the stability of the atherosclerotic plaque (Lemaitre et al., 2003). Since vascular 
SMC are principal elements of the vasculature and MMPs contribute to SMC migration 
and proliferation, this seems to provide a viable therapeutic strategy in IH. 
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 Cardiovascular therapy for vascular remodelling   
Some of the routine cardiovascular therapies utilised for CVD patients show 
additional beneficial effects on SMC phenotype modulation. For example, a further 
function for the lipid-lowering drugs, statins, is a protective effect against vein graft 
failure by retarding SMC dedifferentiation into the synthetic and proliferative 
phenotype and antagonising inflammatory cytokines (Kiyan et al., 2007, Margaritis et 
al., 2012). Angiotensin II (ANG) was reported to activate monocyte chemoattractant 
protein-1 expression and induce vascular inflammation through activation of TGF-β 
and the oxidative factor NADPH oxidase (Niu and Kolattukudy, 2009, Wylie-Sears et 
al., 2014). Thus, this can trigger damage of the vascular endothelial layer and initiation 
of atherosclerosis (Münzel et al., 2008). Additionally, using cultured rat aortic SMC, 
ANG increased vascular SMC proliferation and migration and ECM deposition 
(Nagayama et al., 2015). Therefore, antihypertensive drugs such as ANG receptor 
blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) would be 
expected to reduce the incidence of atherosclerosis and vascular remodelling. 
Moreover, ANG blockers reduce ROS generation and inhibit calcium-activated 
potassium channel and therefore reduced neointimal formation in rats following 
arterial injury (Tharp et al., 2008, Patel et al., 2014). Carvedilol is another 
antihypertensive agent, acts as a β-adrenoceptor antagonist and showed an inhibitory 
effect against the chemoattractant and mitogenic action of PDGF on cultured rat aortic 
SMC (Ohlstein et al., 1993). Aspirin irreversibly inhibits cyclooxygenase and 
suppresses the production of prostaglandins and thromboxane, therefore, mediating 
beneficial antiplatelet and anti-inflammatory effects (Toth et al., 2013). 
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1.5. Diabetes Mellitus 
Diabetes is the most common metabolic disorder and is considered as one of the 
most important cardiovascular risk factors, health burden and threats of our time 
(Berry et al., 2007). There are two types of diabetes. Type 1 diabetes mellitus (T1DM) 
is an autoimmune condition characterised by a lack of insulin secretion and high 
susceptibility to ketoacidosis (Morris et al., 2015). T1DM results secondary to 
pancreatic β-cell destruction by the immune system. Genetic factors and certain viral 
infections may also participate; however, the molecular mechanisms of β-cell death 
and its regulation are poorly understood (Ilonen and Akerblom, 1999). It usually 
presents in children and young adults but it can be diagnosed at any age. T1DM 
accounts for 5-10% of total diabetes and its treatment requires insulin injection (Jun 
and Yoon, 2004). Plasma levels of glycated haemoglobin (HbA1c) provide a 
measurement of blood glucose for the past 8-12 weeks, which is 4-6% in healthy 
individuals (Brown et al., 2010). 
 
 
Type 2 DM (T2DM) accounts for 90-95% of adult diabetic cases, and results when 
target tissues (adipose tissue, liver, skeletal muscle) fail to respond adequately to 
circulating insulin. This activates the pancreas to produce more insulin as a 
compensatory mechanism for insulin resistance until it cannot make enough insulin 
to keep up with the increased demand (Baker et al., 2011). Accordingly, diagnosis of 
T2DM is often made following the insufficient pancreatic insulin secretion failed to 
maintain normoglycemia and symptoms of hyperglycaemia become overt.  
Subsequently, this results in hyperglycaemia and increased free fatty acid levels, 
along with raised insulin levels and insulin resistance; hallmarks of the metabolic 
syndrome (Goossens, 2008). Since 1980, the global number of people living with 
T2DM is dramatically growing all over the world. WHO reported until April 2016, the 
number of people with diabetes has quadrupled to 422 million adults, with most living 
in developing countries (http://www.who.int/mediacentre/news). In the UK, there were 
3.5 million patients diagnosed with T2DM in 2015 and approximately more than half 
a million more people with undiagnosed diabetes (https://www.diabetes.org.uk). 
T2DM has a strong genetic tendency, although physical inactivity, eating an energy-
dense diet and obesity accelerate its prevalence. T2DM patients are usually treated 
orally by metformin as an initial therapy, and in patients with persistent high HbA1c, a 
second oral agent can be added and insulin injection is recommended if the response 
to oral therapy is insufficient (Morris et al., 2015).  
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 T2DM and cardiovascular complications 
Owing to the higher tendency of obesity, sedentary lifestyles and increasing 
longevity, the epidemic of diabetes is an escalating public health problem that causes 
a reduction in life expectancy and raises morbidity due to its cardiovascular 
complications.  
T2DM is associated with debilitating cardiovascular complications (Guay et al., 
2011). Diabetes can confer up to 4-fold increase in the risk of ischemic heart disease 
with poor prognosis and more than double the mortality rate compared to non-diabetic 
(ND) patients (Miettinen et al., 1998, Cordero et al., 2016). Diabetic patients are highly 
susceptible to vascular complications; being either macrovascular (CAD and stroke) 
and/or microvascular (including retinopathy, nephropathy, and neuropathy) (Winer 
and Sowers, 2004). The major risk factors related to CVDs for diabetic patients are 
smoking, hyperglycaemia, hyperinsulinemia, hyperlipidaemia, obesity, hypertension, 
inflammation, hypercoagulability and atherosclerosis (Alexandru et al., 2016). These 
co-existing multiple risk factors of diabetic patients usually produce a hazardous 
response before surgery (Lawrie et al., 1986). Hyperinsulinemia can induce SMC 
proliferation and migration and increase ECM production (Aronson et al., 1996, 
Kannel et al., 1991). Additionally, hyperinsulinemia can produce coronary vasospasm 
and thrombus formation and reduction of fibrinolytic activity (Suzuki et al., 1996, Sobel 
et al., 1998). Following treatment of CAD with both stent and CABG, the reduction in 
long-term survival outcome and unfavourable consequences and complications after 
SV revascularisation remain higher in T2DM patients than ND counterparts (Berry et 
al., 2007, Kubal et al., 2005). Increased arterial wall stiffness (Henry et al., 2003), 
exaggerated neointimal formation, restenosis and inefficient early adaptation to 
arterial conditions in T2DM can limit the graft patency outcome (Owens, 2010). In 
addition to the higher rate of in-hospital mortality, insulin-dependent diabetic patients 
were associated with higher incidence of acute renal failure, deep sternal wound 
infection, and prolonged post CABG surgery hospital stay (Kubal et al., 2005). In a 
cohort study with 4118 participants from 1950-1995, a 50% decline in the incidence 
of CVD was observed in both diabetic and ND patients, however, the absolute risk of 
CVD was still 2-fold higher in diabetic patients (Fox et al., 2004). 
 
In diabetic patients, the endothelial layer is exposed to the diabetic environment, 
therefore, hyperglycaemia and oxidative stress in T2DM have been documented to 
contribute to endothelial membrane stiffness (Calles-Escandon and Cipolla, 2001). In 
the early stages, and even before the diagnosis of diabetes, the irregular glucose 
levels in patients or obese individuals is usually accompanied by insulin resistance, 
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ROS secretion and consequently all can mediate vascular changes, particularly SMC 
and EC abnormalities (Alexandru et al., 2016). Both constant and intermittent high 
glucose levels play a crucial role in endothelial dysfunction by impairing NO 
production and metabolism and inducing changes in F-actin expression and 
arrangement (Chen et al., 2013a). Endothelial impairment and apoptosis in diabetes, 
in addition to the high prothrombin activation, would further increase diabetic patients’ 
susceptibility to atherosclerosis and abnormal blood clotting factors (Dokken, 2008, 
Risso et al., 2001). Moreover, diabetic patients have greater susceptibility to 
myocardial infarction, severe CAD, and coronary thrombosis than ND individuals 
(Hakala et al., 2005). Therefore, the underlying mechanisms accelerating CVD in 
patients with T2DM are variable and need further investigation. 
 
 Glycaemia and metabolic memory 
Normalisation of glucose levels, according to clinical studies published in the 
Diabetic Control and Complications Trial (DCCT) and UK Prospective Diabetes Study 
(UKPDS), is highly effective in retarding microvascular complications in diabetic 
patients (Skyler et al., 2009, Brown et al., 2010). On the other hand, results obtained 
from ACCORD, ADVANCE, and VADT trials have shown that macrovascular 
complications were persistent, at least in the medium-term, especially when the 
cardiovascular complications were well established (Skyler et al., 2009). The UKPDS 
and DCCT studies have revealed that intensive glucose control and intervention in 
the early stages of the disease can minimise cardiovascular events in the long-term. 
However, early diagnosis of T2DM is difficult and more than 50% of patients when 
diagnosed with the disease, already have evidence of cardiovascular complications 
(Stolar, 2010). This was shown by Epidemiology of Diabetes Interventions and 
Complications (EDIC) trial, in which 1441 T1DM individuals were assigned into 
intensive or conventional diabetic therapy and they monitored the incidence of 
cardiovascular complications (myocardial infarction, stroke, death from CVD, angina, 
or the need for CABG) for an average of 17 years follow-up. It was reported that 52 
patients treated with a conventional glucose-lowering therapy developed 98 CVD 
events whereas intensive therapy reduced the incidence to 46 CVDs events in 31 
patients (Nathan et al., 2005). This was also supported by a recent DCCT trial that 
showed intensive diabetic therapy reduced the incidence of CVD by 30% in 30 years 
follow-up study for T1DM patients (Gubitosi-Klug et al., 2016).  
 
It is suggested that in T2DM, early and long exposure to abnormal environmental 
cues (hyperglycaemia, hyperinsulinaemia, and various inflammatory mediators) can 
28 
 
lead to persistent alteration of vascular gene expression and adverse phenotypic 
changes, a phenomenon called “metabolic memory” (Cooper, 2009). Short-term 
exposure of aortic EC to hyperglycaemia induced pro-inflammatory gene expression 
in ND mice in vivo and in vitro, and this was maintained even under subsequent 
normal glycaemic conditions (El-Osta et al., 2008). Moreover, vascular SMC cultured 
from diabetic db/db mouse aortas displayed an increased inflammatory gene 
expression compared to ND cells and this was maintained throughout multiple cell 
culture passages (Li et al., 2006).  
 
Apparently, high glucose levels seem to be the main culprit in pathogenesis of 
diabetes, but other mediators such as pro-inflammatory cytokines, advanced 
glycation end products (AGEs), hyperinsulinaemia and free fatty acids (FFAs), all 
seem to be involved in the diabetes phenotype (Ceriello et al., 2009, Yan et al., 2008). 
Studies have shown that the interaction between AGEs and SMC can stimulate SMC 
migration, cytokine synthesis and ECM deposition (Yan et al., 2008). Collectively, 
these will cause overproduction of oxidative stress that persists despite normalising 
glycaemia. Thus, if a new therapeutic agent could erase this long-term memory 
phenomenon, several diabetic cardiovascular complications could potentially be 
resolved. 
 
 Can T2DM influence SMC phenotype? 
Distinct phenotypes have been observed between human SV-SMC cultured from 
diabetic patients and ND counterparts. SMC cultured in-vitro from T2DM SV exhibited 
rhomboid morphology, F-actin fragmentation and reduced proliferation rate (Madi et 
al., 2009). Additionally, cell area was increased and higher gene expression of ACTA2 
(the gene encoding α-SMA) was observed by our group (Riches et al., 2014); 
characteristics that might contribute to adverse outcome after CABG and poor 
adaptation in diabetes. Conversely, ND cells were spindle in shape, had higher 
proliferation rates and normal alignment of F-actin fibres (Madi et al., 2009). At 
variance to these previous studies, Faries et al. (2001) reported a significant increase 
in SMC proliferation of SV and infragenicular arterial cells of T2DM relative to ND 
counterparts. In addition, T2DM cells had abnormal morphology such as the loss of 
normal hill and valley shape and increased cell migration. Vascular SMC proliferation 
and migration, especially after stent implantation, play an important role in neointimal 
hyperplasia through cellular expansion and ECM aggregation (Lorusso et al., 2003). 
Another study performed by our group also showed that SV-EC cultured from T2DM 
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patients were aberrant; exhibiting 30% lower migration and 40% reduction in 
angiogenic capacity relative to ND EC (Roberts et al., 2015). 
 
 
Experimental animal studies have shown that short-term exposure to 
hyperglycaemia induced persistent phenotypic alterations and even after 
normalisation of blood glucose levels, atherosclerosis progressed in diabetic mouse 
models (Brasacchio et al., 2009). The complexities in the pathogenesis of T2DM make 
it challenging to uncover the culprit factors mediating phenotypic modulation in SMC 
and thus further investigations regarding dysfunctional characteristics such as 
coronary revascularisation and restenosis complications in diabetic SMC phenotypic 
changes are critically important. The UKPDS trial termed the persistent phenotypic 
changes a “legacy” effect as these phenotypes were retained even following tight 
metabolic control (Cooper, 2009), which potentially supports the idea of epigenetic 
changes that would induce vascular dysfunction. 
 
1.6. Current therapy for intimal hyperplasia and 
vascular remodelling  
The pathophysiology of IH is complex and multiple culprit factors have been 
implicated. Although many studies have been conducted to treat vascular diseases, 
IH and vascular restenosis remain a limitation and a remarkable challenge for the field 
of vascular biology following vascular injury. A number of studies are ongoing and a 
newer field of research has emerged for identifying the key component(s) and treating 
neointimal hyperplasia.  
 
 Endothelial layer regeneration 
Due to the EC layer’s pivotal role of being the first line to be damaged during 
surgery, and its ability to trigger the subsequent steps of IH, new research has focused 
on the regeneration of EC in the injured vessel. For example, endothelial progenitor 
cells isolated from bone-marrow or umbilical cord blood have been transplanted into 
injured vessels to replace the damaged EC and repair vascular injury (Asahara et al., 
1999). However, these progenitor cells are limited in number and cannot match the 
clinical requirements, are not totally specific and can affect different areas, and can 
only be used for autologous transplantation due to high immunogenicity (Xu et al., 
2015c). 
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 Gene therapy for SV grafting 
Despite the increasing number of molecular and clinical trials, all of the currently 
available pharmacological therapies have limited impact on early vein graft 
remodelling, long-term patency rate and the accelerated risk of atherosclerosis. 
Therefore, novel therapeutic targets remain a clear clinical requirement for the 
prevention of SV graft failure. A few new gene delivery approaches have been tested 
clinically, however, the creation of efficient gene delivery to the target human tissue 
remain an obstacle (Seo et al., 2013). Moreover, all of the mediators involved in 
neointimal formation and SV graft failure represent potential targets for molecular and 
genetic intervention for prolonging vein graft patency.  
 
Inflammation is one of the important factors in neointima formation and vein graft 
failure and TGF-β is one of the important mediators involved in atherosclerosis and 
IH (Nikol et al., 1992). Blocking TGF-β1 signalling suppressed restenosis and IH 
following porcine coronary artery angioplasty (Kingston et al., 2001) and silencing 
TGF-β1 in a rat jugular vein model led to decreased MMP-1 and increased TIMP-1 
expression and subsequently reduced vein IH (Sun et al., 2012a). In addition, an 
adenoviral vector was widely tested pre-clinically and showed effective blockage of 
vein neointima formation in animal models. For example overexpression of TIMP-3 
using adenovirus delivery therapy was effectively protected ECM and mediated 50% 
reduction in neointima formation via preventing MMP activity in vivo in porcine vein 
graft (George et al., 2011). However, a high concentration of adenovirus is required 
to achieve efficient uptake and therapeutic benefit (White et al., 2013). Additionally, 
adenoviral overexpression of TIMP3 reduced cell migration in human in vitro and ex 
vivo models and porcine SV graft neointima formation (Wan et al., 2012, George et 
al., 2000). Although preclinical trials revealed promising results obtained with gene 
therapy in treating CVD, phase II and III clinical trials did not show a successful result 
similar to those obtained in animal trials. Furthermore, in one animal study adenovirus 
gene therapy mediated vascular inflammation and proliferation using a rabbit model 
of vascular disease (Newman et al., 1995). The results of other animal adenovirus 
gene therapy targeting chemokine receptors (Eefting et al., 2009) and TGF-β 
(Ranjzad et al., 2009) are promising. However, none of these studies reached clinical 
therapeutic approval in retarding CABG complications. Therefore, designing effective 
gene vectors and choosing an appropriate target gene(s) would provide a novel 
therapy for the treatment of CVDs and neointimal hyperplasia following graft surgery. 
 
Delivery of gene therapy can potentially occur during CABG surgery. Isolation of 
the SV provides a great advantage of the selective gene therapy to reach its target in 
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the harvested vein during the clinical window. Therefore, the gene vector must be 
efficient to achieve target gene modulation ex vivo and before vein implantation into 
the arterial circulation. The local and direct administration of gene therapy into the 
vein would also minimise the risk of the therapy reaching the systemic circulation 
(Southerland et al., 2013). Recently, targeting gene expression to ameliorate vascular 
remodelling has emerged as a new specific and non-invasive therapy for vascular 
diseases. For example the use of non-viral antisense therapy including short 
interfering RNA (siRNA) to induce specific gene silencing. These siRNA molecules 
comprise a short double-stranded DNA sequence which is specific to a particular 
target gene, inducing posttranscriptional gene silencing (Kanasty et al., 2013). They 
bind to the RNA interference-induced silencing complex (RISC) which then breaks 
down the target mRNA (Cullen, 2004). Using Edifoligide, an E2F transcription factor 
decoy siRNA, was effective in delaying vein graft IH in rabbits (Mann et al., 1999) 
however, Edifoligide failed to improve patient outcome one year after CABG surgery 
(Lopes et al., 2012). Therefore, identification of suitable targets of IH and in depth 
analysis of the cell signalling of the cells of the injured wall remain important areas for 
research.  
 
 Epigenetic therapeutics 
Whilst SMC proliferation and migration from the media into the intima play a pivotal 
role in the development of vascular occlusion, finding new targets to oppose these 
phenomena is mandatory. The stable and heritable changes that occur in gene 
function without changes in the nucleotide sequence are called epigenetic regulation. 
Epigenetic changes include histone modifications (acetylation or methylation), DNA 
methylation and miRNA (miR)-induced gene silencing (Cheng et al., 2010), which 
have been detected in animal and cell models of diabetes as a result of 
hyperglycaemia (Ling and Groop, 2009, El-Osta et al., 2008). This explains how cells 
with matching DNA sequences can differentiate into different cell types with different 
phenotypes. Long-lasting epigenetic modification causes persistent changes in 
smooth muscle phenotype and altered gene expression of miR in the vasculature 
(Alexander and Owens, 2012).  
As a new strategy of epigenetic regulation, the discovery of miRs in the treatment 
of vascular remodelling has emerged. Recent studies suggest that the modulation of 
SMC phenotype and function during vascular remodelling is controlled by miRs 
(Albinsson and Sessa, 2011). They have the capacity to post-transcriptionally 
regulate the expression of genes responsible for diverse physiological cellular 
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functions, such as differentiation, growth, proliferation and apoptosis (Ambros, 2004, 
Kawai-Kowase and Owens, 2007). However, dysregulation or aberrant expression of 
miRs is often associated with various types of human diseases (Kim et al., 2009). 
Thus, numerous studies have proposed that miRs might play a fundamental role in 
vascular SMC development, differentiation and proliferation (Albinsson et al., 2010). 
 
1.7. MicroRNAs (miRs) 
MiRs are a recently discovered class of endogenous, small (18-25 nucleotides), 
single-stranded and non-coding sequences of RNA (Virtue et al., 2012). MiRs bind 
through base pairing and the residues 2-8 at the 5’ region of miR have a major role in 
miR specificity to interact with its target mRNAs. This region is called the seed and it 
binds to 3’ untranslated regions (3’- UTRs) of the target mRNA (Jazbutyte and Thum, 
2010). MiRs negatively regulate 100s of genes which depend on the sequence 
complementarity. They repress target gene expression and protein synthesis by 
promoting either translational inhibition and/or degradation of their target mRNAs, 
acting either alone or in combination (Chavali et al., 2013). Whilst a single miR can 
control the fate of multiple genes, targeting one or more miRs has potential to provide 
important new therapeutic strategies. 
 
 MiR biosynthesis and action 
The mechanism of miR biosynthesis is a multistep event catalysed by specific RNA 
polymerases (Figure 1.8). Inside the nucleus, miR genes are transcribed from the 
genome by RNA polymerase II (more commonly) or RNA polymerase III into primary 
miR transcripts (pri-miR). Pri-miRs are then processed by sequential endonucleolytic 
cleavages induced by two RNase III enzymes, Drosha (nuclear) and Dicer 
(cytoplasmic) (Kwang Loong and Mishra, 2007). Pri-miR transcripts are transcribed 
by Drosha into precursor pre-miRs (70 nucleotides long) (Kim, 2005). Pre-miRs are 
then exported from the nucleus by Exportin 5 to the cytoplasm. In the cytoplasm pre-
miR undergoes additional processing by Dicer which removes the hairpin loop and 
trims the ends, generating an approximate 22-nucleotide double-stranded mature 
miR-duplex. This mature double-stranded molecule has one guide strand that binds 
and forms a complex with Argonaute 2 (Ago2) (Lee et al., 2002). The other passenger 
strand is usually degraded or sometimes becomes active miR and binds to RISC 
(Haas et al., 2016, Hammond, 2015).  
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Figure 1.8: Biogenesis pathway of miRNAs. 
MiRNA genes are transcribed by RNA polymerase II/ III to form primary-miRNA (pri-
miRNA). Pri-miRNA is processed into precursor miRNA (pre-miRNA, 70 nucleotides 
in length) by Drosha in the nucleus. Pre-miRNA then exposed into the cytoplasm 
through Exportin 5 to be processed by Dicer into mature miRNA (double stranded 20-
22 nucleotides). The mature strand then associates with a complex called RNA 
Induced Silencing Complex (RISC) and Ago2 protein by either perfect binding to the 
target mRNA causing mRNA degradation or imperfect binding causing translational 
repression. The passenger mRNA degraded rapidly or activated into miRNA. 
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The association between miR and Ago2 is known as the RISC (Bartel, 2009). The 
guide strand of the miR directs RISC to the complementary sites in the 3’UTR of 
mRNA by sequence-specific target recognition (Rana, 2007). The perfect binding that 
occurs between miR and its target mRNA cause the latter to be degraded through 
cleavage. However, if the complementarity is imperfect, this will cause translational 
inhibition which stops at the initiation step (Khvorova et al., 2003). 
  
MiRs can be released from cells either by passive leakage from necrotic or 
apoptotic cells or through active secretion inside microvesicles such as microparticles 
and exosomes or in RNA/lipid-protein complexes (Ramachandran and Palanisamy, 
2012). Being inside the microvesicles or binding of miRs into the Ago2 transporting 
protein, enable miRs to be stable in the blood and protect them from cleavage by 
ribonucleases (Busch and Zernecke, 2012). Importantly, miR expression is tissue 
specific (Baer et al., 2013). This will assign the potential role of particular miR 
according to cell type or pathophysiological condition. It is documented that one miR 
can control the expression of multiple target genes and regulate genes according to 
different environmental conditions (Bartel, 2009). On the other hand, one target gene 
can be regulated by multiple different miRs. The human genome encodes an 
estimated 1000 miRs that may directly regulate more than 30% of human protein-
encoding genes (Lewis et al., 2005). These miRs are involved in the regulation of 
major cell functions, suggesting new management strategies for CVDs that may rely 
on targeting miRs in the vasculature. 
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  MiRs in T2DM development and complications  
MiRs are highly conserved and their expression is tissue-specific and affected by 
the severity of diseases (Chen and Stallings, 2007). Indeed, one miR may be highly 
expressed in a particular tissue but have low or no expression in other tissues (Lagos-
Quintana et al., 2002). Recent studies have implicated miRs in the pathogenesis of 
diabetes and its related CVD. Several miRs have been shown to play an important 
part in the normal physiological development of the pancreas, insulin signalling in 
target tissues, and apoptosis (Guay et al., 2011, Shantikumar et al., 2012). The most 
commonly known miRs that have a role in diabetes are miR-375, miR-124a, miR-21, 
miR-34a, miR-146a and miR-133, detailed in Table 1.3.  
 
Current trials are being performed to measure the relevant circulating miRs as 
biomarkers for T2DM. This can help to predict T2DM in early stages of diabetes-
related CVDs. A study performed on 80 diabetic patients showed that circulating 
levels of miR-126 were reduced in individuals with impaired glucose tolerance  
compared to a glucose tolerant group, and the levels in patients with diagnosed T2DM 
were reduced further still (Zampetaki et al., 2010). This suggests that low levels of 
miR-126 in ND individuals might be a helpful guide to predicting early diabetes. 
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Table 1.3 Common miRs mediated changes in diabetes 
 
MiR 
 
Target/species 
 
Action 
 
Reference 
MiR-375 
overexpression 
Pancreatic islets of 
ob/ob mice 
Inhibited insulin 
secretion in response 
to high glucose 
Poy et al. (2004) 
MiR-375 
overexpression 
T2DM patients Pancreatic islet 
amyloid and cellular 
damage 
Zhao et al. 
(2010) 
MiR-124a 
overexpression 
Forkhead box protein 
A2 (Foxa2)-a 
transcriptional factor 
for glucose 
metabolism and 
insulin homeostasis 
β-cell development, 
glucose metabolism 
and insulin secretion 
Baroukh et al. 
(2007) 
MiR-21 
overexpression 
db/db diabetic mouse 
kidney 
Renal fibrosis and 
inflammation 
Zhong et al. 
(2013) 
MiR-21 induced 
by 
hyperglycaemia 
Renal cortices from 
OVE26 T1DM mice 
Reduced PTEN and 
increased Akt 
phosphorylation 
Dey et al. (2011) 
MiR-21 
downregulated 
in vivo and in vitro 
using db/db mice 
Inhibited glomerular 
hypertrophy and 
mesangial expansion, 
proteinuria 
Zhang et al. 
(2009) 
MiR-34a 
overexpression 
Islets of T2DM db/db 
mice 
Fatty acid induced β-
cell dysfunction 
Lovis et al. 
(2008) 
MiR-21, miR-34a, 
and miR-146a 
induced by 
cytokines 
Mouse insulin-
secreting cell line 
(MIN6) 
β-cell dysfunction Roggli et al. 
(2010) 
MiR-1 and     
miR-133 
overexpressed 
Alloxan-induced DM 
model in rabbit 
Abnormal QT 
elongation and heart 
failure 
Xiao et al. 
(2011) 
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 MiRs in CVD and vascular remodelling 
While miRs have been well investigated in the cancer field, more recently, the 
relationship between miRs and CVDs have been explored (Small et al., 2010). 
Growing evidence suggests that miRs are highly expressed in CVDs and their 
aberrant expression profiles play an important role in CVDs, including angiogenesis, 
atherosclerosis, arterial remodelling, vascular injury and restenosis (Wang and Wen, 
2015, Urbich et al., 2008). Because neointimal lesion generation is characterised by 
increased SMC proliferation and migration that is also similar to the mechanism of 
cancer cell spreading, thus miRs could reasonably be expected to be involved in the 
regulation of neointimal lesion formation after revascularisation (Ji et al., 2007). 
However, relatively few studies have directly revealed the exact role of miRs in 
vascular remodelling.  
 
Numerous studies have implicated miRs in vascular SMC phenotypic changes, 
development and regulations. MiR-143/145 were deregulated following mechanical 
balloon-injured rat carotid artery in vivo and in cultured dedifferentiated vascular SMC 
(Cheng et al., 2009a). MiR-21, miR-210 and miR-34a were reported to be the most 
significantly upregulated in atherosclerotic plaque obtained from patients after CABG 
surgery (Raitoharju et al., 2011). MiR-1 has been reported to be elevated in human 
CAD and its overexpression resulted in rat heart induced arrhythmias (Yang et al., 
2007). MiR-29 was reported to be downregulated in infarcted rat heart and this was 
accompanied by increased collagen expression (van Rooij et al., 2008). MiR-208 was 
found also to induce cardiomyocyte hypertrophy and fibrosis in mice (van Rooij et al., 
2007). Other miRs including miR-143/145 and miR-221 have received great attention 
(Albinsson and Sessa, 2011), but intensive research is required to clarify their role in 
proliferative vascular diseases, such as increased rate of proliferation and loss of 
contractile property. Neointimal progression and vascular diseases may therefore 
potentially be resolved by normalising miR expression and preventing detrimental 
phenotypic modulation.  
 
Additionally, studies have shown that miRs can affect ECM molecules in different 
types of tissues and are thus implicated in pathological diseases. For example, miR-
21 overexpression increased collagen 1 deposition in human lung cell lines and 
mammary gland causing fibrogenesis (Li et al., 2011). MiR-301 was found to increase 
human breast cancer cell migration and proliferation through targeting collagen type 
II (Shi et al., 2011). Changes in collagen integrity can affect the differentiation and 
survival of surrounding cells and therefore, miRs can robustly regulate phenotypic 
changes of vascular SMC (Rutnam et al., 2013).  
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Recent clinical studies have demonstrated that some circulating miRs secreted 
from cells into the plasma can serve as sensitive biomarkers for tissue injuries or 
CVDs. For example, an increased plasma level of miR-423 was detected in heart 
failure patients, miR-208 and miR-499 were elevated in myocardial ischemia in rats 
and human samples; respectively (Corsten et al., 2010, Fukushima et al., 2011).  
 
 MiRs and SMC phenotype 
The profound ability of vascular SMC to modulate their phenotype in physiological 
processes and wound healing has further drawbacks, mediating vascular diseases. 
Uncontrolled phenotypic changes in SMC can evoke accelerated migration, 
proliferation, and production of ECM products. Changes in the ECM components and 
their arrangement within the vascular wall contribute also to changes in SMC 
phenotypes. Using a mouse model of carotid artery ligation, miR-145/143 were found 
to be significantly downregulated, resulting in phenotypic modulation of SMC into a 
proliferative phenotype that was accompanied by the reduction of α-SMA marker gene 
(Cordes et al., 2009). Conversely, overexpression of miR-145/143 in human ND SV-
SMC modulated the SMC phenotype by increasing spread cell area and driving the 
appearance of truncated F-actin fibres similar to those observed in native T2DM-SMC 
(Riches et al., 2014). 
 
Recent studies have shown that phenotypic switching of SMC can play an important 
role during atherosclerotic plaque formation and in plaque stability and that a 
beneficial therapeutic outcome could be achieved by targeting SMC phenotypic 
switching (Chaabane et al., 2014, Gomez and Owens, 2012). Several studies have 
shown that miRs are highly expressed in vascular SMC and have a crucial role in 
proliferation and differentiation of SMC, thus, aberrant miR expression can induce 
pathological abnormalities (Zhang, 2009, Ji et al., 2007). In rat carotid arteries, miRs 
have been found to be differentially expressed and to mediate neointimal growth after 
angioplasty (Cheng et al., 2010). Downregulating miR-21 and miR-125 reduced 
expression of SMC marker genes; including α-SMA and calponin, suggesting the 
important role of these miRs in SMC-specific gene expression (Davis et al., 2008). 
Furthermore, both TGF-β and bone morphogenic protein (BMP) through increasing 
miR-21 and miR-199 levels, were able to induce contractile human pulmonary SMC 
phenotypes (Davis et al., 2008).  
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 MiR-21 
Unlike some other selectively expressed miRs, of particular interest, miR-21 is 
generally expressed in most mammalian organ systems including the heart, 
vasculature, lung, pancreas, spleen, intestine, colon and liver (Lagos-Quintana et al., 
2002). MiR-21 is a well-known onco-miR due to its ability to repress the actions of 
various tumour suppressor genes (Bonci, 2010). In addition to its high expression 
profile in cancers, miR-21 has been associated with a variety of CVDs and 
interestingly, following vascular injury, miR-21 is aberrantly expressed in most types 
of cardiovascular cells, including vascular SMC (Ji et al., 2007), EC (Suarez et al., 
2007), cardiomyocytes (Cheng et al., 2007) and cardiac fibroblasts (Roy et al., 2009).  
 
 
 
 MiR-21 in the cardiovascular system 
MiR-21 was found to be upregulated in cardiac fibroblasts promoting cardiac 
fibrosis by activation of the MAPK/ERK signalling pathway (Thum et al., 2008) and 
knocking down miR-21 reversed the levels of interstitial fibrosis and cardiac 
remodelling. This was also regulated by TGF-β inducing miR-21 upregulation which 
repressed sprouty-1 (SPRY)-1 gene expression (Kumarswamy et al., 2012). By 
activation of the MAPK/ERK pathway, miR-21 was also able to induce oxidative stress 
and ROS formation (Sen and Roy, 2012). This resulted in inhibition of SPRY gene in 
human angiogenic progenitor cells (Fleissner et al., 2010) and thus, miR-21 
upregulation appears to play a crucial role in vascular homeostasis and endothelial 
dysfunction.  
 
Both in rat carotid arteries (Zhang, 2008) and human atherosclerotic plaques 
(Raitoharju et al., 2011), miR-21 has been found to be abundantly overexpressed in 
neointimal lesions of the vascular wall. In another in vivo study using a rat balloon 
injured carotid artery, miR-21 was found to be more than 5-fold overexpressed, while 
miR-145 expression was downregulated, relative to uninjured control (Ji et al., 2007). 
MiR-21 has been shown to be overexpressed in cardiac hypertrophy mediated by 
aortic banding while downregulation of miR-21 inhibited cardiomyocyte hypertrophy 
(Cheng et al., 2007). 
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 MiR-21 in SMC 
MiR-21 increased SMC proliferation and inhibited apoptosis after vessel injury 
through repressing phosphatase and tensin homolog (PTEN) and upregulating B-cell 
lymphoma 2 (BCL2) (Ji et al., 2007). Thereafter, using human pulmonary artery SMC, 
miR-21 was also shown to regulate SMC differentiation in response to TGF-β1 and 
BMP via repressing another target; programmed cell death 4 (PDCD4) expression 
(Davis et al., 2008). In keeping with its role in regulating vascular SMC, knocking down 
miR-21 in balloon-injured rat IMA reduced SMC proliferation and protected the artery 
from neointimal lesion formation compared with controls (Wang et al., 2015a), 
indicating the important role of miR-21 in inducing dedifferentiation changes in 
vascular SMC. Furthermore, miR-21 induced cell proliferation and decreased 
apoptosis of porcine vascular wall SMC during abdominal aortic aneurysm 
(Maegdefessel et al., 2012). This was mediated by the suppressing effect of miR-21 
on PTEN and subsequent Akt activation.  
 
 
These various studies highlighted the major mechanisms by which miR-21 is 
implicated in CVDs. Using cultured SMC in vitro and in rat carotid arteries in vivo, the 
anti-apoptotic property and proliferative effect on SMC were the major target of miR-
21 that mediated vascular remodelling. Despite these advanced studies, 
comprehensive knowledge of miR-21’s exact role in SV-SMC and downstream targets 
are not completely known. Manipulation of miRs might be one of the new therapeutic 
strategies to prolong the patency rate of SV graft surgery and retards diabetic vascular 
complications. Therefore, miR-21, which has been shown to be involved in SMC 
differentiation in several studies, might be a possible target for therapeutic 
intervention in vascular remodelling since its expression can be manipulated using 
genetic approaches. These studies revealed a promising value of miR-21 as a new 
therapeutic target for CVDs however, with regard to vascular remodelling, identifying 
the exact role of miR-21 and networks of target genes mediating vascular remodelling 
would provide a novel therapeutic target for prevention or reversal of pathological 
SMC switching in the context of SV graft failure. Additionally, developing a highly 
efficient delivery method and manipulation of miR-21 at the time of vein harvesting, 
and before engrafting, could be promising. This would minimise expression of the 
target genes involved in SMC proliferation and migration and therefore, theoretically 
protect the patient from the risk of neointima formation in the new graft. 
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 Signalling mechanism of miR-21 
MiR-21 is aberrantly expressed in different types of human tissues and diseases, 
acting through numerous targets and signalling mechanisms that are listed in Table 
1.4. Both PTEN and PDCD4 were the two target genes most commonly regulated by 
miR-21 in the literature (Lin et al., 2009, Ji et al., 2007). MiR-21 was initially found to 
induce cell migration, proliferation and anti-apoptosis in various carcinomas through 
targeting tumour suppressor genes including PDCD4 (Lu et al., 2008a), and 
tropomyosin 1 (Zhu et al., 2008). MiR-21 was also documented to control vascular 
SMC growth and survival through repressing PTEN protein and BCL2 gene 
expression (Kumarswamy et al., 2012, Joshi et al., 2012). By posttranscriptional 
inhibition of PTEN expression, miR-21 induced Akt activation and promoted 
proliferation and suppression of apoptosis of rat carotid artery SMC (Ji et al., 2007), 
hepatocellular carcinoma (Meng et al., 2007b), human glomerular mesangial cells 
(Dey et al., 2012), and breast cancer cells (Haverty et al., 2008).  
 
 
Additional mechanisms of proliferation and migration were predicted for miR-21 
action in human pulmonary artery SMC through targeting TGF-β1, BMP, Smads and 
PDCD4 (Davis et al., 2008, Sarkar et al., 2010, Yao et al., 2011). MiR-21 mediated 
the protective effect of vascular SMC apoptosis and death (Lin et al., 2009) and has 
been shown to protect cardiac cell apoptosis following ischaemic reperfusion (Cheng 
et al., 2010) through the transcriptional inhibition of PDCD4. An experimental study in 
mice demonstrated the use of antimiR-21 to reduce interstitial cardiac fibrosis and 
enhance cardiac functions by activation of Spry-1, a negative regulator of MAPK/ERK 
signalling (Thum et al., 2008). Both TIMP3 and Reversion-inducing cysteine-rich 
protein with Kazal motifs (RECK) are negative regulators of MMPs and they are 
additional targets of repression by miR-21 (Selaru et al., 2009). MiR-21 increased 
lung cancer cell line proliferation and invasion through direct inhibition of RECK, PTEN 
and BCL-2 (Xu et al., 2014). Finally, miR-21 has also been involved in the induction 
of oxidative stress by stimulating the MAPK/ERK pathway (Fleissner et al., 2010). 
These targets must be tested in specific cell types because the effect of miRs on gene 
expression and cellular functions are cell-type specific (Jazbutyte and Thum, 2010). 
Based on these reports, it is evident that miR-21 mediates phenotypic changes in 
SMC and may also play a central role in angiogenesis through regulation of various 
targets. Therefore, further studies need to be conducted to determine miR-21’s 
potential biological function specifically in SV-SMC. 
 
Emerging evidence has suggested that miRs are involved in many physiological 
and pathological processes in humans. MiRs have a potential causative role in T2DM 
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and its related cardiovascular complications, as the aberrant miR expression is 
observed in numerous human diseases (e.g diabetes, CVDs, cancer, and tissue 
fibrosis). The accumulating information about the role of miR-21 suggests that it plays 
a crucial role in many biological processes and pathological diseases. However, to 
the best of our knowledge, studies regarding its role in vascular complications and in 
particular human SV graft failure are lacking. Therefore, much additional work is 
needed to identify the precise role of miR-21 in vascular remodelling and to ascertain 
the underlying mechanisms driving its upregulation. 
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Table 1.4 Effect of miR-21 overexpression in different cell types and diseases, mediators involved and signalling mechanisms:  
 
Disease 
 
 
Cell type 
 
Mediators 
involved 
 
Target mRNA 
 
Cellular function/ Relevant 
pathology 
 
Reference 
Cancer Hepatic cell 
carcinoma 
Unknown        PTEN 
PDCD4 
       RECK 
Increased cell migration 
and invasion 
Zhou et al. (2013) 
 Myeloma and 
hepatocellular 
carcinoma cells 
Unknown STAT3 
 
Multiple myeloma Loeffler et al. (2007) 
 Breast tumour cells Unknown        SMAD 
PDCD4 
Breast cancer Qian et al. (2009) 
 Activated fibroblast Unknown PDCD4 Stroma, skin cancer Yao et al. (2011) 
 Keratinocytes 
epithelial cells 
BMP        PTEN 
PDCD4 
Skin cancer Ahmed et al. (2011) 
 Glioblastoma  Unknown        RECK Cancer invasion, glioma Gabriely et al (2008)  
 Lung squamous cell Unknown        RECK  Cancer cell proliferation Xu et al. (2014) 
Kidney Glomerular 
mesangial cells 
Unknown        PTEN Mesengial hypertrophy Dey et al. (2011) 
Heart Cardiac fibroblasts Unknown            PTEN Left ventricular pressure 
and heart fibrosis 
Villar et al. (2013) 
 Cardiac fibroblasts Unknown Spry-1 Heart failure Thum et al. (2008) 
44 
 
Lung Fibrotic lung disease TGF-β1 Smad7 Lung fibrosis Liu et al. (2010) 
Pancreas Islets β cells Unknown PDCD4 Diabetic nephropathy Bravo-Egana et al. 
(2012) 
 β-cells Nuclear factor-
kB 
PDCD4 T1DM Ruan et al. (2011) 
SMC 
 
Pulmonary artery 
SMC 
TGF-β1 
BMP4 
PDCD4 Cell migration and tumour 
metastasis 
Davis et al. (2008) 
 Airway SMC PremiR-21 
transfection 
          PTEN Increased SMC proliferation 
and migration, asthma 
Liu et al. (2015) 
 Pulmonary artery 
SMC 
Unknown PDCD4 
          Spry-2 
Pulmonary hypertension Sarkar et al. (2010) 
 Pulmonary SMC Hypoxia           BMP 
Receptor 2 
Chronic hypoxia-induced 
pulmonary vascular remodelling 
Yang et al. (2012) 
 Femoral artery SMC Unknown Tropomyosin 1 Increased SMC proliferation and 
migration, atherosclerosis of lower 
extremities 
Wang et al. (2011) 
 Carotid artery SMC Angioplasty            PTEN 
           BCL2 
Proliferation, apoptosis 
Neointima formation 
Ji et al. (2007) 
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 Manipulation of miR-21 expression in SV-SMC 
Owing to the ability of individual miRs to manipulate multiple target genes, 
modulating the expression of a single miR can affect an entire gene network involved 
in a particular disease state. Because of the involvement of miR-21 in different types 
of CVDs, manipulation of the level of miR-21 in SMC represents a new promise as a 
novel approach to therapy. To determine its role in vascular remodelling, manipulation 
of miR-21 expression can be achieved by either overexpression of miR-21 to mimic 
its action, or knock down to repress its action in SMC (Patel and Noureddine, 2012). 
 
 Overexpression of miR-21 
PremiR-21 is a duplex oligonucleotide that mimics endogenous precursor miRs. 
One strand has an identical nucleotide sequence to the mature miR-21 (Figure 1.9A). 
This can bind RISC to form a complex that posttranscriptionally inhibits the target 
mRNA. The other strand is the guide/passenger strand that facilitates cellular uptake 
(Martinez et al., 2002).  
 
 Knocking down of miR-21 
In order to inhibit miR expression antimiRs were utilised. They usually have a 
reverse complementary nucleotide sequence to the mature miR of interest (Figure 
1.9B). AntimiR-21 binds to the mature miR-21 and inhibits its action. Therefore, 
antimiR-21 eventually prevents the repression of the target mRNA (Krutzfeldt et al., 
2005). 
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Figure 1.9: Mechanism of modulation of miR-21 expression and function by 
premiR-21 and antimiR-21. 
PremiR-21 is a duplex oligonucleotide with an identical sequence to mature miRNA-
21 and posttranscriptionally inhibits the target mRNAs (A). Conversely, antimiR-21 
has a complementary sequence to the mature miRNA-21 and relieves the repression 
on the target mRNA (B). Modified version from (Patel and Noureddine, 2012).  
3’ UTR5’ UTR
Mature miRNA-21
Add AntimiR-21
Expression of target mRNA
3’ UTR5’ UTR
Mature miRNA-21
Add PremiR-21
Translational repression of target mRNA
A
B
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1.8. Study Hypothesis 
While a large amount of research is directed to targeting IH and prolonging graft 
patency, none of the available therapies treat the original factor(s) involved in this 
process and robust therapeutics are lacking. Recent research highlighted the 
important role of miRs in epigenetic regulation of the vasculature (Alexander and 
Owens, 2012) and in particular, vascular remodelling. MiR-21 is one of the most highly 
expressed miRs in the vasculature and it is aberrantly expressed in vascular 
remodelling. We hypothesise that miR-21 is differentially expressed in SV-SMC from 
patients with and without a diagnosis of diabetes. Secondly, aberrant expression of 
miR-21 plays a key role in human SV-SMC phenotype and function in a manner that 
is detrimental to saphenous vein (SV) bypass graft failure.  
 
1.9. Aims of the study 
1- To determine whether miR-21 is differentially expressed in ND and T2DM 
SV-SMC and to investigate whether manipulation of miR-21 levels in SV-
SMC play a role in phenotypic changes and impaired cell function      
(chapter 3).  
2- To explore which of the diabetic and inflammatory mediator(s) induce miR-
21 upregulation in SV-SMC and to investigate the downstream CVD-related 
target genes affected by miR-21 upregulation in SV-SMC using 
atherosclerosis microarray (chapter 4). 
3- To investigate the effect of miR-21 overexpression on SV-SMC invasion 
using Boyden chamber assay (chapter 5). 
4- To investigate the effect of miR-21 overexpression on SV-SMC proliferation 
and identify the major targets of miR-21 and signalling pathways mediating 
its function in SV-SMC phenotypic changes (chapter 6). 
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Chapter 2 
Materials and methods 
 
2.1. Materials 
 Cell culture 
DMEM, PBS, L-glutamine 200 mM (100X), antibiotic-antimycotic (penicillin, 
Streptomycin and Fungizone), 0.05% Trypsin-EDTA (1X), and Opti-MEM® (1X) were 
all purchased from Life Technologies (Paisley, UK). Foetal calf serum (FCS) was from 
Biosera Ltd (Ringmer, East Sussex, UK). Trypan blue solution (0.4%), cell culture 
grade BSA, DMSO and glycerol/gelatin were from Sigma-Aldrich (Poole, Dorset, UK). 
PD98059 was obtained from Calbiochem and LY294002 was from Alexis 
Biochemicals (Nottingham, UK). Human recombinant TGF-β1 was from Bio-Techne 
(Abingdon, UK). 
 
 
Cell culture chamber inserts and Falcon cell companion plates were purchased 
from Scientific Laboratory Supplies (Hessle, UK). Human collagen solutions type I 
Vitrocol (Cat# 5008) and type III (Cat# 5021) were from Advanced BioMatrix (San 
Diego, California, USA). Haematoxylin was from BDH (Lutterworth, Leicestershire, 
UK) and Eosin 0.5% was from Merck (Nottingham, UK). 
 
Tissue culture flasks (25 cm2 and 75 cm2) and tissue culture plates (6 and 24 well) 
were from Corning Incorporated (Corning, New York (NY; USA). 96-well plates for 
protein assays were from Nunc (Rochester, NY). Microcentrifuge and centrifuge 
Falcon tubes were from STARLAB (Milton Keynes, UK).   
 
 Reagents used for miR-21 induction 
Insulin and glucose were from Sigma-Aldrich (Poole, Dorset, UK). Recombinant 
human PDGF-BB, TGF-β, IL-1α, and TNF-α, were all purchased from Life 
Technologies (Paisley, UK).  
 
 RNA extraction and RT-PCR 
Aurum total RNA mini kit was from BioRAD (Hemel Hempstead, UK) and RNAse 
away spray bottle from Fisher Scientific Ltd (Loughborough, Leicestershire, UK). 
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TaqMan microRNA assays U6 SnRNA (product# 001973), has-miR-21 (product# 
000397) TaqMan micro primers, TaqMan® Gene expression Master Mix, TaqMan® 
Universal Master Mix II, no UNG, TaqMan® microRNA Reverse Transcription Kit and 
all PCR primers listed in Table 2.1 were purchased from Life Technologies (Paisley, 
UK). Reverse gene transcription system was obtained from Promega (Southampton, 
UK). 96 well- PCR plate and 0.2 ml PCR tubes were from STARLAB (Milton Keynes, 
UK). RT2 Profiler human atherosclerosis PCR array (12 plates, Cat# PAHS-038ZA-
12) and RT2 SYBR Green/ROX PCR master mix (Cat# 330522) were from QIAGEN 
(Manchester, UK). 
 
Table 2.1 Real time-PCR primers 
 
TaqMan 
primers 
 
Cat number 
 
Exon 
boundary 
 
Amplicon 
length 
 
Col 1A1 
 
Hs00164004_m1 
 
1 - 2 
 
66 
 
MMP-1 
 
Hs00233958_m1 
 
6 - 7 
 
133 
 
MMP-2 
 
Hs00234422_m1 
 
12 - 13 
 
83 
 
MMP-3 
 
Hs00968305_m1 
 
6 - 7 
 
126 
 
RECK 
 
Hs01019179_m1 
 
20 - 21 
 
69 
 
IL-1α 
 
Hs00174092_m1 
 
6 - 7 
 
69 
 
GAPDH 
 
Hs99999905_m1 
 
3 - 3 
 
122 
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Table 2.2 Atherosclerosis array layout (96-well) 
  
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
 
12 
 
A 
 
ABCA1 
 
ACE 
 
APOA1 
 
APOB 
 
APOE 
 
BAX 
 
BCL2 
 
BCL2A1 
 
BCL2L1 
 
BID 
 
BIRC3 
 
CCL2 
 
B 
 
CCL5 
 
CCR1 
 
CCR2 
 
CD44 
 
CDH5 
 
CFLAR 
 
COL3A1 
 
CSF1 
 
CSF2 
 
CTGF 
 
EGR1 
 
ELN 
 
C 
 
ENG 
 
FABP3 
 
FAS 
 
FGA 
 
FGF2 
 
FN1 
 
HBEGF 
 
ICAM1 
 
IFNAR2 
 
IFNG 
 
IL1A 
 
IL1R1 
 
D 
 
IL1R2 
 
IL2 
 
IL3 
 
IL4 
 
IL5 
 
ITGA2 
 
ITGA5 
 
ITGAX 
 
ITGB2 
 
KDR 
 
KLF2 
 
LAMA1 
 
E 
 
LDLR 
 
LIF 
 
LPA 
 
LPL 
 
MMP1 
 
MMP3 
 
MSR1 
 
NFKB1 
 
NOS3 
 
NPY 
 
NR1H3 
 
PDGFA 
 
F 
 
PDGFB 
 
PDGFRB 
 
PLIN2 
 
PPARA 
 
PPARD 
 
PPARG 
 
PTGS1 
 
RXRA 
 
SELE 
 
SELL 
 
SELPLG 
 
SERPINB2 
 
G 
 
SERPINE1 
 
SOD1 
 
SPP1 
 
TGFB1 
 
TGFB2 
 
THBS4 
 
TNC 
 
TNF 
 
TNFAIP3 
 
VCAM1 
 
VEGFA 
 
VWF 
 
H 
 
ACTB 
 
B2M 
 
GAPDH 
 
HPRT1 
 
RPLP0 
 
HGDC 
 
RTC 
 
RTC 
 
RTC 
 
PPC 
 
PPC 
 
PPC 
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ABCA1: ATP-Binding Cassette A1; ACE: Angiotensin I Converting Enzyme; APOA1: Apolipoprotein A-1; APOB: Apolipoprotein B; APOE: 
Apolipoprotein E; BAX: BCL2-Associated X Protein; BCL2: B-Cell CLL/Lymphoma 2; BCL2A1: B-Cell CLL/Lymphoma 2 -Related Protein 
A1; BCL2L1: B-Cell CLL/Lymphoma 2 -Like 1; BID: BH3 Interacting Domain Death Agonist; BIRC3: Baculoviral IAP Repeat Containing 3; 
CCL2: Chemokine (C-C Motif) Ligand 2; CCL5: Chemokine (C-C Motif) Ligand 5; CCR1: Chemokine (C-C Motif) Receptor 1; CCR2: 
Chemokine (C-C Motif) Receptor 2; CD44: CD44 Molecule (Indian Blood Group); CDH5: Cadherin 5, Type 2 (Vascular Endothelium); 
CFLAR: CASP8 And FADD-Like Apoptosis Regulator; COL3A1: Collagen, Type III, α1; CSF1: Colony Stimulating Factor 1 (Macrophage); 
CSF2: Colony Stimulating Factor 2 (Granulocyte-Macrophage); CTGF: Connective Tissue Growth Factor; EGR1: Early Growth Response 
1; ELN: Elastin; ENG: Endoglin; FABP3: Fatty Acid Binding Protein 3, Muscle And Heart; FAS: Fas Cell Surface Death Receptor; FGA: 
Fibrinogen α Chain; FGF2: Fibroblast GF 2; FN1: Fibronectin 1; HBEGF: Heparin-Binding EGF-Like Growth Factor; ICAM1: Intercellular 
Adhesion Molecule 1; IFNAR2: Interferon (α, β And Ω) Receptor 2; IFNG: Interferon, γ; IL1A: Interleukin 1, α; IL1R1: Interleukin 1 Receptor, 
Type I; IL1R2: Interleukin 1 Receptor, Type II; IL2: Interleukin 2; IL3: Interleukin 3; IL4: Interleukin 4; IL5: Interleukin 5; ITGA2: Integrin, α2; 
ITGA5: Integrin, α5; ITGAX: Integrin, α X; ITGB2: Integrin, β2; KDR: Kinase Insert Domain Receptor; KLF2: Kruppel-Like Factor 2; LAMA1: 
Laminin, α1; LDLR: Low Density Lipoprotein Receptor; LIF: Leukemia Inhibitory Factor; LPA: Lipoprotein, Lp(A); LPL: Lipoprotein Lipase; 
MMP1: Matrix Metallopeptidase 1; MMP3: Matrix Metallopeptidase 3; MSR1: Macrophage Scavenger Receptor 1; NFKB1: Nuclear Factor 
Of Kappa Light Polypeptide Gene Enhancer In B-Cells 1; NOS3: Nitric Oxide Synthase 3 (Endothelial Cell); NPY: Neuropeptide Y; NR1H3: 
Nuclear Receptor Subfamily 1, Group H, Member 3; PDGFA: Platelet-Derived Growth Factor α Polypeptide; PDGFB: PDFG β Polypeptide; 
PDGFRB: Platelet-Derived Growth Factor Receptor, β Polypeptide; PLIN2: Perilipin 2; PPARA: Peroxisome Proliferator-Activated Receptor 
α; PPARD: Peroxisome Proliferator-Activated Receptor δ; PPARG: Peroxisome Proliferator-Activated Receptor γ; PTGS1: Prostaglandin-
Endoperoxide Synthase 1; RXRA: Retinoid X Receptor, α; SELE: Selectin E; SELL: Selectin L; SELPLG: Selectin P Ligand; SERPINB2: 
Serpin Peptidase Inhibitor, Clade B (Ovalbumin), Member 2; SERPINE1: Serpin Peptidase Inhibitor, Clade E (Nexin, Plasminogen Activator 
Inhibitor Type 1), Member 1; SOD1: Superoxide Dismutase 1; SPP1: Secreted Phosphoprotein 1; TGFB1: Transforming Growth Factor, β1; 
TGFB2: Transforming Growth Factor, β2; THBS4: Thrombospondin 4; TNC: Tenascin C; TNF: Tumor Necrosis Factor; TNFAIP3: TNF α -
Induced Protein 3; VCAM1: Vascular Cell Adhesion Molecule 1; VEGFA: Vascular Endothelial Growth Factor A; VWF: Von Willebrand 
Factor; ACTB: Actin, β; B2M: β-2-Microglobulin; GAPDH: Glyceraldehyde-3-Phosphate Dehydrogenase; HPRT1: Hypoxanthine 
Phosphoribosyltransferase 1; RPLP0: Ribosomal Protein, Large, P0; HGDC: Human genomic DNA contamination; RTC: Reverse  
transcription control; PPC: Positive PCR control.   
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 Western blotting reagents  
Pierce BCA protein assay was from Life Technologies (Paisley, UK), copper (II) 
sulphate solution, PMSF, sodium vanadate, SDS, TEMED, and APS were purchased 
from Sigma-Aldrich (Poole, Dorset, UK). ProtoFLOWgel Acrylamide was from 
Flowgen Bioscience (Nottingham, UK) and molecular weight marker precision plus 
protein from Bio-RAD Laboratories (Hemel Hempstead, UK). PVDF transfer 
Immobilon-P membrane from Merck Millipore (Nottingham, UK). 
 
Primary monoclonal antibodies were all purchased from Cell Signaling Technology 
New England Biolabs (Hitchen, Hertfordshire, UK), except β-actin that was from 
Abcam (Cambridge, UK). ECL Horseradish peroxidase (HRP)-conjugated secondary 
antibodies anti-rabbit and anti-mouse IgG, and Amersham ECL Prime Western 
blotting detection reagent were all from GE Healthcare (Little Chalfont, 
Buckinghamshire, UK). Developer and fixer solutions were from Kodak GBX 
(Rochester, NY, USA).  
 
 Modulation of miR-21 levels in SV-SMC 
Lipofectamine® 2000 reagent was purchased from Invitrogen (Paisley, UK). Anti-
miR miRNA inhibitor (has-miR-21-5p; product# AM17000), anti-miR negative control 
(product# AM17010), pre-miR miRNA precursor (has-miR-21-5p; product# AM17100) 
and premiR negative control (product# AM17110) were all obtained from Life 
Technologies (Paisley, UK). 
 
 Staining reagents 
Glass coverslips (10 mm diameter) were obtained from Scientific Laboratory 
Supplies (Hessle, UK). Paraformaldehyde, Triton X-100, normal goat serum and 
mouse monoclonal anti-α-SMA clone 1A4 were from Sigma-Aldrich (Poole, Dorset 
UK). SM-MHC antibody was from Cambridge (UK) and Vectashield® mounting media 
with DAPI counterstain was from Vector Laboratories (California, USA). The 
fluorescent cyanine dye (Cy3), and tagged FITC secondary IgG antibodies were 
obtained from Jackson ImmunoResearch (Newmarket, Suffolk, UK). Rhodamine 
phalloidin was from Life Technologies (Paisley, UK). 
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2.2. Methods 
 Cell culture 
Human SV specimens were obtained from T2DM and ND patients undergoing 
elective CABG surgery at the General Infirmary of Leeds. Patient consent was 
obtained before each surgery and local ethical committee guidelines were followed 
(LREC reference is CA01/040). SV was chopped into small fragments and cultured in 
2 ml of 10% FCS in DMEM, containing normal concentration of D-glucose (5.5 mM), 
1% antibiotic-antimicotic and glutamine (full growth media; FGM) in 25 cm2 tissue 
culture flask with a constant supply of 5% CO2 at 37 oC in a humidified incubator. Cells 
were then explanted and allowed to grow to confluence in FGM using an explant 
technique (Porter et al., 2002) as shown in Figure 2.1. Half media was changed twice 
a week and when confluence was reached, the cells were subcultured to passage 
number 1 into a 75 cm2 tissue culture flask and after confluence, cells divided for the 
second passage of 3 75 cm2 flasks. All following experiments were performed using 
cells at passages 3 to 5 and all repeat experiments were performed on cells derived 
from different individuals.  
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Figure 2.1: Diagram shows SMC explants from intact SV segment. 
SV segment was obtained from a patient undergoing CABG surgery (A), chopped SV 
was cultured in 2 ml of FGM in 25 cm2 tissue culture flask (B). Representative phase 
contrast microscopic image of SMC explanting from small fragments (C) until they 
reach confluence (D), original magnification (x100). 
 
  
C D 
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 Modulation of miR-21 levels in SV-SMC  
Under sterile conditions, SV-SMC of ND and T2DM patients were plated in six-well 
plates at a density of 70,000 cells in 2 ml of FGM and grown for 24 h before 
transfection.  
 
 
For miR-21 overexpression, ND SMC were transfected with premiR-21 at a final 
concentration of 30 nM according to the protocol listed in Table 2.3. For miR-21 
knockdown, cells were transfected with antimiR-21 at a final concentration of 100 nM 
as described in Table 2.4. In each case, reagents in tube 1 were mixed and allowed 
to incubate for 5 min, this was then added to the mixture in tube 2 and incubated for 
20 min at room temperature (RT). Pre-warmed (37 oC) 0.4% FCS media; which is the 
minimum growth media (MGM) was then added (2 ml) to transfection reagents in tube 
2, this will make 4 ml total volume of each treatment and subsequently 2 ml of the 
mixture was loaded into the cells in each well after being washed once in PBS. The 
plate was then incubated for 6 h, old media was replaced by fresh MGM, and cells 
harvested after 72 h or at a particular time point.  
 
Table 2.3 PremiR-21 transfection reagents 
 
 
 
Tube 1 
 
Tube 2 
 
Reagent 
30 nM 
PremiR-
21 
30 nM 
PremiR-ve 
 
Optimem 
 
Lipofectamine 
 
Optimem 
 
Un-
transfected 
 
- 
 
- 
 
1 ml 
 
- 
 
1 ml 
 
Mock 
 
- 
 
- 
 
1 ml 
 
10 µl 
 
990 µl 
 
PremiR-ve 
 
- 
 
6 µl 
 
994 µl 
 
10 µl 
 
990 µl 
 
PremiR-21 
 
6 µl 
 
- 
 
994 µl 
 
10 µl 
 
990 µl 
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Table 2.4 AntimiR-21 transfection reagents 
 
 
 
Tube 1 
 
Tube 2 
 
Reagent 
100 nM 
AntimiR-
21 
100 nM 
AntimiR-   
-ve 
 
Optimem 
 
Lipofectamine 
 
Optimem 
AntimiR-ve  
- 
 
20 µl 
 
980 µl 
 
10 µl 
 
990 µl 
AntimiR-21  
20 µl 
 
- 
 
980 µl 
 
10 µl 
 
990 µl 
 
 Characterisation of SMC 
 
 α-SMA and SM-MHC immunostaining 
SMC were seeded on 10 mm glass coverslips in a 24 well plate and serum-starved 
for 3 days. Coverslips were then washed with PBS and cells were fixed with 200 µl of 
4% paraformaldehyde in PBS for 20 min on the rocking plate. After washing with PBS 
(x3), cells were permeabilised with 0.1% Triton X-100 in PBS for 30 min followed by 
washing twice with 5% BSA-PBS-Tween. Nonspecific binding was subsequently 
blocked by incubating the coverslips in 5% BSA-PBS-Tween-20 for 15 min at RT, then 
coverslips were washed and incubated overnight with primary antibody (1:200 for α-
SMA and 1:100 for SM-MHC) at 4 oC in a humidified chamber.  
 
 
After 24 h, coverslips were washed and incubated with the secondary fluorescent 
tagged FITC IgG with a dilution of 1: 200 (anti-mouse) and 1:400 (anti-rabbit) 
antibodies in PBS-Tween for 4 h at RT in the dark. After this time, the slips were 
washed with PBS-Tween (x3), PBS (x2) and distilled water (x1) and finally mounted 
using ProLong® Gold Antifade Mountant with the nuclear stain; DAPI and cells were 
visualised using LSM510 Upright Confocal microscope with x200 magnification 
power. Cy3 excitation wavelength of 550 nm and 570 nm emission and FITC 
excitation wavelength of 495 and emission at 519 nm.  
 
 F-actin staining with Rhodamine phalloidin 
Cells were grown on glass coverslips, transfected with premiR-21 and antimiR-21 
(as described in section 2.2.2) and incubated with MGM for 72 h. They were washed 
and fixed as previously mentioned (section 2.2.3A). The cells were then permeablised 
and blocked for nonspecific binding for 5 min using 10% goat serum in 0.05% Triton 
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X-100 in PBS. Cells were incubated for 20 min in the dark with rhodamine phalloidin 
(1:40) in PBS that was utilised to label F-actin fibres. Coverslips were washed and 
mounted and F-actin fibres were visualised using a LSM510 Upright Confocal 
microscope.  
 
 Cell proliferation  
SV-SMC proliferation was determined by in vitro cell counting using a 
haemocytometer. Cells were seeded at a density of 1 x 104 cells/well in 1 ml of FGM 
in 24-well tissue culture plate in quadruplicate wells and incubated for 24 h to allow 
cell attachment. The next day, cells were incubated in serum-free media (SFM) for 72 
h. For cell counting, media was removed, cells were washed with 1 ml PBS, gently 
detached by 200 µl trypsin then pelleted in 800 µl FGM by centrifugation at 600 x g 
for 6 min at 4 oC. 50 µl of the precipitate was resuspended with 50 µl of trypan blue 
dye and cells were counted using the haemocytometer under the microscope (x200 
power). This was designated as day 0, and SFM in remaining cells was replaced by 
1 ml of FGM containing appropriate stimuli to allow cell growth. Afterwards, the 
number of cells was counted for the days specified to construct the proliferation curve. 
 
 Cell morphology 
Light microscopic images were captured for subconfluent cells (~60%) in a T75 
culture flask under the light microscope at x100 magnification that was connected to 
the camera. For each patient, cell area was measured by tracing the areas of 50 cells 
using imageJ program (1.46r, USA; http://rsb.info.nih.gov/ij/). Fluorescence and 
immunostaining images were visualised using a LSM510 Upright Confocal 
microscope. 
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 Boyden chamber assay 
Migration and invasion of SV-SMC were assayed using a modified Boyden 
chamber technique (Figure 2.2) in a 24 well-specialised plate, in which the upper and 
lower compartments were separated by 6.4 mm diameter filter membrane with 8 µm 
pores.  
 
 
Figure 2.2: A modified Boyden chamber Diagram. 
SMC were placed in the upper compartment of the insert and allowed to migrate 
through the porous membrane toward the media containing chemoattractant in the 
lower compartment. 
 
 Migration assay 
ND SV-SMC were serum starved for 48 h prior to being trypsinised and 
resuspended in FGM. The resultant cell suspension was then centrifuged at 600 x g 
for 6 min at 4 oC and the pellet was re-centrifuged in SFM and finally suspended in 
MGM.  
 
Chemoattractant PDGF-BB (10 ng/ml) was added to 0.75 ml of MGM in the lower 
chamber of the 24 well plate to stimulate cell migration towards the lower 
compartment. Cells migrated towards MGM alone as a control group was also carried 
out. 1 x105 cells in each insert in 0.5 ml of cell suspension of MGM were gently added 
to the top chamber and migration was allowed to proceed for 6 h inside the incubator.  
Cells were fixed in pre-cooled (-20 oC) 70% Ethanol for 30 min, then chambers were 
rinsed with water 3 times and non-migrating cells in the upper compartment were 
scraped off by cotton swabs and washed out. 
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Migrated cells on the underside of the chamber were stained with haematoxylin-
purple to stain the nuclei then eosin-orange colour solutions to stain the proteins and 
cytoplasm of the cell, each for 30 seconds (s) and inserts were dipped in water 
between the 2 stains. The stained membrane was then briefly dried, peeled off the 
insert and mounted on a labelled glass microscope slide, using warm glycerol gelatin 
drops and pressed by coverslips. The number of migrated cells in 10 random fields 
was finally determined by counting the number of stained nuclei. Data were expressed 
as the average number of migrated cells (10 high-power fields/well) per view (at x200 
magnification power) on duplicate membranes for each condition. 
 
 Invasion assay 
The invasion assay was essentially the same as the migration assay, except it used 
inserts in which the 8 µm pores were pre-occluded with collagen I or III and was 
performed by incubation for 24 h to allow cells to digest the collagen before migrating 
towards the chemoattractant. Conditioned media (CM) in the upper compartment 
were collected to measure MMP-1 secreted from invaded cells, centrifuged to pellet 
out the debris, snap frozen and stored at -80 oC. Invaded cells were counted as 
described in the previous paragraph. 
 
 Measurement of MMP-1 protein using ELISA 
 
 Human Pro-MMP-1   
The MMP-1 Human ELISA (Enzyme-Linked Immunosorbent Assay) is an in vitro 
assay for the quantitative measurement of human pro-MMP1 form in the CM collected 
from invading cells through Boyden chambers. 
 
The assay was conducted according to the manufacturer’s protocol. Briefly, 
standards (concentration from 0.156 - 10 ng/ml) were prepared from calibrator diluent 
RD5-19 and reconstituted Pro-MMP-1 standard. 100 µl of the assay diluent RD1-52 
was added into the appropriate wells of the ELISA plate precoated with a monoclonal 
antibody specific for human pro-MMP-1. 100 µl of the standard and sample aliquots 
of CM were loaded into the specific wells in duplicate, the plate was sealed and 
incubated for 2 h at RT on a horizontal shaker. 
 
The wells were washed four times using diluted washing buffer (25x diluted), by 
filling each well using a squirt bottle with complete removal of all washing buffer by 
inverting the plate over a piece of tissue and striking on the lab bench. 200 µl of the 
Pro-MMP-1 conjugate was added to the wells, then the plate was incubated for 2 
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hours (h) at RT. Wells were washed again and 200 µl of substrate solution was added 
and the plate incubated for 20 minutes (min) in the dark.  
 
Finally, 50 µl of stop solution was added to the substrate, making the colour change 
from blue to yellow. Finally, the optical density was determined within 30 min using a 
microplate reader at 450 nm wavelength. Then the standard curve was constructed 
and average readings for standard and samples were measured. If any sample has 
been diluted, the concentration reading was multiplied by the dilution factor. 
 
 Human active MMP-1 ELISA 
This was a fluorimetric assay, in which the fluorescence intensity represented the 
MMP-1 activity. In brief, the MMP-1 standard was reconstituted with calibrator diluent 
RD5-25 and standard serial dilution was processed from highest concentration 25 
ng/ml to lowest 0.39 ng/ml. 100 µl of assay diluent was added to each well of the 
monoclonal antibody pre-coated MMP-1 black microplate, followed by 150 µl of the 
standard or samples in duplicate. The plate was covered and incubated for 3 h at RT 
on a horizontal shaker. After washing away any unbound substances as mentioned 
in section 2.2.7A, an activation reagent p-Amino Phenyl Mercuric Acetate (APMA) 
was added to the standard wells and 200 µl reagent diluents 2 was added to samples. 
  
The plate was then sealed and incubated for 2 h at 37 oC in a humidified incubator. 
Wells were washed and 200 µl of fluorogenic substrate linked to a quencher molecule 
was added to all wells in a low light environment and the plate was incubated for 18 
h in a dark humidified incubator. Any available active enzyme would split the peptide 
bond between the fluorophore and the quencher molecule. This cleavage produced a 
fluorescent signal that was measured at a wavelength of 320 nm and an emission 
wavelength 405 nm. The relative fluorescence units were assessed by using Fluostar 
Omega reader BMG Labtech (Offenburg, Germany). 
 
 Reverse transcription real time –polymerase chain reaction (RT- 
PCR) 
To analyse mRNA expression, three main steps were performed. Firstly RNA was 
extracted from pelleted cells (A), secondly the complementary DNA (cDNA) was 
synthesised from RNA (B), and finally amplification of cDNA by real time- PCR was 
performed using specific TaqMan primers/ probes (C). All steps were carried out in a 
DNA-free environment to avoid amplification of contaminating DNA. 
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 Pellet preparation and RNA extraction 
For cells in 6 and 12 well plates: wells were washed with 2 ml PBS then cells were 
trypsinised with 0.5 ml trypsin and cells collected in 6 ml (3 ml each time) of cold (4 
oC) PBS in a 15 ml falcon tube. Cells were centrifuged at 600 g for 6 min, the 
supernatant was poured off and tubes were drained upside down before storage at      
-80 oC.  
 
Total RNA was extracted using the BioRad Aurum Total RNA mini kit. According to 
the manufacturer’s instructions, the pellet was treated with 350 µl lysis solution and 
350 µl RNAse-free 70% ethanol and the mixture was transferred to the corresponding 
labelled total RNA mini-column within a collection tube, then centrifuged at 13,000 g 
for 30 s. The flow-through was discarded, then the column was washed with 700 µl 
low stringency wash solution and centrifuged for 30 s. To remove genomic DNA 
contamination, 80 µl of diluted DNAse (5 µl of DNAse 1 : 75 µl DNA dilution solution) 
was added to each column and incubated at RT for 15 min. Afterwards, the column 
was centrifuged at 13,000 g for 30 s. The column was washed with 700 µl high 
stringency solution followed by 700 µl low stringency wash solution and centrifuged 
twice to dry the column. Finally, 80 µl of preheated (70 oC) elution solution was added 
to the column, incubated for 1 min and microfuged into a clean microcentrifuge tube 
at 13,000 g for 2 min. RNA samples were stored at -80 oC until required. 
 
 Real time PCR for gene expression 
Step 1: Generating cDNA and reverse transcription  
cDNA was prepared from RNA according to the Promega Reverse Transcription 
System manufacturer’s protocol. The extracted RNA was thawed and 5 µl in 0.2 ml 
PCR tube was preheated using the pre-RT program on BIO-RAD T100 Thermal 
cycler, in which the RNA was heated up to 70 oC for 10 min then cooled back to 4 oC 
to remove any secondary structure produced by the RNA extraction process. For each 
RNA sample, reverse transcription was carried out by preparation of master mix from 
the following reagents listed in Table 2.5.  
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Table 2.5 Master mix reagents used for RNA reverse transcription 
 
Reagents 
 
Volume 
(µl) 
 
Function 
 
25 mM MgCl2 
 
4 
Helps primer annealing and acts as a 
cofactor for reverse transcriptase 
 
RT 10X buffer 
 
2 
 
Regulates pH of the reaction at 8.5 
 
10 mM dNTP 
 
2 
 
Building blocks for new cDNA strand 
 
RNAsin 
 
0.5 
Inhibits ribonuclease, to minimise RNA 
degradation in the reaction 
 
AMV RT 
 
0.6 
Reverse transcriptase enzyme, uses RNA 
template to synthesise new cDNA strand  
Random 
primers 
 
1 
For RT enzyme to anneal to the RNA and 
provides 3’OH group as a starting point 
 
H2O 
 
7.9 
 
Makes the total volume up to 18 µl 
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To generate cDNA in a 20 µl reaction, 2 µl from each heated RNA sample was 
mixed with 18 µl of the master mix in an individual 0.2 ml PCR tube and loaded in the 
thermal cycler on the reverse transcription program. In which total 33 min, divided 
between 10 min at 25 oC to permit the random primers to anneal to the RNA, 15 min 
at 42 oC to reverse transcribe the second strand, 5 min at 95 oC to terminate the 
reaction and denature the reverse transcriptase enzyme and finally hold at 4 oC. 
  
Step 2: Gene expression analysis 
Applied Biosystems TaqMan® Gene expression Assays, were used to amplify 
cDNA. TaqMan probes consist of a specific TaqMan® probe with a fluorogenic FAM 
reporter dye label on the 5’ end and a nonfluorescent quencher at the 3’ end and 
primers specific to the gene of interest. In a small tube, 10 μl of TaqMan Universal 
MasterMix II containing UNG (to prevent DNA contamination) was mixed with 0.5 μl 
specific TaqMan primer/probe (primers used are listed in table 2.1) and 7.5 μl 
nuclease free water. 18 μl of this mixture was loaded into each well in a 96-well plate 
plus 2 μl of each cDNA was used to measure target and control genes. To ensure 
accurate measurements, each sample was measured in triplicate.  
 
The plate was sealed and centrifuged for 10 s to pull down all ingredients, then RT-
PCR was performed using 7500 Real-Time PCR System under the following 
conditions: heating the samples up to 50 °C for 2 min (for optimal AmpErase ® UNG 
activity), then 95 °C for 10 min for activation of DNA polymerase and then 50 cycles 
of reaction at 95 ºC for 15 s and 60 °C for one min to enable primer/ probe annealing 
and DNA synthesis. When the complementary second strand was synthesised, the 
DNA polymerase cleaved the probe 5` to 3`, liberating the fluorescent FAM from the 
3` quencher. Results were analysed using 7500 System SDS software version 1.2.3. 
  
Fluorescent signals were normalised to an internal reference and the threshold 
cycle number (Ct) calculated, which is the number of amplification cycles of the PCR 
reaction at which fluorescence reached a defined threshold in the linear region of the 
curve (see Figure 2.3). The difference between Ct values for the target gene and 
endogenous control (GAPDH) gene is referred as ΔCt (i.e. ΔCt = Ct (target) – Ct 
(control)). The difference between ΔCt values for the target and endogenous control 
reflect the relative amount of target gene in comparison to the control and it is 
calculated as the following: 
ΔΔCt = ΔCt (target gene) - ΔCt (endogenous control) 
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Relative quantification (RQ) represents relative quantification based on the relative 
expression of a target gene versus a reference gene and it was calculated by the 
formula (RQ) = 2-ΔΔ Ct. 
 
 
Figure 2.3: Amplification plots for RT-PCR. 
Amplification plots showing the fluorescent signal from each sample plotted against 
cycle number (Ct). The threshold line was fixed at 0.2 in the exponential amplification 
region for both control and sample Ct. 
 
  
(Ct) 
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 Specific RT-PCR for microRNA-21 expression 
 
Step 1: Reverse transcription for miR-21 expression 
To detect miR-21 expression levels in SV-SMC relative to U6 (internal control), 
RNA was first reverse transcribed with TaqMan® MicroRNA Reverse Transcription 
Kit to produce cDNA. Master mix was prepared (each reaction) by mixing 0.08 μl 
dNTP (100 mM) (source of dNTPs to form the new cDNA strand), 0.54 μl multiscribe 
TM reverse transcriptase enzyme (50 U/ μl) (to synthesize the new strand) 0.8 μl 10 
x RT buffer, 0.103 μl RNase inhibitor (20 U/ μl) (to prevent any RNAse in the reaction) 
plus 3.815 μl nuclease free water. 5.34 μl of the prepared master mix was loaded into 
labelled 0.2 ml PCR tubes, 1.05 μl of each RNA sample was added into the PCR tube 
and 1.6 μl of TaqMan specific primer (miR-21 and U6; x 5).  
 
Contents were mixed and tubes were then centrifuged for 10 s, kept on ice for 2 
min and finally placed in a BIO-RAD T100 Thermal cycler and exposed to microRNAs 
reverse transcription program, which heats the RNA up to 16 oC for 30 min to help 
random primers to anneal to RNA, then to 42 oC for 30 min to allow reverse 
transcriptase enzyme to catalyse synthesis of the second strand and 85 oC for 5 min 
to stop the reaction and denature the reverse transcriptase enzyme. Finally, tubes 
were held at 4o C to be used for the next step. 
 
Step 2: Measuring miR-21 expression 
This was carried out by mixing (for 1 reaction) 10 μl of TaqMan® Universal Master 
Mix II (no UNG) plus 1 μl of the fluorescent TaqMan specific primer (miR-21 or U6; x 
20) and 7 μl nuclease free water. Then 18 μl of these two mixtures was added to the 
specified well in the 96 well PCR plate and 2 μl of the cDNA was added subsequently 
then real-time PCR was performed as previously described in step 2 section 2.2.8. 
% Relative to U6 = 2-ΔΔCt x 100 was used to calculate expression level of miR-21 
normalised against U6 and an average of 5 experiments with a standard error of the 
mean is commonly presented.  
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 Atherosclerosis microarray analysis 
The purpose of the array was to detect the potential cardiovascular genes that can 
be regulated by using RNA samples from premiR-21 transfected cells. An individual 
full RT2 Profiler human atherosclerosis PCR microarray (96 well plate) was utilised for 
each RNA sample of the premiR-negative and premiR-21 transfected cells of 4 
different patients. 2.5 µl of the preheated RNA sample was added to the master mix 
that was prepared as listed in Table 2.5. cDNA was then diluted 6 times with distilled 
H2O into 121 µl diluted cDNA and 2 µl of it was used for GAPDH RT-PCR analysis 
test to check the quality of cDNA before being loaded onto the plate. RT2 SYBR 
Green/ROX PCR master mix (1350 µl) was added to 102 µl of the diluted cDNA and 
1248 µl of dH2O (experimental cocktail). 25 µl of this cocktail was loaded to wells of 
the microarray plate in which each well contains different primers of genes involved 
in cardiovascular related diseases. 5 wells for housekeeping genes were also 
included in each plate and others that act as positive and negative controls and one 
for DNA contamination. The plate was then covered by the adhesive film, briefly 
centrifuged and placed in the 7500 RT-PCR System (See figure 2.4). 
 
The SYBR Green PCR array protocol was followed which involved first 2 stages 
set at 95 oC at 10 min (for DNA denaturation) and at 15 s (for primers annealing and 
DNA extension) for 50 cycles then the third stage at 60 oC for 1 min for detection. For 
each patient, the difference between ΔCt values for the target and the average of 5 
endogenous controls reflect the relative amount of target gene in comparison to the 
control: ΔΔCt = ΔCt (Target gene) - ΔCt (average of housekeeping genes). 
Ct values were exported to an excel file to create a table of Ct value for each gene 
in each pair. RQ represents relative quantification based on the relative expression of 
a target gene versus a reference gene and it was calculated manually by the formula 
(RQ) = 2-ΔΔCt. 
 
The cut-off value was measured for each plate by adding 12 (arbitrary number to 
take into account the undetectable Ct values above 35 cycles) to the average 
geometric Ct value of their housekeeping genes and this value was then replaced any 
test Ct value above the cut-off. Finally, fold change between 2^-dCt of the test (premiR-
21) over control (premiR-negative) was calculated manually for each pair and genes 
that showed sizeable and consistent fold change in premiR-21 transfected cells were 
then verified by RT-PCR using TaqMan specific primers. 
 
68 
 
 
Figure 2.4: Protocol showing the PCR array procedure. 
SV-SMC of ND patients were transfected with 30 nM of premiR-21 or premiR-negative 
for 6 h followed by 72 h incubation in MGM. Cells were then pelleted, RNA extracted 
and mixed with the master mix to form cDNA. This was then diluted with water and 
mixed with RT2 SYBR Green/ROX PCR master mix. 25 µl of this cocktail was loaded 
to wells of the microarray plate which was placed in the 7500 RT-PCR System to 
measure amplification of genes. 
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 Western immunoblot analysis 
Proteins isolated from SV-SMC were determined by western blot analysis, in which 
70,000 cells/ well were cultured in a 6-well plate and harvested at a particular time 
point using sample lysis buffer, separated by gel electrophoresis, protein transferred 
onto PVDF membranes and finally probed with the appropriate antibody.  
 
 Cell lysate 
Cells were washed once with 2 ml of cold PBS (4 oC) and lysed in 80 µl of SDS-
PAGE sample lysis buffer (Table 2.6) together with 0.5% PMSF (protease inhibitor) 
and 1% sodium vanadate (phosphatase inhibitor). For example; for 2 wells, 0.25 ml 
of sample buffer was mixed with 1.25 µl of PMSF and 2.5 µl of sodium vanadate. 
 
 
                     Table 2.6 SDS-PAGE sample lysis buffer preparation 
 
Reagent 
 
Volume 
 
500 mM Tris-HCl, pH 6.8 
 
25 ml 
 
Glycerol 
 
20 ml 
 
dH2O 
 
43 ml 
 
100 mM EDTA 
 
2 ml 
 
20% SDS 
 
2 ml 
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After mixing with sample buffer using a cell scraper, cells were collected in 1.5 ml 
screw-cap eppendorf tubes and samples were then boiled for 5 min in a water bath.  
8 µl (1 tenth of the total volume) of cooled protein was removed into a separate tube 
for subsequent protein analysis. β- mercaptoethanol and bromophenol blue solution 
was mixed in a ratio of 10:1 and 8 µl of this mixture were added to each sample tube. 
Samples were then mixed, boiled again for 4 min, cooled and freezed at -20 oC until 
analysis. 
 
 Protein assay 
Protein concentrations of total cell lysates were measured using Pierce 
bicinchoninic acid (BCA) protein assay kit. Protein samples were diluted 1:8 with dH2O 
by adding 56 µl water to the 8 µl of protein samples. A standard curve was then 
prepared in 96 well protein assay plate using 1 mg/ml BSA by aliquoting 25 µl of 
standard samples of 0, 31.25, 62.5, 125, 250, 500 and 1000 µg/ml and experimental 
diluted samples all in duplicate wells. 200 µl of BCA protein assay (a ratio of 50:1 
mixture of BCA and 4% copper II sulphate solution) was added to each well using a 
multichannel pipette and the plate incubated at 37 oC for 30 min. Absorbance was 
measured at 562 nm using (BIORAD iMark) microplate reader, a standard curve was 
generated and protein content of samples was estimated from the standard curve. 
 
 SDS-PAGE immunoblotting 
After assembling gel equipment with 1 mm casting cassettes, separating and 
stacking gels were prepared from reagents listed in Table 2.7, and TEMED was added 
immediately before pouring the gels. 
 
Separating buffer gel was poured into the double glass plate and top surface was 
covered with thin layer of water-saturated isobutanol. After polymerisation, isobutanol 
was poured off and any remaining dried with filter paper, stacking buffer gel was 
added into the top layer, the comb was placed directly over it and gel allowed to 
polymerise for 20 min.  
 
Afterwards, 350 ml of running buffer was prepared from 70 ml 5x running buffer 
(144 g of glycine, 30 g of Tris-base and 10 g of SDS made up to 2 litres with dH2O) 
and 280 dH2O and poured to fill the bottom of assembled gel apparatus with the 2 
plates of gel facing each other inside the tank. For immunoblotting, an equal amount 
of protein of cell lysates (20 - 30 µg) per well was loaded onto the SDS-PAGE 10% 
polyacrylamide gels (unless otherwise stated) with the addition of sample buffer in the 
blank wells and pre-stained molecular weight markers. Electrophoresis was then run 
at 150 V for 55 min until the blue dye front reached the bottom of the gel.  
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    Table 2.7 Polyacrylamide gel (10 and 7.5 %) ingredients 
 
Reagents 
 
Separating gel 
 
Stacking gel 
  
10% gel 
 
7.5% gel 
 
 
dH2O 
 
6 ml 
 
7.5 ml 
 
3.05 ml 
ProtoFLOWgel 
Acrylamide 
 
5 ml 
 
3.5 ml 
 
0.65 ml 
 
Separating gel buffer 
 
3.75 ml 
 
3.75 ml 
 
-- 
 
Stacking gel buffer 
 
-- 
 
-- 
 
1.25 ml 
 
10% SDS 
 
150 µl 
 
150 µl 
 
50 µl 
 
10% APS (100 mg/ml) 
 
75 µl 
 
75 µl 
 
25 µl 
 
TEMED 
 
30 µl 
 
30 µl 
 
20 µl 
 
 
Separated proteins were transferred onto pre-wetted (methanol, dH2O, then 
transfer buffer, 5 min each) labelled PVDF membranes that were stacked in the 
transfer cassette in the middle of 2 wet sponges and 6 filter papers for each gel, this 
was subjected to electrophoresis at 100 V for 2 h (on ice) in a tank filled with transfer 
buffer (188 mM glycine, 25 mM tris-base, and 20% methanol).  
 
Following transfer, membranes were allowed to dry for at least 30 min to maximise 
protein binding, rewetted with methanol (10 s), dH2O (5 min), then with TBS-Tween 
(5 min) and then blocked for 1 h at RT with 5% of non-fat dried milk diluted with 40 ml 
TBS-Tween (blocking solution) on a horizontal rocker. 10x TBS was prepared by 
adding 12.1 g (0.1 M) of tris-base plus 87.65 g (1.5 M) of NaCl to 1 litre dH2O (pH 
7.4). One litre of TBS-Tween was then prepared by diluting 1:10 of 10x TBS in dH2O 
plus 20 µl of Tween-20. 
 
The membrane was incubated with specific primary antibody in blocking solution 
overnight on a roller at 4 oC (see Table 2.8 for primary antibody dilution and species). 
Membranes were then washed with TBS-Tween for 4 min (x3) before being incubated 
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with HRP-conjugated secondary (anti-rabbit or anti-mouse) antibody at a dilution of 1: 
4000 in blocking solution rotating for 1 h at RT. After 3 washes, each membrane was 
incubated in 1.5 ml of ECL Prime western blotting detection reagent (mixing equal 
volumes of reagent A and B) for 2 min. The membrane was then exposed to x-ray film 
using developer and fixer Kodak solutions. Toward the end of the lab work, blot 
imaging of RECK protein were measured by SynGENE G:BOX System (Cambridge, 
UK).  
 
Furthermore, the suitable concentration of the gel utilised for PTEN, PDCD4 and 
Sprty-1 that have molecular weight of 35 – 60 kDa was 10% acrylamide gel and β-
Actin (42 kDa molecular weight) was used as a loading control. Analysis of RECK 
protein with a high molecular weight of 110 kDa required the use of 7.5% gel 
concentration. The loading control β-Actin was undetectable on the lower 
concentration gel thus, it was replaced with α-tubulin which has a 52 kDa molecular 
weight. 
 
 Finally, the membrane was allowed to dry after washing off ECL for 5 min (with 
water and methanol). Bands intensities were then quantified by densitometry using 
imageJ and normalised with image densities of β-actin or α-tubulin which were used 
as loading controls. The molecular mass of sample proteins was always estimated by 
comparison with precision plus protein molecular weight markers. 
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                Table 2.8 Primary antibodies used in immunoblotting 
 
Primary antibody 
 
Dilution 
 
Secondary 
Akt1 
Cat# 2967 
 
1:1000 
 
Mouse 
α-Tubulin 
Cat# 3873 
 
1:1000 
 
Mouse 
β-actin 
Cat# ab8226 
 
1:1000 
 
Mouse 
PDCD4 
Cat# 9535S 
 
1:1000 
 
Rabbit 
PTEN 
Cat# 9188S 
 
1:2000 
 
Rabbit 
RECK 
Cat# 3433S 
 
1:1000 
 
Rabbit 
REK-MAP kinase 
Cat# 9102 
 
1:1000 
 
Rabbit 
Sprouty 1 
Cat# 13013S 
 
1:200 
 
Rabbit 
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 Statistical analysis 
All results presented are expressed as a mean ± standard error of the mean (SEM). 
Statistical analysis was performed using GraphPad Prism 6 by one-way ANOVA, 
followed by Newman-Keuls multiple comparisons post hoc-test. An unpaired t-test 
was used to compare 2 different group of patients (ND and T2DM) and paired ratio t-
test was performed on log transforms of all normalised data to test statistical 
difference as appropriate. P values of < 0.05 were considered statistically significant. 
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Chapter 3 
The role of miR-21 in changing morphological and 
functional characteristics in saphenous vein smooth 
muscle cells from diabetic and nondiabetic donors 
 
3.1. Introduction 
Diabetes is the most common metabolic disorder and is considered to be one of 
the most serious health burdens worldwide. Patients with T2DM account for more 
than 90% of adult diabetes cases and such individuals are at increased risk of 
cardiovascular complications and SV graft failure following CABG surgery (Berry et 
al., 2007, Guay et al., 2011). Despite the co-expression of α-SMA and SM-MHC in 
SMC from both diabetic and ND populations (Owens et al., 2004), distinct 
morphologies of human SV-SMC cultured from T2DM patients have been observed 
when compared to ND cells. Non diabetic cells exhibited a classical spindle shape 
while diabetic cells had a predominantly rhomboidal shape morphology (Madi et al., 
2009, Riches et al., 2014). In addition, the appearance of disrupted F-actin 
cytoskeleton and truncated fibres in T2DM cells was observed in comparison to the 
classical helical F-actin filaments in ND cells (Riches et al., 2014). 
  
Vascular SMC compose the majority of the wall of blood vessels mainly in the 
underlying media layer, and their principal function is to maintain prominent plasticity 
and adjust the calibre of the blood vessels in the body (Newby and Zaltsman, 2000). 
Under normal physiological conditions, vascular SMC proliferate at a very low rate 
and remain in a differentiated, contractile quiescent state to regulate blood pressure 
and flow. They exhibit remarkable plasticity and can switch between two distinct 
phenotypes upon injury, such as that which occurs moderately in the case of 
revascularisation procedures or excessively in diseases such as intimal hyperplasia 
and atherosclerosis (Rzucidlo, 2009). Thus, SMC can become dedifferentiated and 
transform into a proliferative and migratory phenotype (Alexander and Owens, 2012) 
and the mechanism by which this phenotypic switching from the quiescent contractile 
state to the synthetic and migratory phenotype, still needs to be further investigated. 
Whilst currently available pharmacological therapies are highly efficient in treating 
cardiovascular remodelling problems, the mortality rate following coronary 
intervention remains high. Therefore, a better understanding of the biological 
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mechanisms underlying the vascular SMC response to injury could disclose novel 
therapeutic targets. 
  
MicroRNAs are a recently discovered class of endogenous, small, single-stranded 
non-coding sequences of RNA that control nearly 30% of all genes. They negatively 
regulate gene expression and protein synthesis by promoting either translational 
inhibition and/or degradation of their target mRNAs, acting either alone or in 
combination (Ji et al., 2007). One miR can control the expression of multiple target 
genes which have related to cellular function and can regulate genes according to 
different environmental conditions (Bartel, 2009). They play an important part in the 
normal physiological development of the pancreas, insulin signalling in target tissues, 
apoptosis, vascular SMC phenotypic changes, development and regulation (Seyhan, 
2015). In addition to their physiological contributions, the pivotal role of miRs in the 
pathological processes of SMC dedifferentiation and proliferation is documented in 
various studies (Albinsson et al., 2010, Urbich et al., 2008).  
 
The nature of miR expression is tissue-specific and highly affected by the severity 
of diseases (Lagos-Quintana et al., 2002). Recent studies have implicated miRs in 
both the pathogenesis of diabetes and its related cardiovascular complications 
(Shantikumar et al., 2012).  
 
A High Throughput Sequencing approach (Vertis Biotechnologie AG) was carried 
out in our laboratory to analyse the miR transcriptome using RNA samples from SV-
SMC from 6 ND (average age 65.7, range 47-82 years) and 6 T2DM (average age 
63.4, range 50-85 years) donors. From this, the top five most differentially regulated 
miRs were obtained (listed in Table 3.1).  
  
Despite the apparently highest fold increase in T2DM versus ND SMC (Table 3.1), 
being for miR-1260a/b there are no data regarding the role of either miR-1260a/b or 
miR-1280 in the vasculature or cardiovascular conditions, although miR-1280 was 
studied in bladder cancer and shown to inhibit cell invasion (Majid et al., 2012). Whilst 
miR-145 and miR-21 were also among the highest-ranked significant miRs in T2DM 
versus ND cells, miR-145 is known to be highly expressed in the vasculature and it 
has been thoroughly explored by several groups. In both in vitro studies using murine 
aortic SMC (Cordes et al., 2009) and in human SMC studies, miR-145 has been 
shown to drive cell differentiation and phenotypic changes, aspects that have been 
previously studied by others (Cheng et al., 2009a) and in our own research group 
(Riches et al., 2014). 
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Table 3.1 MicroRNAs showing the greatest fold increase in expression in SV-
SMC of T2DM relative to ND donors 
MiRs Fold increase in T2DM 
 
miR-1260b 320 
 
miR-1260a 292 
 
miR-1280 56 
 
miR-145 45 
 
miR-21 41 
 
Out sourced to Vertis Biotechnology (2012) 
 
 
MiR-21 is known to be involved in various physiological conditions (Zhang, 2008) 
and is expressed in several tissues including the vasculature. Experimental animal 
studies showed that miR-21 is upregulated in different types of pathology such as 
fibrosis (Thum et al., 2008), diabetes complications (Guay et al., 2011), cancer 
(Jazbutyte and Thum, 2010), cardiovascular diseases including cardiac hypertrophy 
(Syed et al., 2015) and atherosclerosis (Cheng and Zhang, 2010). Furthermore, it has 
been shown that miR-21 is upregulated in rat balloon-injured arteries and in mouse 
ligation models, inducing a proliferative vascular SMC effect through targeting various 
genes (Ji et al., 2007, Stein et al., 2014). MiR-21 has also been found to be highly 
upregulated and play important roles in human atherosclerotic plaques (Raitoharju et 
al., 2011) and arteriosclerosis by modulating human artery SMC proliferation and 
migration (Ruan et al., 2011). However, the role of miR-21 in inducing human vascular 
remodelling particularly in diabetic SV grafting has received little attention.  
  
To be able to detect changes in cells induced by miR-21 modulation, we utilised the 
transfection technique. MiR-21 was artificially overexpressed using premiR-21 and 
knocked down using antimiR-21 in SV-SMC. PremiRs are double-stranded RNAs with 
sequence analogous to the mature miR of interest, for example, miR-21. One strand 
is identical to and effectively mimics the endogenous mature miR-21. Thus, when 
premiRs enter the cell they are processed into mature miR, bind RISC then post-
transcriptionally inhibit the target mRNA. In contrast, the antimiRs are single-stranded 
RNA-based inhibitors. They have a complimentary sequence to the miR of interest 
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such that they bind to and prevent complementary pairing of a mature miR with its 
target mRNA (Patel and Noureddine, 2012) (see Figures 1.9 A/B).  
  
We confirmed the upregulation of miR-21 observed in SV-SMC from T2DM patients 
obtained using a high throughput screening approach (Table 3.1), by real-time PCR 
using Bio-Rad and a SYBR Green-based miR-21 assay on 5 different patients. On 
average, the relative expression levels of miR-21 were 60% higher in T2DM SMC 
than cells from ND donors (Figure 3.1, K. Riches, unpublished data 2012).  
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Figure 3.1: Expression of miR-21 in cultured SV- SMC from ND and T2DM 
donors.  
Bar chart showing difference in miR-21 expression between SV-SMC from T2DM and 
ND donors, to confirm result obtained from high throughput sequencing data. Error 
bars denote SEM; *P< 0.05; unpaired t-test, two tailed. MiR-21 was normalised to U6 
as an internal control (n= 5/ group). Data provided by Dr K Riches, 2012.  
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3.2. Aims  
The aims of this chapter were: 
 To determine functional differences between human SV-SMC cultured 
from T2DM and ND donors 
 To investigate whether manipulation of miR-21 levels in human SV-SMC 
play a role in impaired cell function.  
 
3.3.  Comparison between T2DM and ND SV-SMC 
 Morphology 
SV-SMC were harvested from T2DM and ND patients undergoing CABG surgery. 
Cells were cultured in a T75 flask and grown to sub-confluence using the method 
described in 2.2.1. Cell images were captured at approximately 50% confluence using 
phase contrast microscopy and all experiments were conducted on cells from equal 
passage numbers (3 - 5). Images were obtained for eight different patients in each 
group from 20 random fields of view. Distinct morphology was exhibited between SV-
SMC cultured from T2DM and ND patients (Figure 3.2). SV-SMC from ND donors 
predominantly exhibited classical spindle-shaped elongated SMC morphology as 
presented in Figure 3.2A, whilst T2DM cells were mainly rhomboid in shape (Figure 
3.2B). 
  
To confirm the SMC specificity and characterisation, α-SMA and SM-MHC were 
visualised by immunostaining. T2DM and ND SV-SMC were plated at an equal 
density on glass coverslips in 24 well plates in FGM as described in section 2.2.3A. 
The co-expression of α-SMA and SM-MHC positively identified the cells as SMC in 
both ND and T2DM patients. Additionally, α-SMA staining clearly demonstrated 
spindle-shaped fibres in ND patients (Figure 3.3A). In contrast, the cells obtained from 
T2DM patients, clearly showed an increase in cell size with more pronounced α-SMA 
fibres (Figure 3.3B).  
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A- Non-diabetic 
 
 
 
 
 
 
 
 
 
 
 
B- Diabetic  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Representative phase contrast images of cultured human ND and 
T2DM SV-SMC.  
SV-SMC of two representative ND (A) and two T2DM donors (B). Original 
magnification (x100) and scale bar =100 µm. 
  
100 µm 
100 µm 100 µm 
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      A- Non-diabetic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Representative fluorescent microscopy images of cultured ND and 
T2DM SV-SMC.  
Representative fluorescence images after staining ND SV-SMC (A) and T2DM SV 
SMC (B) with DAPI (nucleus, blue), α-smooth muscle actin (α-SMA, green), and 
smooth muscle myosin heavy chain (SM-MHC, red) antibodies. Power magnification 
x200 and scale bar =100 µm.  
B- Diabetic 
100 µm 
100 µm 
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 Proliferation and cell area 
Given the role of SMC proliferation in effective adaptation during arterialisation and 
vascular remodelling, proliferation rate was measured in SV-SMC obtained from 
T2DM and ND patients in a parallel manner. Cell proliferation was determined by cell 
counting as described in Section 2.2.4 over a 7-day time course. 
 
To compare proliferation between T2DM and ND SV-SMC, equal passage numbers 
of SMC were used in a parallel for six T2DM and six ND patients. SV -SMC were 
plated at a density of 1 x 104 cells/well in quadruplicate in a 24-well plate in FGM and 
incubated overnight, then quiesced in SFM for 72 h. SMC cultured from T2DM had a 
slower proliferation rate than cells from their ND counterparts, this difference became 
significant from day 4 onwards (P< 0.05) (Figure 3.4A). Area under the proliferation 
curve (AUC) analysis showed a significant reduction (approximately 50%) in AUC of 
T2DM compared to ND SV-SMC (Figure 3.4B). This finding implies that diabetes can 
impair the rate of cell proliferation. 
  
To investigate cell morphology, multiple images of parallel passage number (3 and 
4) SV-SMC were captured under light microscopy. Cell area of 50 cells per patient 
were measured by drawing around the perimeter of each cell and measured using 
ImageJ. Average cell area was calculated and mean cell area and distribution curves 
were constructed. The distribution of size graph plotted for T2DM was wider and 
shifted to the right compared to the graph obtained from ND SV-SMC (Figure 3.4C). 
Additionally, there was a significant increase in the average cell area of cells from 
T2DM compared to ND individuals. Average cell area of SV-SMC in ND donors was 
8518 µm2 whilst in T2DM it reached 11623 µm2 showing a 1.4 fold increase relative 
to ND (Figure 3.4D, n= 8, P< 0.05). 
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Figure 3.4: Differential proliferation and average cell area of SV-SMC from ND 
and T2DM patients.                  
A- Proliferation rate graph showing increase in cell number over 7 days. SV-SMC of 
T2DM patients proliferated more slowly to cells from ND donors (*P< 0.05, n= 6; mean 
± SEM; Two-way ANOVA and Newman-Keuls multiple comparisons test). B- Area 
under the curve (AUC) of counted cells from ND and T2DM donors (*P< 0.05, n= 6, 
unpaired t-test). C- Frequency distribution of cell areas in 5000 µm2 intervals for ND 
and T2DM SV-SMC (n= 8). D- Average cell area comparison between cells from ND 
and T2DM donors (mean ± SEM; *P< 0.05, unpaired t-test, two-tailed, n= 8). 
  
A- Proliferation time course B- Area under the curve 
C- Frequency distribution cell area D- Average cell area 
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3.4. Manipulation of miR-21 levels in ND SV-SMC 
Having shown that miR-21 was elevated in SV-SMC of T2DM, we artificially 
overexpressed miR-21 in ND SV-SMC in an effort to determine whether miR-21 could 
induce phenotypic changes similar to those observed in cells from T2DM. Cells of six 
different ND patients were plated at a density of 70,000 cells/ well in a 6-well plate 
and transfected with 30 nM premiR-21 or premiR-negative (control) for 6 h and then 
incubated with MGM for 72 h according to the protocol in Section 2.2.2. This was 
carried out alongside untransfected and mock groups to check if the transfecting 
reagents themselves induced any effect on the cells. Cells were trypsinised and 
pelleted for subsequent RNA extraction and RT-PCR which revealed that premiR-21 
transfected cells showed significant upregulation of miR-21 expression levels 
compared to the three control groups (P< 0.001, Figure 3.5).  
 
3.5. Downregulation of miR-21 in ND SV-SMC 
Having obtained a sizeable overexpression of miR-21 using 30 nM premiR-21, 30 
nM antimiR-21 was selected at first to attempt to downregulate miR-21 expression in 
ND native SV-SMC. Following 72 h cells were pelleted and RNA was extracted to 
measure miR-21 expression using RT-PCR. The knock down of miR-21 was not 
sufficient under these conditions, thus to optimise the antimiR-21 concentration and 
time of sample collection, the concentration was increased to 60-500 nM for up to 7 
days. However, none of these trials showed significant or strong miR-21 knockdown 
(data not shown). 
 
Owing to the low level of endogenous miR-21 in native ND SV-SMC, we decided 
to overexpress miR-21 to provide a bigger “window” of miR-21 expression against 
which we could test the effectiveness of knockdown with antimiR-21. Thus, SV-SMC 
from four different donors were seeded in a 6-well plate and antimiR-21 (100 nM) was 
combined together with premiR-21 in the same well. Overexpression of miR-21 by 
using 30 nM premiR-21 in SV-SMC significantly upregulated miR-21 expression 
(approximately 3100-fold increase) relative to premiR-negative 72 h after transfection 
(Figure 3.6). Furthermore, the addition of antimiR-21 to premiR-21 induced a 
significant 95% reduction in miR-21 expression in SV-SMC compared with cells 
transfected with premiR-21 alone thus indicating the strong efficacy of 100 nM 
antimiR-21 concentration in knocking down overexpressed miR-21 (Figure 3.6).  
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Figure 3.5: Overexpression of miR-21 in SV-SMC from ND donors. 
ND SV-SMC were transfected with either 30 nM premiR-21, 30 nM premiR-negative 
(PremiR-ve), mock (lipofectamine), or untransfected (un; Optimem). Bars showing 
RT-PCR for miR-21 expression after 72 h (***P< 0.001, One way ANOVA and 
Newman-Keuls multiple comparisons test, n= 6). Expression of miR-21 was 
normalised to U6 and error bars denote SEM. Note the log scale on the y-axis. 
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Figure 3.6: Effect of antimiR-21 on ND SV-SMC overexpressing miR-21.  
ND SV-SMC were transfected with either 30 nM premiR-negative (P-ve), 30 nM 
premiR-21 (P-21), 100 nM antimiR-ve (Anti-ve) or 30 nM premiR-21 + 100 nM 
antimiR-21. RT-PCR for miR-21 expression after 72 h (***P< 0.001, ##P< 0.01, One 
way ANOVA and Newman-Keuls multiple comparisons test, n= 4). Expression of miR-
21 was normalised to U6 and error bars denote SEM. Note the log scale on the y-
axis. 
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3.6. Knockdown of miR-21 in T2DM SV-SMC 
Having shown the increased expression of miR-21 in T2DM relative to ND SV-SMC, 
knockdown of miR-21 was performed in T2DM SV-SMC to try to alter the phenotypic 
characteristics to those of ND cells. Because the 500 nM concentration of antimiR-21 
did not show an extra knockdown of miR-21 compared with either 60 nM or 100 nM 
antimiR-21, cells from five different T2DM patients were transfected with antimiR-21 
or antimiR-negative at a final concentration of 100 nM. Additionally, to determine the 
optimal time to achieve significant knockdown of miR-21 expression, a time course 
experiment was performed. Cells were harvested daily from T2DM transfected SV-
SMC up to day 7, RNA extracted and RT-PCR for miR-21 expression was performed. 
An approximate 40-50% reduction in miR-21 expression was achieved by antimiR-21 
relative to antimiR-negative, with the maximum drop in miR-21 expression obtained 
at day 5 (Figure 3.7A, P< 0.05). 
  
To compare the total amount of miR-21 expression between the two groups, AUC 
for these samples was measured for the 7 days and a significant 47% total reduction 
in the AUC of antimiR-21 transfected cells was obtained relative to antimiR-negative 
transfected cells, indicating that around 50% reduction of miR-21 expression was 
achieved in the antimiR-21 transfected cells relative to basal controls (Figure 3.7B, 
P< 0.01).  
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Figure 3.7: Time course comparison and AUC of knockdown of miR-21 in SV-
SMC from T2DM donors. 
A- T2DM SV-SMC were transfected with 100 nM antimiR-21 or antimiR-negative 
(antimiR-ve). Bars showing RT-PCR measurement of miR-21 expression in cells at 
24 h intervals for 7 days (*P< 0.05, 2 way ANOVA and Newman-Keuls multiple 
comparisons test). Expression of miR-21 was normalised to U6. B- AUC of miR-21 
knockdown in the antimiR-21-transfected cells relative to antimiR-negative 
transfected T2DM cells for a total 7 days (**P< 0.01, paired t-test), n= 5 and error bars 
denote SEM. 
  
A 
B 
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3.7. Effect of overexpression miR-21 levels in SV-SMC 
on cell morphology 
Since the level of miR-21 is reportedly upregulated in different cardiovascular 
diseases and T2DM is one of the major risk factors, we investigated whether miR-21 
overexpression could drive the phenotypic changes similar to those observed in 
T2DM SMC. PremiR-21 and premiR-negative transfected SV-SMC were seeded in 6-
well plates in FGM and 72 h after transfection (Section 2.2.2) images of the cells were 
captured and the imageJ program was used to calculate average cell area (Section 
2.2.5). Representative images presented in Figure 3.8A/B revealed the relatively 
enlarged cell area in the premiR-21 transfected ND cells as compared to premiR-
negative transfected SV-SMC. The cells overexpressing miR-21 showed a 1.7-fold 
increase in cell area compared to negative control, indicating the important role of 
miR-21 in inducing phenotypic changes in SV-SMC (Figure 3.8C, P< 0.001, n= 7).  
  
Studies have shown that F-actin bundling into fibres is related to SMC 
differentiation, and phenotypic modulation of vascular SMC is accompanied by 
changes in actin cytoskeleton alignment (Han et al., 2009). Thus, F-actin fibres were 
visualised to test their organisation and as a sign of differentiation status in the 
premiR-21 and antimiR-21 transfected SV-SMC. To visualise F-actin fibres, premiR-
21 and antimiR-21 transfected cells were seeded on coverslips and stained with 
rhodamine-phalloidin as in Section 2.2.3B. Representative images were obtained by 
fluorescent microscopy and revealed premiR-21 transfected cells (Figure 3.9B) did 
exhibit a slight enlargement in F-actin fibres area compared to premiR-negative 
transfected cells (Figure 3.9A), with the maintenance of the characteristic well-aligned 
F-actin fibres of ND SV-SMC. This suggests that miR-21 overexpression did not 
disorganise the alignment of F-actin in SV-SMC. 
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A- PremiR-negative            B- PremiR-21 
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Figure 3.8: Representative phase contrast images and average cell area of the 
effect of miR-21 overexpression on ND SV-SMC. 
Representative phase contrast images were captured for ND SV-SMC 72 h following 
miR-21 overexpression using 30 nM premiR-negative (A) or premiR-21 (B). Scale bar 
=100 µm. C- Average cell area of SV-SMC overexpressing miR-21 relative to premiR-
negative transfected cells (***P< 0.001, paired t-test, two-tailed, n= 7, 50 cells for 
each). Error bars denote SEM.  
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A-PremiR-negative 
 
 
B-PremiR-21  
 
 
Figure 3.9: Representative fluorescent microscopy images showing the effect 
of miR-21 overexpression on the F-actin cytoskeleton in ND SV-SMC. 
Representative fluorescent microscopy images of F-actin cytoskeletons captured for 
ND SV-SMC 72 h following transfection with 30 nM premiR-negative (A) or premiR-
21 (B) and stained with rhodamine phalloidin. Cells were visualised using LSM510 
Upright Confocal microscope (x200) and scale bar =100 µm. 
  
DAPI                F-actin                   Merged  
DAPI                F-actin                  Merged  
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3.8. Effect of knockdown of miR-21 in T2DM SV-SMC on 
cell morphology  
Whilst high levels of miR-21 are documented in cardiovascular diseases (Jazbutyte 
and Thum, 2010), we performed knockdown of miR-21 expression in SV-SMC from 
five different T2DM donors to determine whether the cells could be rescued to the ND 
phenotype. SMC were cultured in six-well plates and transfected with 100 nM antimiR-
21 or antimiR-negative control. After 72 h, microscopic images were taken and 
ImageJ was utilised to measure cell area over 7 days. A representative image at day 
3 of the antimiR-21 transfected T2DM cells showed a general reduction in cell area in 
comparison to the control cells (Figure 3.10A/B). This indicates the important role of 
miR-21 in mediating phenotypic changes in SV-SMC, particularly increasing cell area. 
  
There was a trend for a reduction in average cell area in the antimiR-21 transfected 
SV-SMC compared to antimiR-negative controls at all time points. The average cell 
area was reduced by 14 – 34 % across the whole time course (Figure 3.10C).  
To visualise F-actin fibres images were obtained using fluorescent microscopy 
taken 72 h after transfection. A representative image of antimiR-21 transfected cells 
showing indistinguishable changes in F-actin fibres size or shape from control is 
shown in Figure 3.11A/B, suggesting an insignificant role of miR-21 knockdown in 
mediating changes in F-actin fibre cytoskeleton in SV-SMC.  
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A- AntimiR-negative       B- AntimiR-21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Representative phase contrast images and effect of miR-21 
knockdown on cell area in T2DM SV-SMC.         
Representative phase contrast images captured at 72 h for T2DM SV-SMC following 
transfection with either 100 nM antimiR-negative control (A) or antimiR-21 (B). Scale 
bar =100 µm. C- Effect of antimiR-21 transfection on average cell area relative to 
control over a 7 day period (*P< 0.05, **P< 0.01 and ***P< 0.001; 2 way ANOVA and 
Newman-Keuls multiple comparisons test, n= 5). Error bars denote SEM.  
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A-AntimiR-negative 
 
 
B-AntimiR-21  
 
 
Figure 3.11: Representative fluorescence microscopic images of the effect of 
knocking down miR-21 on F-actin cytoskeleton in T2DM SV-SMC. 
Fluorescent microscopy images of F-actin cytoskeleton for T2DM SV-SMC 72 h 
following transfection with 100 nM antimiR-negative (A) or antimiR-21 (B) stained with 
rhodamine phalloidin. F-actin fibres were visualised using LSM510 Upright Confocal 
microscope at a magnification x200 and scale bar =100 µm.   
DAPI                  F-actin                            Merged  
DAPI                F-actin                                Merged 
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3.9. Differential gene expression measurement between 
ND and T2DM SV-SMC 
Because of the established role of activation of MMPs such as MMP-2 and   MMP-
3 and decomposition of collagen in vascular remodelling and intimal lesion formation 
(de Kleijn et al., 2001), the difference in type I collagen α1 (COL1A1) and matrix 
regulatory gene expression between T2DM and ND SV-SMC was tested in eight 
different patients. Cells from both groups were collected and RNA samples were 
extracted for gene analysis using RT-PCR. There was no significant difference 
between SV-SMC obtained from T2DM and ND patients (Figure 3.12) with respect to 
COL1A1 (A), MMP2 (B) and MMP3 (C) mRNA expression. This indicates that the 
expression of these genes, in our SV-SMC samples utilised, is not regulated by the 
diabetic milieu or any regulation in vivo is not maintained in culture.  
 
3.10. Correlation between miR-21 and collagen 1A1, 
MMP2 and MMP3 in SV-SMC obtained from ND and T2DM 
patients 
Having obtained no significant difference in COL1A1, MMP2 and MMP3 gene 
expression between ND and T2DM SV-SMC we proceeded to analyse the correlation 
between miR-21 expression level and expression of these genes in SV-SMC of both 
diabetic and ND patients. Correlation figures were compiled showing a high 
correlation between miR-21 expression and COL1A1 mRNA (R2= 0.81, Figure 3.13A) 
in ND cells but this correlation was absent in cells obtained from T2DM patients (R2= 
0.33, Figure 3.13D). In normal healthy cells there is a strong correlation between miR-
21 and COL1A1 mRNA. However, this relationship appears to have been lost in T2DM 
as evident by the lack of correlation. Expression of the other two genes, MMP2 (Figure 
3.13 B and E) and MMP3 (Figure 3.13 C and F) showed no correlation with miR-21 
expression in either ND or T2DM SV-SMC (n= 8/ each group). 
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Figure 3.12: Comparison of collagen 1A1, MMP2 and MMP3 mRNA levels 
between ND and T2DM SV-SMC. 
Bar chart showing a comparison between ND and T2DM SV-SMC for collagen 1A1 
(A), MMP2 (B) and MMP3 (C) mRNA expression using RT-PCR. (ns= not significant, 
unpaired t-test, n= 8). Gene expression was normalised to the endogenous control 
GAPDH and error bars denote SEM.   
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Figure 3.13: Correlation between miR-21 expression and Collagen 1A1, MMP-2 
and MMP-3 in ND and T2DM SV-SMC. 
Correlation between miR-21 expression in ND SV-SMC and COL1A1 (A), MMP2 (B) 
and MMP3 (C) and T2DM SV-SMC and COL1A1 (D), MMP-2 (E) and MMP-3 mRNA 
(F) (each group n= 8).  
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3.11. Effect of overexpression/ knockdown of miR-21 on 
collagen 1A1 expression in ND SV-SMC 
To examine the effect of miR-21 manipulation in ND SV-SMC on COL1A1 
expression (which accounts for 85% of the ECM content (Kong et al., 2013), RT-PCR 
was performed on RNA samples from miR-21 overexpressing or underexpressing 
cells to measure COL1A1 mRNA levels. Overexpression (Figure 3.14A, n= 7) or 
knockdown of miR-21 levels (Figure 3.14B, n= 4) did not induce changes in COL1A1 
expression relative to premiR-negative and antimiR-21 transfected control cells. 
 
3.12. Comparison of miR-21 expression levels between 
ND and T2DM patients in different cardiovascular cell 
types  
Several studies have documented the increased miR-21 expression in 
cardiovascular diseases and one particular study also showed the 
upregulation of miR-21 expression in mice after SV grafting (McDonald et al., 
2013). As comparable results were obtained for COL 1A1, MMP2 and MMP3 
expression in SV-SMC obtained from ND and T2DM donors, we decided to 
measure the miR-21 expression level in a larger population (n= 11/ each 
group) to check the level of miR-21 expression between the two groups. The 
samples used in our previous pilot data (Figure 3.1) were tested again using 
the TaqMan-based assay by ABI 7500 Real-Time PCR System. As shown in  
Figure 3.15A there was a significant increase in miR-21 in the diabetic SV-SMC 
compared to ND counterparts. In contrast to the results obtained from the 
small sample size, when using a larger population of eleven samples the real-
time PCR analysis of the RNA samples revealed comparable levels of miR-21 
expression between the two groups ( 
Figure 3.15B). Lastly, even when the samples of the pilot data were added, the 
expression of miR-21 between T2DM and ND SV-SMC was similar. 
  
Other cardiovascular tissues were utilised to compare miR-21 expression 
between T2DM and ND donors; namely cardiac fibroblasts and endothelial 
cells. The real-time PCR analysis of miR-21 expression showed a trend toward 
an increase in miR-21 expression in the RNA samples from T2DM cardiac 
fibroblasts ( 
Figure 3.15C) and no difference in miR-21 expression in the endothelial cells ( 
Figure 3.15D) compared to the RNA samples obtained from ND patients (n= 6). 
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Figure 3.14: Measurement of collagen 1A1 mRNA in premiR-21 and antimiR-21 
transfected ND SV-SMC. 
RT-PCR measurement of COL1A1 mRNA expression for SV-SMC 72 h following 
transfection with either 30 nM premiR-21 or premiR-negative (A, n= 7) and 100 nM 
antimiR-21 or antimiR-negative (B, n= 4). Gene expression was normalised to 
GAPDH and error bars denote SEM (ns= not significant, paired t-test). 
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Figure 3.15: Comparison measurement of miR-21 in ND and T2DM SV-SMC, 
cardiac fibroblasts and endothelial cells. 
RT-PCR for miR-21 expression levels in SV-SMC of T2DM compared to ND donors 
(A, *P< 0.05, n= 5). B- MiR-21 expression after adding the 5 samples in (A) into 11 
different ND or T2DM SV-SMC samples (each n= 16). MiR-21 expression level in 
cardiac fibroblasts (C, each n= 6) and endothelial cells (D, each n= 6) obtained from 
T2DM relative to ND patients (unpaired t-test). Expression of miR-21 was normalised 
to U6 and error bars denote SEM.  
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3.13. Discussion 
The results in this chapter have highlighted the distinct appearance of SV-SMC 
cultured from T2DM relative to ND donors. The diabetic cells were predominantly 
distinguishable by their rhomboidal shape as compared to the classical spindle shape 
of cells from ND counterparts and this is consistent with the previously published work 
from our department (Madi et al., 2009). Furthermore, cells from T2DM donors had a 
significantly lower proliferative rate, which was also shown by Riches et al., 2014, and 
increased spread cell area compared to ND counterparts. Confirmation that all 
cultured cells were SMC was demonstrated by immunostaining that showed co-
expression of α-SMA and SM-MHC in both ND and T2DM SV-SMC. Overexpressing 
miR-21 in ND SV-SMC led to a significant increase in average cell area, whereas 
knocking down miR-21 in T2DM cells significantly reduced cell area versus negative 
controls.  
  
A number of miRs have been implicated in vascular remodelling and cardiovascular 
diseases, such as miR-21, miR-210 and miR-34a which were implicated in human 
atherosclerosis (Raitoharju et al., 2011) and miR-208 and miR-499 which were 
involved in rat and human ischemia (Corsten et al., 2010, Fukushima et al., 2011). 
The outcome of the high throughput screen showed an obvious upregulation of miR-
1260 in cells from T2DM patients. However, a thorough search of the literature failed 
to identify a potential role of miR-1260 in cardiovascular diseases. Despite miR-1260a 
and miR-1260b showing an approximate 300-fold increase in T2DM SV-SMC relative 
to ND in our pilot data (Table 3.1), there are just three published studies that focus 
exclusively on upregulation of miR-1260b in lung cancer cells mediating metastasis 
(Xu et al., 2015b), prostate cancer (Hirata et al., 2014a) and renal cancer (Hirata et 
al., 2014b). Another recent study proposed a possible diagnostic role for miR-1260a 
in asthmatic patients (Wang et al., 2015c). However, no studies have explored or 
confirmed the role of this miR in vascular remodelling. 
 Both miR-145 and miR-21 also showed high expression levels in T2DM relative to 
ND SV-SMC and recent evidence has supported the role of these miRs in inducing 
phenotypic changes of vascular SMC. Overexpression of miR-145 in (non-diabetic) 
SMC has proven to be involved in regulating SMC phenotypes such as mediating a 
reduction in the proliferation rate of rat aortic and pulmonary artery SMC (Cordes et 
al., 2009). Additionally, it has been confirmed by our group that T2DM SV-SMC 
showed elevated levels of miR-145 expression. Knocking down miR-145 in T2DM SV-
SMC reverted cells into a ND phenotype and its overexpression in ND cells drove the 
diabetic phenotypes (Riches et al., 2014).  
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Emerging evidence has shown that miR-21 expression is one of the highly 
deregulated miRNAs in the cardiovascular system in diseases such as proliferative 
vascular disease, cardiac fibrosis, cardiac hypertrophy and ischaemic heart disease 
(Cheng and Zhang, 2010, Small and Olson, 2011), providing the cause-effect 
relevance between the expression level and regulation of miRNAs and cardiovascular 
diseases. Various studies have shown that miR-21 is significantly upregulated in most 
cardiovascular cell types and can mediate cardiovascular pathological problems. For 
example, miR-21 was found to be upregulated in vascular SMC mediating neointimal 
lesion formation (Ji et al., 2007), endothelial progenitor cells of atherosclerotic patients 
(Zuo et al., 2015), cardiomyocytes mediating cardiac hypertrophy in mice (Cheng et 
al., 2007) and cardiac fibroblasts inducing fibrosis (Roy et al., 2009). MiR-21 was also 
found to be increased 4.6-fold in atherosclerotic plaques in comparison to control 
human arteries (Raitoharju et al., 2011). Additionally, in a key study performed by 
McDonald et al. (2013), miR-21 was found to be significantly upregulated and 
mediated neointimal formation after vein grafting in mice. Therefore, miR-21 was 
selected in this project for investigating whether regulating its expression levels could 
alter SMC phenotypes in both ND and T2DM cells and contribute to SMC dysfunction 
that is relevant to vascular remodelling. 
   
In addition to the divergent morphological features exhibited in T2DM SV-SMC, a 
disrupted F-actin cytoskeleton can also accompany the phenotypic changes mediated 
by overexpression of miR-145 (Riches et al., 2014). Overexpression of miR-21 in SV-
SMC from ND donors significantly increased average cell areas by 56% (Figure 3.8). 
This rhomboidal shape is characteristic of the dedifferentiated SMC phenotype that 
was found to be dominant in atherosclerosis formation and has also been known to 
augment neointima thickness (Hao et al., 2003). However, this was not accompanied 
by F-actin fragmentation or disruption.   
  
On the contrary, knocking down miR-21 in SV-SMC from T2DM donors reduced 
the average cell area to be more like a ND cell with a differentiated phenotype (Figure 
3.10). These changes in cell area mediated by miR-21 manipulation underline the 
important role of miR-21 expression in cell morphology. As SMC compose the majority 
of cells in the blood vessel wall, the accumulation of these cells in the intima is greatly 
linked to blood vessel occlusion and restenosis following vascular injury. T2DM is 
considered as a major risk factor for cardiovascular diseases and contributes to poor 
prognosis, developing in-stent restenosis (Berry et al., 2007), reduction in long-term 
survival outcome and unfavourable consequences after SV revascularisation in 
CABG surgery (Kubal et al., 2005). This increase in SMC area induced by miR-21 
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may be important in T2DM or it could play an important role in driving phenotypic 
changes similar to these seen in T2DM or dedifferentiated SV-SMC phenotypes. 
Therefore, miR-21 could be the driving cause behind phenotypic changes such as the 
rhomboidal SMC shape associated with T2DM vascular SMC. 
  
Having observed the significant upregulation of miR-21 using 30 nM premiR-21 
(Figure 3.5), a series of optimisation experiments were carried out to achieve robust 
miR-21 knockdown in native SV-SMC. Because miR-21 has been suggested to be 
expressed at high levels in pathological conditions we decided to enhance the miR-
21 (i.e. overexpress) and follow this with a reduction. The knockdown could not be 
detected unless we artificially overexpress miR-21 in which we obtained a 95% 
reduction (Figure 3.6).  
  
Studies have shown a high correlation between diabetes and matrix alterations that 
is involved in poor wound healing (Brem and Tomic-Canic, 2007), vascular stiffness 
(Henry et al., 2003) and dysfunctional remodelling (Chow et al., 2013). Diabetes is a 
major risk factor that augments expression of ECM proteins in different organs (Law 
et al., 2012). The increased matrix protein cross-linking that is seen in T2DM 
enhances scaffold stiffness in both radial and circumferential directions in diabetic rats 
compared to ND (Chow et al., 2013). Thus, changes in ECM-related genes in vascular 
SMC can play a crucial role in cellular phenotypes including the process of SMC 
proliferation and migration which can lead to atherosclerosis or restenosis following 
CABG surgery. Collagen provides the main structural integrity to tissue and 
represents the major ECM component of the atherosclerotic plaque (Kong et al., 
2013). Studies have shown that disturbances in collagen metabolism in diabetic 
patients contribute to poor wound healing (Knas et al., 2015). T2DM patients exhibited 
an increased deposition of matrix collagen in arteries and this was contributed to the 
downregulation of MMPs (Chung et al., 2007). Both MMP2 (gelatinase A) and MMP3 
(stromelysin 1) play a major role in ECM degradation and collagen deposition. It has 
been shown that hyperglycaemia enhanced MMP2 mRNA expression and activity in 
rat aortic SMC (Hao and Yu, 2003). A study using human umbilical vein EC showed 
that hyperglycaemia induced upregulation of MMP2 and downregulation of MMP3 
(Death et al., 2003). Moreover, as MMP3 has a high ability to degrade collagen 
(Chung et al., 2007), these two genes were selected to test their levels in SV-SMC of 
diabetic patients and whether their differential level contributed to collagen variation 
in diabetes relative to ND. Collagen, MMP2 and MMP3 are known to be involved in 
vascular restenosis and neointimal formation, surprisingly, our data revealed that the 
levels of collagen 1A1, MMP2 and MMP3 mRNA expression in SV-SMC were 
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comparable between the two populations (Figure 3.12). It could be that these genes 
levels are normalised into their basal levels in culture and their levels become similar 
to the ND sample because they are deprived of the diabetic milieu.  
   
However, of particular interest, we did note a positive correlation between miR-21 
and COL1A1 expression level in ND SV-SMC that was not observed in cells obtained 
from T2DM donors, suggesting that this correlation is lost. A study by Li et al. (2011) 
demonstrated that the upregulation of miR-21 was positively linked with collagen 1 
accumulation in lung fibrogenesis. Studies have shown that miRs can regulate the 
expression of multiple collagens (Ji et al., 2010), therefore, we manipulated miR-21 
expression levels in ND SMC to determine whether this could modulate COL1A1 
expression. However, neither overexpressing nor knocking down miR-21 in ND-SMC 
affected COL1A1 expression (Figure 3.14). This confirms that COL1A1 is not directly 
and solely regulated by miR-21, but by other genes. The metabolic abnormalities 
associated with T2DM, including hyperglycaemia, hyperinsulinaemia, 
hyperlipidaemia and increased protein glycation perhaps modified SMC response to 
collagen and disturbed the positive association between miR-21 and collagen 1A1 
levels. As a result of the metabolic disturbance in T2DM, expression of growth factors 
is also dysregulated (Aronson et al., 1996). This could also contribute to phenotypic 
changes in SMC leading to the vanished response observed in miR-21 correlation to 
collagen expression. Following on from this, the exact missing link in diabetes needs 
further investigation. Additionally, it is still unclear what the significance of this 
relationship is and therefore, further studies are required to determine its importance.  
  
T2DM is a chronic metabolic disease and growing evidence has suggested that 
dysregulated miR expression is implicated in the pathogenesis of T2DM. MiRs have 
been shown to be upregulated in adipose tissue, liver and pancreatic beta cells of 
T2DM patients (McCullough et al., 2010). Furthermore, aberrant expression of miRs 
is implicated in several vascular pathologies including atherosclerosis, CAD, vascular 
inflammation, and other diabetic vascular complications such as the microvascular 
diseases (Arunachalam et al., 2015, Athyros et al., 2015). The early metabolic milieu 
may induce modulation in gene expression and aberrancies of vascular SMC function, 
which negatively affect SMC plasticity and contribute to poor outcome after CABG in 
T2DM patients (Hakala et al., 2005). Our initial experiment shown in Figure 3.1 
revealed a 60% increase in miR-21 expression in SV-SMC of T2DM relative to ND 
when a small population sample was used (n= 5 per group). The present study has 
shown that this difference in miR-21 expression between the two populations was 
indistinguishable when the sample size was increased to 16. Additionally, a power 
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calculation of sample means revealed that to obtain 80% power of detecting a 50% 
difference between these 2 groups we needed a total of 11 per group. Therefore, the 
initial experiment on 5 samples was underpowered. A total of 16 samples in this assay 
were powered enough to conclude that there was no significant relationship between 
miR-21 expression in SV-SMC and diabetic status.  
  
There is a high incidence of mortality and morbidity from cardiovascular 
complications following CABG surgery in diabetic patients (Berry et al., 2007). As 
miRs have a different expression profile in different tissues (Small and Olson, 2011) 
and after finding no difference in miR-21 expression in SV-SMC between T2DM and 
ND patients, the expression of miR-21 in other cardiovascular cell types was tested; 
namely cardiac fibroblasts and endothelial cells. These cell types, in addition to SMC, 
have an important role in inducing vascular restenosis after injury and cardiac fibrosis. 
The result showed comparable levels of miR-21 expression in both fibroblasts and 
endothelial cells between the two populations.  
  
This chapter has highlighted an important role for miR-21 in SMC function as miR-
21 mediated differentiation changes in SV-SMC by inducing a significant increase in 
cell area that is partially characteristic to the dedifferentiated phenotype. However, we 
did not observe any differences in miR-21 expression between T2DM and ND SV-
SMC. Therefore, all of the experiments conducted in the subsequent chapters were 
performed only on SV-SMC from non-diabetic patients.  
106 
 
 
Chapter 4 
Factors modulating miR-21 expression and 
identification of cardiovascular target genes in 
human ND SV-SMC 
 
4.1. Introduction 
    Neointimal lesion formation in proliferative vascular disease shares similar 
molecular mechanisms with cancers, as both are characterised by excessive cell 
proliferation and migration (Owens et al., 2004). Given the abundance of research 
demonstrating the role of miRs in the development of cancer, it has been 
hypothesised that miRs could also play an important role in neointimal lesion 
formation after revascularisation; however, relatively few studies have been 
conducted to reveal the precise role of miRs in vascular remodelling. The level of miR 
expression is highly affected by the severity of diseases and their expression is tissue-
specific (Cheng and Zhang, 2010). Indeed, one miR may be highly expressed in one 
tissue type, but have low or no expression in other tissues (Small and Olson, 2011). 
This will assign the potential role of a specific miR according to cell type or 
pathophysiological situation. Neointimal progression and vascular diseases may 
therefore potentially be resolved by normalising miR expression and preventing 
phenotypic modulation in a manner that may be detrimental. 
  
The high induction of miR-21 in the vast majority of cancers (Selcuklu et al., 2009b), 
fibrosis (Thum et al., 2008) and cardiac disorders (Cheng and Zhang, 2010) has 
attracted the attention of researchers in an effort to assign potential mechanistic 
functions of miR-21 in the context of cardiac remodelling, atherosclerosis, aneurysms 
and restenosis injury (McDonald et al., 2013). It has been documented that miR-21 is 
significantly upregulated in different types of human tissues and diseases, acting 
through numerous targets and signalling mechanisms (Krichevsky and Gabriely, 
2009). MiR-21 was one of the significantly upregulated miRs in human atherosclerotic 
plaque compared with healthy individuals and multiple target genes were 
downregulated (Raitoharju et al., 2011). However, further investigations to identify the 
precise role of miR-21 in T2DM and vascular diseases, and to ascertain the underlying 
mechanisms driving its upregulation, are challenging to uncover. In an experimental 
study, using a mouse insulin-secreting cell line (MIL6) treated with proinflammatory 
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cytokines; miR-21 was among the most highly expressed miRs and its subsequent 
blockade protected β-cells from death caused by cytokines (Roggli et al., 2010, Bravo-
Egana et al., 2012). Therefore, cytokine-induced miR over production and the 
consequent recruitment of inflammatory mediators together with the diabetic milieu 
could be predicted to contribute to diabetic cardiovascular complications. 
   
Following vascular injury and bypass grafting, the initial response to injury lies at 
the level of endothelial dysfunction, inflammation and platelet adhesion (Zernecke and 
Weber, 2010). This stimulates secretion of various growth factors such as PDGF and 
TGF-β, cytokine secretion (e.g., interleukins and TNF-α) and degradation and 
deposition of the ECM (Chung et al., 2007). When this exceeds the level required for 
healing and adaptation to the new environment of arterial haemodynamics, it can lead 
to uncontrolled SMC proliferation and migration towards the intima. This may lead to 
intimal hyperplasia, restenosis and subsequently, graft failure (Lafont and Faxon, 
1998, Chen et al., 2012).  
  
TGF-β has been shown to control miR-21 biosynthesis at the post-transcriptional 
level in human pulmonary artery SMC (Davis-Dusenbery and Hata, 2010); and 
treating SV-SMC with TGF-β led to a 2.5-fold increase in miR-143/145 after 48 h 
(Riches et al., 2014). PDGF-BB is among the growth factors known to be upregulated 
in response to vascular injury and following angioplasty (Sun et al., 2012b). It is also 
involved in tumour diseases and is a crucial stimulator of growth and motility in many 
cell types including EC, fibroblasts and SMC (Board and Jayson, 2005, Alvarez et al., 
2006). PDGF-BB is known to induce dysregulation of miR expression in different cell 
types; inducing down-regulation of miR-145 and upregulation of miR-221 and -222 in 
vascular SMC (Cheng et al., 2009a), increasing miR-21 expression in mouse glioma 
cells (Polajeva et al., 2012) and increasing miR-21 expression in human hepatic cell 
lines (Wei et al., 2013). PDGF activates two well-characterised signalling pathways, 
mitogen-activated protein kinase extracellular regulated kinase 1/2 (MAPK/ERK1/2) 
and phosphatidylinositol 3-kinase/protein kinase B pathway (PI3K/Akt) (Xu et al., 
2015a).  
  
The expression of miRs in SMC is controlled by a number of different factors. As 
inflammatory cytokines and other diabetic mediators are elevated in the circulation of 
diabetic patients we sought to identify if any of these factors mediated the proposed 
increase in miR-21 expression observed in T2DM SV-SMC. In the present study, we 
selected various stimuli known to be altered in T2DM, such as IL-1α, TNF-α, glucose, 
insulin, TGF-β, PDGF-BB and combinations thereof, and measured the effect of these 
on ND SV-SMC miR-21 expression.  
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The aims of this chapter were: 
 To explore the ability of diabetic stimuli and other inflammatory 
mediators to modulate miR-21 expression in ND SV-SMC 
 To investigate the downstream target genes affected by miR-21 
upregulation in SV-SMC.  
 
4.2. Effect of interleukin-1α exposure on miR-21 
expression in ND SV-SMC 
IL-1α is a proinflammatory cytokine that is usually elevated alongside other diabetic 
mediators, in the blood of T2DM patients and in various CVDs (Ruscitti et al., 2015). 
Initial time course experiments were conducted on ND SV-SMC that were cultured in 
6 well plates (120,000 cells/ well) in FGM for 24 h. To determine the time point at 
which miR-21 expression was most significantly modulated by acute IL-1α exposure, 
cells were quiesced in SFM prior to the addition of 10 ng/ml IL-1α. Cells were then 
trypsinised, harvested and pelleted at intervals between 2 and 24 h and RNA 
extracted to measure miR-21 expression using RT-PCR (as described in Section 
2.2.9). Interleukin-1-treated cells showed a decline in miR-21 expression at all time 
points compared to untreated control collected at time zero (Figure 4.1A). There was 
a significant reduction in miR-21 expression between 4 and 8 h (P< 0.05) and the 
maximum drop observed relative to control was at 6 h (P< 0.01, n= 4). This 
demonstrated the negative response mediated by IL-1α on the expression of miR-21. 
  
In another set of experiments, to compare the effect of short and long-term 
exposure of SV-SMC to IL-1α, SV-SMC from 3 different donors were exposed to IL-
1α for either: a short time (4 h) prior to replenishment with SFM or continuous 
exposure to IL-1α. Cells were harvested at 24, 48 and 72 h alongside untreated cells 
which had been maintained in parallel in MGM containing vehicle (0.1% BSA) and 
used as a control at each time point. Short-term exposure to IL-1α caused a significant 
downregulation in miR-21 at 48 h (P< 0.01, Figure 4.1B), whilst continuous exposure 
to IL-1α induced a reduction in miR-21 expression at an earlier time (24 h), but no 
comparable changes at later time points (Figure 4.1C). This suggested that the effect 
of IL-1α on miR-21 is transient and lasts up to 48 h.   
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Figure 4.1: MiR-21 expression in ND SV-SMC exposed to IL-1α treatment. 
RT-PCR for miR-21 expression in SV-SMC exposed to 10 ng/ml of IL-1α. A. Effect of 
IL-1α on miR-21 expression over a time course up to 24 h (*P< 0.05, **P< 0.01, n= 
4). B. Effect of short (4 h) IL-α treatment on expression of miR-21 at time points 24-
72 h (**P< 0.01, n= 3). C. Effect of continuous treatment with IL-1α from 24-72 h on 
miR-21 expression (n= 3). MiR-21 transcript levels were normalised to the 
endogenous control, U6 and error bars denote SEM; Newman-Keuls multiple 
comparisons test after One way ANOVA. 
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4.3. Effect of diabetic stimuli on miR-21 expression in 
ND SV-SMC  
Most of the complications of T2DM are related to the cardiovascular system. 
Diabetes is considered a major risk factor for cardiovascular diseases and contributes 
to unfavourable consequences for CABG (Rong et al., 2016). Thus, we next 
investigated whether miR-21 expression could be modulated by “classical” diabetic 
mediators. SMC from five different ND donors were seeded in 6 well plates after being 
cultured in physiological low levels of glucose media (5.5 mM) for 14 days. Cells were 
then exposed to one of 5 different treatments over time points from 6 – 48 h in MGM 
containing (1) high glucose (25 mM), (2) 100 nM insulin, (3) IL-1α and TNF-α (both 10 
ng/ml), (4) 10 ng/ml of TGF-β or (5) a combination of high glucose with insulin, IL-1α 
and TNF-α. Paired cells were cultured in parallel in low-glucose MGM as a control. At 
each time point, cells were pelleted and RNA extracted to measure miR-21 expression 
by RT-PCR. None of the diabetic stimuli (Figure 4.2A/B) and/or inflammatory 
mediators (Figure 4.3A/B) or the combination (Figure 4.3C) at the concentrations 
tested were capable of inducing significant changes in miR-21 expression levels as 
compared to their relevant controls.  
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Figure 4.2: Effect of diabetic stimuli on miR-21 expression level in ND SV-SMC. 
RT-PCR of miR-21 expression in SV-SMC treated with 25 mM high glucose (A) or 
100 nM insulin (B) for 6, 24, or 48 h. (n= 5, One way ANOVA and Newman-Keuls 
multiple comparisons test). MiR-21 transcript levels were normalised to the 
endogenous control U6 and error bars denote SEM. 
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Figure 4.3: Effect of inflammatory mediators and diabetic stimuli on miR-21 
expression level in ND SV-SMC. 
RT-PCR of miR-21 expression in SV-SMC treated with 10 ng/ml of IL-1α and TNF-α 
(A), 10 ng/ml of TGF-β (B) or combination of high glucose (25 mM), insulin (100 nM), 
IL-1α and TNF-α (C) for 6, 24 or 48 h. (n= 5, One way ANOVA and Newman-Keuls 
multiple comparisons test). MiR-21 transcript levels were normalised to the 
endogenous control U6 and error bars denote SEM.   
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4.4. Effect of PDGF-BB exposure on miR-21 expression 
in ND SV-SMC 
Other mediators known to be involved and upregulated in diabetes and vascular 
remodelling include the chemoattractant and mitogen PDGF-BB (Levran and Hwang, 
1990). To test its effect on regulation of miR-21 expression level, PDGF-BB was 
utilised in another set of experiments, in which SV-SMC were seeded in 6 well plate 
in FGM and incubated for 72 h. Cells were serum starved for 24 h and then stimulated 
with 1 or 10 ng/ml PDGF over a time course up to 72 h. Paired cells exposed to the 
vehicle (0.1 M acetic acid and 1% BSA in PBS) were cultured in parallel as controls. 
At each time point, cells were pelleted and RNA extracted for measurement of miR-
21 expression by RT-PCR. Exposure of SV-SMC for 24 h to both low and high 
concentrations of PDGF led to approximately 60% and 30% increase in miR-21 
expression, respectively (Figure 4.4A). By prolonging the exposure time to 48 and 72 
h, both concentrations of PDGF-induced an 80% increase in miR-21 expression that 
reached statistical significance as compared to their respective controls (Figure 
4.4B/C, P< 0.05, P< 0.01, n= 5). 
 
4.5. Effect of PDGF-BB signalling inhibition on miR-21 
expression in SV-SMC 
Having demonstrated that miR-21 expression was elevated by PDGF-BB, we 
proceeded to investigate whether the PDGF signalling pathway was involved in this 
upregulation. Phosphorylation of Akt and ERK1/2 by PDGF was determined by using 
phospho-specific and expression antibodies. In order to confirm the effectiveness and 
specificity of PDGF signalling pathway inhibitors, SV-SMC were seeded in FGM and 
serum starved for 24 h. Cells were then incubated for 1 h with/without 10 µM 
LY294002 (Akt inhibitor) or with/without 30 µM PD98059 (ERK1/2 inhibitor) in MGM 
prior to 20 minutes stimulation with 1 ng/ml PDGF. Control groups were cultured 
alongside having been exposed to the relevant vehicle controls: DMSO with LY or PD 
and (0.1 M acetic acid with 1% BSA in PBS) with PDGF-BB. Cell lysates were 
prepared and protein was separated using SDS-PAGE 10% polyacrylamide gel and 
transferred into PVDF membrane. Membrane was then probed with the particular 
antibody as described in Section 2.2.11 and phospho- Akt and phospho- ERK1/2 
protein levels were normalised to Akt and ERK1/2 expression, respectively. Western 
blots showed that PDGF-induced phosphorylation of Akt and ERK1/2 pathways 
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(Figure 4.5A/B) and that both Akt (Figure 4.5A) and ERK1/2 (Figure 4.5B) inhibitors 
selectively inhibited PDGF-induced phosphorylation of these two pathways.  
 
Having shown that 48 h treatment with 1 ng/ml PDGF was sufficient to upregulate 
miR-21 expression, these conditions were utilised to test the effect of PDGF-BB in the 
presence of signalling pathway inhibitors. Cells were incubated with PD98059 and 
LY294002 for 1 h prior to the addition of PDGF for 48 h. Control cells were incubated 
with the inhibitors alone in parallel. Cells were pelleted and RNA extracted to measure 
miR-21 expression by RT-PCR. PDGF significantly upregulated miR-21 expression 
compared with control (P< 0.05) and the expression level of miR-21 was significantly 
reduced (P< 0.05) when either Akt or ERK1/2 signalling pathway was blocked as 
compared to cells treated with PDGF alone (Figure 4.5C), confirming that both 
pathways are important for PDGF-induced miR-21 upregulation. 
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Figure 4.4: Effect of PDGF-BB on miR-21 expression level in ND SV-SMC. 
RT-PCR of miR-21 expression in SV-SMC treated with either 1 or 10 ng/ml PDGF-BB 
and compared to vehicle-treated controls (0.1 M acetic acid and 1% BSA in PBS). 
Cells were incubated with PDGF for 24 h (A), 48 h (B) or 72 h (C). (n= 5, *P< 0.05, 
**P< 0.01, One way ANOVA and Newman-Keuls multiple comparisons test). MiR-21 
transcript levels were normalised to the endogenous control U6 and error bars denote 
SEM.  
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Figure 4.5: Representative blot of the effect of selective inhibition of Akt and 
ERK1/2 on PDGF-BB-induced phosphorylation of Akt and ERK1/2 and the effect 
of their inhibition on miR-21 expression in SV-SMC.  
Representative blot of Akt (A) and ERK1/2 (B) phosphorylation by PDGF-BB in SV-
SMC. Signalling pathways of 1 ng/ml PDGF were blocked by 10 µM of LY294002 (Akt 
inhibitor) or 30 µM PD98059 (ERK1/2 inhibitor), compared with vehicle (V, 0.1 M 
acetic acid and 1% BSA in PBS, or DMSO). (C) Effect of PDGF-BB signalling 
inhibition on miR-21 expression in SV-SMC. (n= 5, *P< 0.05 vs vehicle control, #P< 
0.05 vs PDGF-BB, One Way ANOVA and Newman-Keuls multiple comparisons test). 
MiR-21 transcript levels were normalised to the endogenous control U6 and error bars 
denote SEM.  
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4.6. Human atherosclerosis microarray 
Having identified PDGF-BB as a positive stimulator of miR-21 and owing to the 
pertinent role of PDGF-BB as a mediator known to be involved in atherosclerosis and 
vascular remodelling, we sought to determine the potential target genes mediating 
cardiovascular disorders that were affected by miR-21 upregulation by using a human 
atherosclerosis specific microarray. RNA samples of premiR-21 and premiR-negative 
(control) transfected SV-SMC of 4 different ND donors were analysed with a human 
atherosclerosis RT-PCR array. The array enables the investigation of 84 different 
genes involved in atherosclerosis and cardiovascular diseases and it was performed 
according to the manufacturer’s instructions as described in method Section 2.2.10 
and the genes included are listed in Table 2.2. The pattern of gene expression 
distribution affected by miR-21 overexpression is presented in a volcano scatter plot 
that displays the statistical significance versus fold change (Figure 4.6). Fold-change 
values greater than one indicate genes which are upregulated whilst fold-change 
values less than one indicate genes which are downregulated. Out of the 84 genes, 
10 genes had a fold change ≥ ± 1.5 and these are listed in Table 4.1. 
  
The genes that showed the highest fold changes were MMP1 and IL1A. MMP1, 
MMP3, IL1R2, PPARG and ITGB2 displayed ≥ 1.5 fold increase in the premiR-21 
transfected cells relative to control SV-SMC whilst IL1A, KDR, BIRC3, VWF and IL5 
showed > 1.5 fold decrease in the premiR-21 transfected cells relative to control cells. 
Fold change and P values for the 10 genes analysed by ratio paired t-test are 
presented in Table 4.1. 
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Figure 4.6: Volcano plot of atherosclerosis array data of premiR-21 versus 
premiR-negative transfected ND SV-SMC. 
The difference in expression level on log 2 scale indicated in the x-axis and the y-axis 
indicates statistical significance in -log 10 scale. Values located above the dotted 
horizontal line indicating P value of < 0.05 (ratio paired t-test). Only genes that had ≥ 
+/-1.5 fold changes are labelled. Genes that are upregulated (yellow,) and 
downregulated (red) in RNA samples from SV-SMC transfected to overexpress miR-
21 (using 30 nM premiR-21) 72 h after transfection compared to premiR-negative 
transfected SV-SMC, using RT2 Profiler human atherosclerosis PCR microarray (n= 
4 in each group).  
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Table 4.1 Human atherosclerosis array genes log 2 fold change ≥ +/- 1.5 (up or 
down regulated) and P-values as a result of miR-21 overexpression relative to 
premiR-negative in SV-SMC. 
  
Gene 
Log 2 fold change 
(treated/control) 
P-value 
Ratio paired t-test 
1 MMP1 3.46 0.12 
2 MMP3 3.08 0.17 
3 PPARG 2.99 0.22 
4 IL1R2 2.96 0.19 
5 ITGB2 1.5 0.33 
6 IL5 -1.91 0.34 
7 VWF -2.06 0.41 
8 BIRC3 -2.62 0.49 
9 KDR -3.62 0.18 
10 IL1A -5.32 0.02 
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The 10 genes that showed a fold change ≥ ± 1.5 in the premiR-21 relative to 
premiR-negative transfected SV-SMC were grouped according to function (Figure 
4.7). RT-PCR analysis of the individual functional groups was also performed to 
examine the individual gene relative quantification and P values within each group. 
Four genes (IL1A, IL5, IL1R2 and ITGB2) were classified in immunity and 
inflammation category, 3 genes were involved in cell growth and proliferation (BIRC3, 
KDR and PPARG), 2 genes (MMP1 and MMP3) mediated ECM degradation and one 
gene (VWF) was involved in platelet adhesion and haemostasis (Figure 4.8). 
However, the result was variable and only the IL1A gene had a statistically significant 
reduction in premiR-21 transfected SV-SMC (P< 0.05).  
  
Given the degree of variability and the limitations of the array of only having one 
primer set per well for each gene and the non-specific property of SYBR Green, the 
results were validated using specific TaqMan probes and RT-PCR using RNA 
samples from six different patients, including the four samples that were analysed on 
the array. RT–PCR of IL1A mRNA expression revealed a slight but non-significant 
reduction in the premiR-21 relative to the premiR-negative transfected control SV-
SMC (Figure 4.9A). On the contrary, there was a significant increase in MMP1 
expression in the premiR-21 versus control cells (P< 0.05, Figure 4.9B). 
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Figure 4.7: Pie chart of the genes affected by premiR-21 transfection using 
human atherosclerosis array organised according to gene function. 
A pie chart showing the distribution of genes of SV-SMC transfected with 30 nM 
premiR-21 or premiR-negative using the human atherosclerosis array (n= 4). When 
the results were classified according to functional groups 40% of the genes were 
involved in immunity and inflammation, 30% modulate cell growth and proliferation, 
20% mediate ECM degradation and 10% are involved in platelet adhesion and 
haemostasis. 
   
122 
 
 
0 . 0 0 0 1
0 . 0 0 1
0 . 0 1
0 . 1
1
L
o
g
 r
e
la
t
iv
e
 q
u
a
n
t
i
f
ic
a
t
io
n
I L 1 A         I L 5           I L 1 R 2        I T G B 2
  *
0 . 3 4
0 . 3 3
0 . 1 9
A - I m m u n i t y  a n d  i n f l a m m a t i o n
0 . 0 0 0 1
0 . 0 0 1
0 . 0 1
0 . 1
1
L
o
g
 r
e
la
t
iv
e
 q
u
a
n
t
i
f
ic
a
t
io
n
B I R C 3         K D R           P P A R G
B - C e l l  g r o w t h  a n d  p r o l i f e r a t i o n
0 . 4 9
0 . 1 8
0 . 2 2
P r e m i R - v e
P r e m i R - 2 1
0 . 0 0
0 . 0 5
0 . 1 0
0 . 1 5
0 . 2 0
R
e
la
t
iv
e
 q
u
a
n
t
i
f
ic
a
t
io
n
M M P 1          M M P 3
C - E C M  b r e a k d o w n
0 . 1 2
0 . 1 7
0 . 0 0
0 . 0 2
0 . 0 4
0 . 0 6
R
e
la
t
iv
e
 q
u
a
n
t
i
f
ic
a
t
io
n
V W F
D P l a t e l e t  a d h e s i o n
0 . 4 1
 
Figure 4.8: Effect of miR-21 overexpression on genes modulating immunity and 
inflammation, cell growth and proliferation, ECM breakdown and platelet 
adhesion using human atherosclerosis array. 
Relative quantification in the premiR-21 relative to premiR-negative (control) 
transfected SV-SMC, using a human atherosclerosis array. Ten genes showed a fold 
change ≥ ±1.5. The 10 genes are distributed in either immunity and inflammation, cell 
growth and proliferation, ECM breakdown or platelet adhesion (n= 4, *P< 0.05, ratio 
paired t-test, error bars denote SEM). Note the log scale on the y-axis of figures A 
and B. 
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Figure 4.9: Effect of miR-21 overexpression on IL1α and MMP1 mRNA 
expression in SV-SMC. 
RT-PCR of IL-1A (A) and MMP1 (B) mRNA expression in SV-SMC transfected with 
30 nM premiR-21 or premiR-negative (control). Both n= 6, *P< 0.05, ratio paired t test. 
Transcript levels were normalised to the endogenous control GAPDH and error bars 
denote SEM. 
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A number of the other genes that are linked to cardiovascular disorders and showed 
fold change > ± 2 on the array were also followed up using RT-PCR. PPARG showed 
a 3-fold increase on the array in the premiR-21 relative to premiR-negative transfected 
(control) cells, however, its RT-PCR data showed no significant difference between 
the two groups (Figure 4.10A). Array data for KDR also revealed a 3.6 fold reduction 
in the premiR-21 transfected cells relative to control, and its RT-PCR follow-up 
showed a variable response (Figure 4.10B). Besides MMP1, other matrix modulating 
enzymes were also tested. MMP3 array data revealed a 3.1-fold increase in the 
premiR-21 transfected cells relative to control, however by using RT-PCR, there was 
a moderate 30% reduction in MMP3 expression in premiR-21 transfected cells (Figure 
4.10C). Additionally, MMP2 (which was not included in the array) expression in the 
RT-PCR showed a slight increase in the premiR-21 transfected cells relative to control 
(Figure 4.10D), however, due to the high degree of variation between samples neither 
of these RT-PCR results reached statistical significance. 
  
Therefore, having thoroughly studied by RT-PCR the genes highlighted to be 
modulated by miR-21 overexpression and finding a high degree of variability and no 
significant differences the previously discussed genes were eliminated from further 
assessment. Lastly, owing to the significant upregulation of MMP1 by miR-21 
overexpression and its pertinent role in ECM degradation and vascular remodelling, 
MMP1 was selected for follow-up examination to study its mechanistic role in relation 
to miR-21 manipulation. 
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Figure 4.10: Effect of miR-21 overexpression on PPARG, KDR, MMP3 and MMP2 
expression in SV-SMC. 
RT-PCR of PPARG (A, n= 6), KDR (B, n= 2), MMP3 (C, n= 4) and MMP2 (D, n= 6) 
mRNA expression in SV-SMC transfected with 30 nM premiR-21 or premiR-negative 
control. Ratio paired t-test, transcript levels were normalised to the endogenous 
control GAPDH and error bars denote SEM. 
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4.7. Effect of PDGF-BB on IL1α and MMP1 
Having shown that PDGF-BB was able to increase miR-21 expression, and that 
miR-21 induced upregulation of MMP1 and downregulation of IL1α expression as 
illustrated in Figure 4.11; we proceeded to explore a link between PDGF, miR-21 
upregulation and expression of MMP1 and IL1α. Thus to examine the effect of PDGF 
on the two genes affected by premiR-21 transfection; the expression of IL1α and 
MMP1 was measured in PDGF-treated RNA samples of SV-SMC by RT-PCR. A high 
concentration of PDGF (10 ng/ml) was able to progressively impair IL1α expression 
by 40%, 55% and 61% at 24, 48 and 72 h post treatment; respectively compared with 
control group in a manner similar to that produced by premiR-21 transfected cells 
(Figure 4.12).  
 
Additionally, treating SV-SMC with a high concentration of PDGF-induced a 2.4-
fold significant upregulation of MMP1 expression after 24 h treatment relative to 
control (Figure 4.13A). Although there was a high degree of variability, this effect of 
PDGF was maintained for 48 h with a modest transient 1.4-fold increase in MMP1 
expression (Figure 4.13B) and declined to control levels by 72 h treatment (Figure 
4.13C). Finally, the low concentration of PDGF (1 ng/ml) induced no notable 
difference in IL1α (Figure 4.12) or MMP1 expression levels (Figure 4.13).  
 
 
 
Figure 4.11: Schematic diagram showing the effect of PDGF-BB on miR-21 and 
its relationship with MMP-1 and IL-1α. 
Diagram illustrating PDGF-BB-induced upregulation of miR-21 expression in SV-
SMC. The upregulation of miR-21 expression increased MMP-1 and decreased IL-1α 
mRNA expression that could be linked to PDGF. Solid lines represent experimental 
results and dashed line indicates an unknown pathway. 
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Figure 4.12: Effect of PDGF-BB on IL-1α gene expression in SV-SMC. 
RT-PCR of IL1α expression in SV-SMC treated with low (1 ng/ml) or high (10 ng/ml) 
concentration of PDGF, for 24 (A), 48 (B) and 72 h (C), relative to vehicle control 
(acetic acid and 1% BSA in PBS). (n= 5, *P< 0.05, **P< 0.01, ns: not significant P> 
0.05, One way ANOVA and Newman-Keuls multiple comparisons test). Transcript 
levels were normalised to the endogenous control GAPDH and error bars denote 
SEM. 
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Figure 4.13: Effect of PDGF-BB on MMP1 gene expression in SV-SMC. 
RT-PCR of MMP1 expression in SV-SMC treated with low (1 ng/ml) or high (10 ng/ml) 
concentration of PDGF, for 24 (A), 48 (B) or 72 h (C), relative to vehicle control (acetic 
acid and 1% BSA in PBS). (n= 5, *P< 0.05, ns: not significant P > 0.05, One way 
ANOVA and Newman-Keuls multiple comparisons test). Transcript levels were 
normalised to the endogenous control GAPDH and error bars denote SEM. 
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4.8. Discussion 
In this chapter, the factors modulating miR-21 expression and downstream target 
genes of miR-21 were investigated. The principal finding was that miR-21 was 
significantly upregulated (2-fold) by PDGF-BB in SV-SMC and inhibition of either of 
the main signalling pathways of PDGF, Akt and ERK phosphorylation, completely 
prevented miR-21 induction. On the other hand, exposure of native SV-SMC to IL-1α 
significantly reduced miR-21 expression by up to 50%. In addition to this, we have 
identified several genes that are regulated by miR-21 overexpression in SV-SMC. 
Analysis of genes involved in atherosclerosis revealed that miR-21 overexpression 
significantly downregulated IL1α and surprisingly upregulated MMP1 expression. 
Lastly, comparable changes were mirrored with miR-21 overexpression in SV-SMC 
treated with PDGF-BB. 
  
Whilst many cytokines and growth factors are secreted during vascular remodelling 
and vascular SMC proliferation and migration, PDGF-BB is one of the key players that 
is both mitogenic and chemotactic. PDGF-BB is widely expressed in several tissues, 
including SMC and belongs to a subfamily of PDGF-AA, PDGF-AB, PDGF-CC and 
PDGF-DD, which produce their effects through binding and activation of structurally 
related tyrosine kinase receptors, PDGFRα and PDGFRβ (Heldin and Westermark, 
1999). It plays an important role in physiological repair and is therefore implicated in 
SMC phenotype regulation and proliferative vascular diseases such as 
atherosclerosis and restenosis (Zemskov et al., 2012). Among the diabetic molecules 
and mediators tested in this study, only PDGF-BB markedly and significantly 
upregulated miR-21 in SV-SMC (Figure 4.4), suggesting the positive connection 
between PDGF and miR-21 and the possible important role of miR-21 in SMC 
behaviour in the pathogenesis of a variety of vascular diseases (for example 
atherosclerosis, cardiac hypertrophy, aneurysm and heart failure). Additionally, 
inhibition of PDGF-induced Akt and ERK1/2 phosphorylation in SV-SMC returned 
miR-21 expression to a level comparable with non-stimulated cells (Figure 4.5). This 
observation indicates that both pathways are required for PDGF to induce miR-21 
upregulation and inhibition of either Akt or ERK1/2 can prevent PDGF-induced miR-
21 expression. This positive link between PDGF and miR-21 is in agreement with one 
published study by Horita et al. (2011). They reported a 1.5-fold increase in miR-21 
expression in rat aortic SMC treated with 20 ng/ml PDGF for 72 h, which concurs with 
the result obtained in human clinically relevant SV-SMC, where we observed a 2-fold 
increase in miR-21 expression induced by 1 and 10 ng/ml PDGF at 48 and 72 h.  
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Having demonstrated that miR-21 overexpression reduced IL-1α and increased 
MMP-1, we then investigated whether PDGF could also modulate these two factors. 
With regards to the effect of PDGF on MMP1 upregulation, this was also consistent 
with another study that demonstrated the effect of PDGF alone and in combination 
with TGF-β inducing MMP1 upregulation through the ERK1/2 pathway (Ito et al., 
2009). Although they did not relate their finding to miRs, as an extension of our own 
findings and the study by Ito et al. (2009), it would be interesting to identify whether 
the upregulation of MMP1 is associated with miR-21 upregulation as ERK1/2 was one 
of the important signalling pathways through which PDGF upregulated miR-21 
expression (Figure 4.14A).  
  
The use of the atherosclerosis array to provide relative quantification of differences 
in gene expression between the treated (premiR-21 transfected) and control (premiR-
negative) RNA samples of SV-SMC was performed to provide a broad indication of 
the genes regulated by miR-21. However, often the results from the array could not 
be recapitulated when samples were reanalysed using specific TaqMan primers for 
RT-PCR. This can be explained by a number of limitations with the array. For 
example, genes on the array were normalised to the Ct values of the geometric mean 
of five housekeeping genes, which may show more variation than the standard 
housekeeping gene, GAPDH which was used to quantify expression using the 
TaqMan primers. Additionally, the fluorescence detection using SYBR Green has 
lower specificity and reproducibility compared to the specific TaqMan probe/primer 
(Petrov et al., 2014). Compared to TaqMan primers, SYBR Green dye is considerably 
more likely to yield false positive results if it binds to any nonspecific double-stranded 
DNA within the sample. Furthermore, the array was provided in 96 well plate format, 
such that only one replicate per gene was performed for each RNA sample, whereas 
all of the TaqMan specific RT-PCR experiments were performed in triplicate. 
   
The ten genes most affected by miR-21 overexpression in SV-SMC were classified 
into four main categories namely (Figure 4.8); immunity and inflammation, cell growth 
and proliferation, ECM degradation and platelet adhesion and haemostasis. This may 
suggest the important role of miR-21 in affecting genes involved in cardiovascular 
diseases. The category with the greatest number of genes affected by miR-21 
overexpression was immunity and inflammatory response, accounting for four of the 
ten genes. Samples overexpressing miR-21 showed ≥ 1.5 fold increase in IL1R2 and 
ITGB2 genes and < -1.5 fold decrease in IL1A and IL5 expression, this perhaps 
suggests the crucial role of miR-21 in immunity. However, the confirmatory RT-PCR 
of IL1A was not significant, suggesting that this was a false positive result. The trend 
131 
 
 
of reduction in IL1A mRNA expression induced by miR-21 upregulation was 
consistent in both the array and RT-PCR data. Perhaps it was a subtle change owing 
to the use of small sample size, and thus increasing sample size would confirm the 
effect of miR-21 overexpression on IL1A. 
 
In the current study, it was intriguing to observe an unexpected upregulation of 
MMP1 induced by miR-21 overexpression both in the array and the confirmatory RT-
PCR. This was a surprising result because miRs always act as negative regulators of 
gene expression at the post-transcriptional levels (Krol et al., 2010, Guo et al., 2010). 
There is no evidence in the literature to suggest that miR-21 has a direct positive 
regulatory effect on gene expression, therefore, it is possible that the effect of miR-21 
on MMP1 is not direct, but perhaps through a mediator or possibly by de-repression 
of a gene that normally acts as a negative regulator of MMP1. 
   
In support of an indirect relationship between miR-21 and MMPs, a previous study 
using a human glioma cell line showed that miR-21 significantly reduced mRNA and 
protein levels of two inhibitors of MMPs; namely RECK and TIMP3 (Gabriely et al., 
2008). RECK is a membrane-anchored MMP inhibitor (Oh et al., 2001) and TIMP3 is 
a tissue inhibitor of MMPs (Qi et al., 2003); their inactivation increases cell invasion. 
Collectively, this suggests that miR-21 can directly downregulate TIMPs and RECK 
leading to upregulation of MMP-1 (Figure 4.14B). Therefore, further exploration of the 
downstream signalling pathway linking miR-21 and TIMPs inhibition would be useful 
to help explain the correlation between miR-21 and MMP1. TIMPs are tissue specific, 
endogenous inhibitors of MMPs, all are capable of inhibiting and modulating the 
activity of most known MMPs (Arpino et al., 2015); however, the activity of MMP 
inhibition varies with each TIMP (Baker et al., 2002). Therefore, future studies could 
use ELISA to measure TIMPs in the conditioned media collected from premiR-21 and 
antimiR-21 transfected SV-SMC to indicate whether miR-21 modulates the secretion 
of TIMPs.  
  
MiR-21 induction by cytokines and several diabetic mediators has been described 
in multiple studies in different types of tissues. MiR-21 has been documented to be 
upregulated by IL-6 and TGF-β in cervical tissues and cardiac fibroblasts 
(Bumrungthai et al., 2015, Lamoke et al., 2015). In this chapter, SV-SMC were 
subjected to different stimuli relevant to atherosclerosis and vascular remodelling. IL-
1α is one of the important cytokines that has proinflammatory effects. It is secreted 
into the extracellular milieu by activated macrophages following vascular injury in 
response to bypass surgery, atherosclerosis and neointimal hyperplasia (El Sayed et 
al., 2016). The result of this study showed that the exposure of SV-SMC to IL1α  
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Figure 4.14: Diagram demonstrating the proposed relationship between PDGF, 
miR-21 and MMP1 expression. 
PDGF increases miR-21 expression in SV-SMC and the upregulated miR-21 induced 
MMP1 overexpression and this could be via suppression of inhibitors of MMP1. The 
upregulation of MMP1 could be linked to PDGF through ERK1/2 signalling pathway 
together with miR-21 overexpression. The red arrow represents our experimental 
results and blue arrows are unknown pathways. 
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significantly repressed miR-21 expression, however, the mechanism involved in this 
effect and the consequence of miR-21 downregulation are still unclear. Thus, further 
investigation of the molecular mechanism by which IL1α downregulated miR-21 and 
the importance of this relationship are required. This can be tested by knockdown of 
IL-1A in ND SV-SMC and measuring whether miR-21 expression could be affected in 
the presence and absence of IL-1α.  
  
We also studied the effect of other inflammatory mediators including TNF-α and 
TGF-β on miR-21 expression, nevertheless, none had any modulatory effect on miR-
21 expression. These data were in contrast to other studies which showed that miR-
21 was among miRs that were upregulated by 10 ng/ml of IL-1β, TNF-α and INF-γ in 
mouse pancreatic β-cells (Roggli et al., 2010) and by TGF-β in human pulmonary 
SMC (Davis et al., 2008). Possible reasons for the discrepancy between our data and 
published research could be due to the tissue-specific expression of miRs and the 
differences in the response between animal and human cells for each miR (Ji et al., 
2007). 
  
The epidemic of diabetes is a severe and growing health problem around the world. 
In the UK, it is reported that 3.5 million people are diagnosed with T2DM and 
approximately half a million have the disease but are undiagnosed 
(https://www.diabetes.org.uk/About_us/What-we-say/Statistics/2015-as-published-
2016/). Diabetic patients experienced long-term metabolic disturbances of 
hyperglycaemia, hyperinsulinaemia and increased inflammatory mediators even 
before being diagnosed. Additionally, studies have revealed that the fluctuated 
glucose levels can induce a significant increase in oxidative damage to the vascular 
endothelial layer and thus deteriorate the protective NO secretion (Chen et al., 
2013a). Those patients are predisposed to cardiovascular complications due to their 
fluctuating metabolic abnormality as a result of untreated high glucose and high levels 
of insulin secretion as a compensatory mechanism of the pancreas. 
 
Therefore, we sought to determine if exposure to diabetic factors could influence 
the expression of miR-21 in ND SV-SMC. MiR-21 has been shown to be upregulated 
in vitro by high glucose (25 mM glucose for 24 h) in glomerular mesangial and 
proximal tubular epithelial cells of diabetic mice (Dey et al., 2011). However, treating 
SV-SMC with 25 mM glucose for 24-72 h in the present study did not alter miR-21 
expression levels. Although insulin can effectively treat hyperglycaemia, it can itself 
increase SMC proliferation and migration (Begum et al., 1998), and SV organ culture 
incubated with cell culture media supplemented with 100 nM insulin were shown to 
increase neointimal formation (Mughal et al., 2010). However, in our study treating 
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SV-SMC with diabetic stimuli (high concentration of either glucose or insulin or in 
combination with inflammatory mediators) produced no appreciable activation of miR-
21 expression. This is most likely because miR-21 expression was not affected by the 
diabetic milieu and this is in agreement with the results obtained in the previous 
chapter that miR-21 expression levels was comparable in SV-SMC obtained from 
T2DM and ND counterparts (Figure 3.16B). Additionally, culturing SMC in the 
presence of hyperglycaemia, hyperinsulinemia or inflammatory cytokines for a short 
period of time (24 -72 h) fails to replicate the hallmarks of diabetic cells, which likely 
retain a metabolic memory of exposure to a diabetic milieu over an extended time 
period (e.g. years).   
  
In summary, PDGF-BB significantly upregulated miR-21 expression in SV-SMC 
through activation of Akt and ERK pathways. Target genes of miR-21 were analysed 
using an atherosclerosis array and MMP-1 was surprisingly upregulated by miR-21 
overexpression. Functionally, MMP1 is highly correlated with cell migration and 
invasion as it facilitates degradation of collagen and ECM and is also involved in 
atherosclerosis, intimal hyperplasia and vascular remodelling (Lee et al., 2011). 
Therefore, MMP1 is explored in detail in the following chapter to examine whether the 
upregulation of MMP-1 mRNA mediated by miR-21 overexpression was further 
inducing MMP-1 activity.
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Chapter 5 
Functional effect of miR-21 overexpression on     
SV-SMC migration 
 
5.1. Introduction 
Whilst miRs play a central role in controlling various physiological processes, there 
is accumulating evidence suggesting that dysregulation of miRs, including miR-21, is 
associated with the pathophysiology of many processes including cardiovascular 
disorders (Wang et al., 2011). MiR-21 is documented to be involved in the 
development of intimal hyperplasia following experimental balloon injury (Cheng et 
al., 2007) and in human arterial atherosclerosis formation (Raitoharju et al., 2011). It 
has been reported that miR-21 plays a crucial role in pulmonary artery SMC migration 
mediated by hypoxia (Sarkar et al., 2011). Additionally, in the field of cancer research, 
miR-21 overexpression in hepatocellular carcinoma has been shown to increase cell 
migration and invasion (Zhou et al., 2013). 
  
Having previously confirmed the significant upregulation of MMP-1 mRNA induced 
by miR-21 overexpression using the human atherosclerosis array and by validating 
using TaqMan-specific RT-PCR primers we decided to study the effect of miR-21 on 
functional modulation of SMC through MMP-1. MMPs are a superfamily of zinc-
dependent endopeptidases that play an essential role in ECM turnover and have been 
shown to be expressed in human atherosclerotic plaque (Shah et al., 1995). The ECM 
degradation process is triggered by the enzymatic activity of active collagenases 
(MMPs- 1, 8, 13 and 18) that digest collagens (Kar et al., 2010), followed by 
gelatinases (particularly MMP-2 and MMP-9) that digest collagen fragments, gelatins 
and basement membrane components such as collagen IV, laminin and elastin (Shi 
et al., 2009). Thus, the proteolytic effect of MMPs plays an essential role in tissue and 
vascular remodelling and cell migration during physiological processes and when this 
becomes dysregulated the resultant increase in cell migration, invasion and 
proliferation can lead to a variety of pathological conditions (Galis and Khatri, 2002). 
In particular, MMP-1 predominantly degrades the triple helical collagen thereby 
increasing its susceptibility to further degradation by the other collagenases and 
proteases. MMP-1 is capable of digesting collagens type I, II, and III, but has the 
highest affinity for type III (Kar et al., 2010). 
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Since intimal hyperplasia plays a key role in the complex process of vascular 
remodelling (Weintraub, 2007), and the uncontrolled proliferation and migration of 
SMC towards the intima mediates the development of vascular diseases such as 
atherosclerosis and restenosis following vein graft surgery (Doran et al., 2008), the 
focus of this chapter was therefore on the role of miR-21 in modulation of SV-SMC 
migration that might be regulated by MMP-1.  
 
5.2. Effect of PDGF-BB on SV-SMC migration  
To examine the effect of PDGF-BB on SV-SMC migration, Boyden chamber inserts 
were used (as described in Section 2.2.6A), in which the chemoattractant PDGF-BB 
(10 ng/ml) was contained in 750 µl of MGM and loaded into the lower chamber in a 
24-well plate. MGM alone acted as a negative control. ND SV-SMC (1 x 105 cells in 
0.5 ml of MGM) were seeded in the Boyden chamber inserts, after being serum 
starved for 48 h. After 6 h, cells which had migrated towards the lower chamber were 
counted in duplicate wells per treatment. The representative image in Figure 5.1A 
shows a higher number of cells migrated towards PDGF versus control. PDGF 
induced a significant 2-fold increase in cell migration towards the lower chamber in 
comparison to control cells (Figure 5.1B, P< 0.01, n= 4).  
 
5.3. Effect of occluding Boyden chamber membranes 
using increasing concentration of collagens on SV-SMC 
invasion 
Owing to the indispensable role of ECM degradation for the remodelling of vascular 
structure, and to the effect of miR-21 on MMP-1 overexpression obtained in the 
previous chapter, a series of experiments were performed to optimise the coating of 
Boyden chambers with collagen. The MMP-1 substrates collagen I and III were tested 
at a range of concentrations (5-100 µg) to select a suitable concentration. Membranes 
were coated with collagen type I or III solutions by adding 100 µl of a serial dilution of 
the stock solution of each collagen. The gel was allowed to stabilise for 2-3 h at RT, 
then incubated at 37 °C to allow pore occlusion. After 24 h, the chamber was washed 
briefly with 0.5 ml of PBS and the remaining solvent and excess collagen were 
removed.   
 
SV-SMC were resuspended in MGM and equivalent numbers of cells were seeded 
on the top chambers coated with the five different concentrations of collagen I or III in 
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comparison to wells coated with 0.01 M HCl (vehicle control). Cells were allowed to 
migrate for 24 h towards MGM supplemented with PDGF-BB (10 ng/ml) in the lower 
chamber and the cells which invaded were stained and counted as described in 
Section 2.2.6. As might be expected, the degree of cell invasion was inversely 
proportional to the concentration of collagen I (Figure 5.2A) and collagen III (Figure 
5.2B). The concentration response curves of percent cells invaded versus collagen 
concentration were plotted and from this, the 50% inhibitory concentration (IC50) for 
collagen I (Figure 5.3A) and collagen III (Figure 5.3B) were calculated to be 
approximately 35 µg. This yielded a window of opportunity to observe the effect on 
cell migration and invasion (either increase or decrease) mediated by miR-21 
manipulation. 
  
138 
 
 
 
 
 
 
 
 
N
u
m
b
e
r
 o
f
 c
e
ll
s
/h
ig
h
 p
o
w
e
r
 f
ie
ld
C o n t r o l P D G F  
0
2
4
6
8
1 0
* *
 
Figure 5.1: Effect of PDGF-BB on SV-SMC migration through Boyden chambers. 
A- Representative images of the underside of the migration membrane showing the 
nuclei of cells which have migrated towards PDGF versus control (MGM). The white 
arrows indicate the nucleus and the red arrows indicate the pores of the membrane. 
Scale bar = 50 µm at x200 magnification. B- Average number of migrated SV-SMC 
using Boyden chamber inserts for 6 h towards the lower chamber of MGM alone or 
MGM containing 10 ng/ml of PDGF (n= 4, **P< 0.01, paired t-test).  
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Figure 5.2: Concentration-dependent effect of coating Boyden chambers with 
collagens I and III on ND SV-SMC invasion. 
Number of SV-SMC which migrated within 24 h through Boyden chamber inserts 
coated with collagen type I (A) or III (B) towards the lower compartment of MGM 
containing 10 ng/ml of PDGF or 0.01 M HCl (control) (n= 2).  
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Figure 5.3: Normalised curves quantifying half maximum inhibitory 
concentration of collagen I and III versus % cells migrated. 
Calculation of a suitable concentration of collagen that inhibits SV-SMC invasion by 
approximately 50% through collagen I (A) or collagen III (B) (n= 2). The concentration 
that inhibited 50% (IC50) of cell invasion was 35 µg for each collagen type. 
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5.4. Time course of miR-21 upregulation in SV-SMC 
Before commencing any functional assay, it was necessary to investigate whether 
the upregulation of miR-21 following transfection was maintained for sufficient 
duration to perform the migration experiments. A time course study was conducted to 
measure miR-21 expression in SV-SMC between 24 – 96 h post transfection with 
either 30 nM premiR-21 or premiR-negative. Cell pellets were collected each day and 
used for RNA extraction and RT-PCR. Within 24 h premiR-21 transfection showed a 
marked 5600-fold increase in miR-21 expression which fell rapidly, but was still 
significantly upregulated to 550-fold at 96 h. This confirmed that miR-21 
overexpression would be maintained over the required period of time following 
transfection (n= 6, Figure 5.4, P< 0.001). 
 
5.5. Effect of miR-21 overexpression or knockdown on 
SV-SMC invasion through collagen I or III coated Boyden 
chambers 
To explore the role of miR-21 overexpression or knockdown on the invasion and 
migration capacity of SV-SMC from five different donors, Boyden chamber 
membranes were coated with either 35 µg collagen I or III before being loaded with 
mock, premiR-21 and antimiR-21 transfected cells together with their negative 
controls (transfection method is described in Section 2.2.2). The lower chambers were 
loaded with either MGM as a control or MGM containing 10 ng/ml PDGF-BB. 
Transfected SV-SMC were incubated in MGM for 48 h then 1 x 105 cells were seeded 
into the coated chambers in duplicate wells for 24 h to allow collagen degradation and 
invasion of cells through the coated membranes. Conditioned medium from the upper 
chambers was collected to measure secreted MMP-1 and invaded cells were counted 
in 10 different fields under high power as described in Section 2.2.6. All cells migrated 
towards PDGF, regardless of their transfection type, such that a significant 3-fold 
increase in cell invasion was observed relative to control (Figure 5.5). Unexpectedly, 
overexpression of miR-21 did not augment the invasion capacity of SV-SMC through 
either collagen I or collagen III (Figure 5.5A). Moreover, miR-21 knockdown in SV-
SMC did not affect the invasive capacity of cells through either collagen type (Figure 
5.5B). 
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Figure 5.4: Time course of miR-21 expression for 96 h post transfection in SV-
SMC. 
RT-PCR of miR-21 expression in ND SV-SMC transfected with 30 nM premiR-21 or 
premiR-negative (control) over a time course of 24-96 h (n= 6, ***P< 0.001; One Way 
ANOVA, with Newman Keuls post-hoc test). 
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Figure 5.5: Effect of overexpression or knock down of miR-21 on SV-SMC 
invasion through collagen I or III. 
Number of invaded SV-SMC following transfection with either 30 nM premiR-21 or 
premiR-negative (A) or 100 nM antimiR-21 or antimiR-negative (B) compared to mock 
transfected (lipofectamine only) cells. Cells invaded through Boyden chambers 
coated with 35 µg collagen I or collagen III and allowed to migrate for 24 h towards 
MGM (control) or 10 ng/ml of PDGF-containing MGM. (Each group n= 5, *** and ### 
P< 0.001, One way ANOVA, with Newman Keuls post-hoc test), ns= not significant. 
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5.6. Pro-MMP-1 secretion by transfected SV-SMC 
during invasion through collagen I and II coated Boyden 
chambers 
In order for SV-SMC to be capable of migrating through collagen coated Boyden 
chambers towards the chemoattractant PDGF-BB they must secrete MMPs. In 
particular, MMP-1, by cleaving collagen, has emerged as a key contributor to vascular 
remodelling and atherosclerosis (Sukhova et al., 1999). The conditioned medium 
collected from the upper chamber of the Boyden chambers was therefore utilised to 
analyse the secretion of pro-MMP1 (precursor of MMP-1) by the invaded cells, using 
an ELISA kit as described in 2.2.7A. PremiR-21 transfected cells migrating towards 
PDGF through both collagen types showed a modest increase in pro-MMP-1 
secretion in comparison to premiR-negative (control) cells (Figure 5.6A). Additionally, 
the highest increase in pro-MMP1 secretion was observed in the mock transfected 
group migrating through both collagen I and III towards PDGF-BB (n= 5, Figure 5.6A). 
However, conditioned medium from antimiR-21 transfected SV-SMC showed no 
significance difference in pro-MMP-1 secretion compared with its antimiR-negative 
control group (n= 5, Figure 5.6B).  
 
5.7. Correlation between SV-SMC invasion through 
collagen I and III and pro-MMP-1 secretion 
To determine whether there was a correlation between the number of invaded 
transfected SV-SMC and pro-MMP-1 secretion into the conditioned medium, the 
number of cells invaded through collagen was plotted against the amount of pro-MMP-
1 secretion. There was no correlation between the increase in cell invasion through 
collagen I (R2 = 0.04, Figure 5.7A) or collagen III (R2 = 0.011, Figure 5.7B) with the 
secreted amount of pro-MMP-1 (n= 40). 
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Figure 5.6: Measurement of pro-MMP-1 secretion into conditioned media 
collected from premiR-21 and antimiR-21 transfected SV-SMC invading through 
collagen I or III coated Boyden Chambers. 
Pro-MMP-1 secretion in the CM of invaded SV-SMC transfected with either 30 nM 
premiR-21 or premiR-negative (A), 100 nM antimiR-21 or antimiR-negative (B) 
compared to mock transfected (lipofectamine only) cells using ELISA. Cells were 
allowed to migrate through Boyden chambers coated with 35 µg collagen I or collagen 
III for 24 h towards MGM (control) or 10 ng/ml PDGF-containing MGM. The actual 
ELISA measurement of MMP-1 concentration secreted by invaded SV-SMC through 
collagen type I and III was 0.09 – 5.12 ng/ml and 0.04 - 5.2 ng/ml; respectively (n= 5, 
*P< 0.05, One way ANOVA, with Newman Keuls post-hoc test), ns= not significant. 
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Figure 5.7: Correlation between the number of cells invaded through collagens 
and pro-MMP-1 secretion. 
Correlation between SV-SMC invasion through Boyden chambers coated with 35 µg 
collagen I (A) or collagen III (B) and pro-MMP-1 secretion in the CM measured using 
ELISA. Cells were transfected with 30 nM premiR-negative or premiR-21, 100 nM 
antimiR-negative and antimiR-21 or mock (lipofectamine only) towards MGM (control) 
or 10 ng/ml of PDGF-containing MGM (n= 40).  
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5.8. Measuring pro- and active MMP-1 secretion in 
premiR-21 and antimiR-21 transfected SV-SMC 
Although we observed that the secretion of pro-MMP-1 was not significantly 
increased by miR-21 overexpression, this did not rule out a change in MMP-1 activity 
and it remains possible that the ratio between pro-MMP-1 and active MMP-1 was 
varied. In another set of experiments, the effect of miR-21 overexpression or 
knockdown on pro-MMP-1 expression and activity was measured in transfected 
unstimulated SV-SMC that were collected 3 days after transfection. Conditioned 
medium was then collected to analyse pro-MMP-1 and active MMP-1 using two 
different ELISA kits (described in Section 2.2.7A/B). PremiR-21 transfected cells did 
not show a significant difference in pro-MMP-1 secretion relative to control cells nor 
did anti-miR-21 transfected cells (n= 4, Figure 5.8A). Measuring the active MMP-1 
secretion in another three different sets of transfected cells also showed no significant 
difference between premiR-21 or anti-miR-21 treated cells relative to their negative 
controls (n= 3, Figure 5.8B).   
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Figure 5.8: Measurement of pro-MMP-1 and active MMP-1 in conditioned media 
of premiR-21 and antimiR-21 transfected (non-stimulated) SV-SMC using 
ELISA. 
Measuring pro-MMP-1 (A, n= 4) and active MMP-1 (B, n= 3) secretion in CM of SV-
SMC transfected with 30 nM premiR-negative (PremiR-ve) or premiR-21, 100 nM 
antimiR-negative (antimiR-ve) or antimiR-21 for 72 h using ELISA (ratio paired t-test).  
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5.9. Discussion 
The data in this chapter have validated the efficient chemoattractant activity of 
PDGF-BB and also confirmed that SV-SMC invasion through collagen I or III coated 
membranes was inversely proportional to the concentration of collagen. 
Overexpression of miR-21 in SV-SMC following transfection with 30 nM premir-21 
was demonstrated to still be significantly upregulated for 96 h. Surprisingly, the 
overexpression and knockdown of miR-21 did not modulate the invasive capacity of 
cells through either collagen I or III. Neither the invaded nor unstimulated premiR-21 
transfected cells mediated a distinguishable effect on the levels of secreted pro-
MMP1 and active MMP-1.  
  
PDGF-BB is known to be an important chemoattractant and mitogenic agent for 
normal angiogenesis and wound healing. In terms of vascular injury, PDGF activates 
SMC migration from the media and accumulation of ECM into the intima which leads 
to intimal hyperplasia, atherosclerosis and coronary occlusion (Newby and Zaltsman, 
2000). In the present study, the main focus was on the regulation of SV-SMC 
migration and invasion by miR-21 manipulation in the presence of 10 ng/ml PDGF-
BB. As expected, this study showed a significant 2-fold increase in SV-SMC migration 
towards PDGF when compared to cells migrating towards MGM alone (Figure 5.1), 
confirming the chemotactic effect of this agent. We confirmed miR-21 overexpression 
reached the maximum significant 5600-fold increase 24 h after premiR-21 
transfection, followed by a reduction to 550 fold increase, which was maintained at 96 
h post transfection (Figure 5.4). 
  
  Having previously shown that MMP-1 mRNA expression levels were enhanced by 
miR-21 overexpression in SV-SMC, it was hypothesised that miR-21 could enhance 
cell invasion and migration through Boyden chamber membranes coated with MMP-
1 substrates. MMP-1 activity was reported to correlate well with ECM breakdown, cell 
migration and invasion (Shi et al., 2009). We employed a transwell invasion system 
by coating the membranes of a double well chamber with collagen I or collagen III. 
Therefore, the SV-SMC were encouraged to secrete MMP-1, degrade the coating and 
finally invade through the membrane towards PDGF. MMP-1 is an important interstitial 
collagenase, capable of degrading collagen type I, II, and the highest affinity to cleave 
collagen type III in the adventitial layer of the vascular wall, thus facilitating cell 
migration through the matrix barrier (Lemaitre and D'Armiento, 2006, Cooley, 2013). 
Treating a mouse carotid artery injury model with MMP-1 signalling inhibitor 
significantly reduced cell migration and intimal hyperplasia formation (Austin et al., 
2013b). It has been upregulated with other MMPs following femoral artery injury in 
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mice (Lijnen et al., 1999) and MMP-1 upregulation has been reported in a monolayer 
of vascular SMC line (Rb-1 cells) in response to mechanical injury (James et al., 
1993). 
 
In our study, the number of cells that migrated to the lower chamber was inversely 
proportional to increasing collagen concentration (Figure 5.2). After analysis, the 
approximate amount of collagen that prevented 50% of cell invasion (IC50) was 35 µg 
for both collagen I and III. This was applied separately to occlude the pores in the 
Boyden chamber membranes and provide a “window” to see the functional effect for 
the premiR-21 and antimiR-21 transfected cells.  
  
Following loading the transfected SV-SMC in parallel to their controls in the upper 
compartment of the Boyden insert, significant migration was seen in all cells exposed 
to PDGF. Surprisingly, overexpressing miR-21 did not increase the invasive capacity 
of cells above the negative control treatment. Multiple reasons could explain the lack 
of response in cells overexpressing miR-21 (Figure 5.5). Firstly, having observed that 
miR-21 overexpression enhanced MMP1 mRNA expression, this suggests that MMP-
1 is an indirect target of miR-21 in SV-SMC. MiR-21 may affect the expression of 
gene(s) that negatively regulate MMP-1 gene expression and activity such as TIMPs. 
Secondly, studies have shown that MMP-1, when upregulated, can activate other 
cytokines such as IL-1β (Schonbeck et al., 1998), and in the previous chapter, IL-1α 
showed a negative regulation of miR-21 expression. This indicates that the secreted 
cytokines which might accompany MMP-1 secretion could mask the possible effect 
by miR-21 in inducing SMC migration. This could be confirmed by knocking down IL-
1α and comparing the effect of premiR-21 transfection on cell invasion both in the 
presence and absence of IL-1α. Thirdly, the result may also suggest that cells reached 
the maximum migratory capacity in response to PDGF and no further effect, if 
produced, by miR-21 and MMP-1 was noticeable. Repeating the invasion assay using 
PDGF concentrations less than 10 ng/ml would be helpful to identify whether a 
suitable lower submaximal concentration of PDGF would allow miR-21 manipulation 
to modulate the invasive capacity of SV-SMC. 
  
Cell invasion and migration is a complex process that is mainly initiated by 
adhesion, locomotion, invasion and chemotaxis (Ross, 1993). For the vascular SMC 
to migrate, cell surface receptors are stimulated that lead to series of coordinated 
remodelling events which in turn change the cytoskeleton structure. This starts with 
actin polymerisation which directs the cells toward the chemoattractant agent. All 
organelles of the cells are then carried along with the remodelling cytoskeleton by 
adaptor and motor proteins to support cell transfer with the cytoskeleton. Additionally, 
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reactive oxygen species secretion and activation of MAPK/ERK signaling pathway are 
mediators usually stimulated in response to PDGF chemoattractant activity (Xi et al., 
1999, Schroeder, 2014).  
 
  
The role of miR-21 in inducing cell migration and invasion has been reported in the 
majority of cancer cells (Selcuklu et al., 2009a), however, little is known about its role 
in vascular SMC migration. MiR-21 overexpression increased migration of 
hepatocellular carcinoma through targeting PTEN, PDCD4 and RECK (Zhou et al., 
2013) and miR-21 inhibition decreased hepatocellular cell proliferation and migration 
(Meng et al., 2007b). MiR-21 has been reported to induce tumour invasion and 
metastasis by targeting multiple tumours and metastasis suppressor genes including 
PTEN, PDCD4, and tropomyosin 1 (Zhu et al., 2008, Liu et al., 2013) and therefore, 
miR-21 knockdown may provide a useful anticancer therapeutic target. MiR-21 
overexpression was reported to increase cell migration and invasion of esophageal 
squamous cell carcinoma by suppression of PDCD4 gene (Liu et al., 2014), gastric 
cells by inhibiting PTEN (Zhang et al., 2012), bladder cell carcinoma through targeting 
PTEN (Lei et al., 2015), breast cancer by suppressing smad7 (Han et al., 2016). 
Additionally, miR-21 overexpression showed a significant increase of airway SMC 
migration using transwell assay and that was through targeting PTEN (Liu et al., 
2015). 
 
Numerous studies have also reported the ability of miRs to regulate multiple 
components involved in the cellular adhesion process (Valastyan and Weinberg, 
2011). In particular, tropomyosin 1 is widely distributed in different cell types and it is 
an important actin cytoskeletal regulatory protein which stabilises microfilaments 
(Perry, 2001). Repression of tropomyosin 1 mRNA and protein levels by miR-21 could 
play an important role in enhancing cell migration (Zhu et al., 2007). 
  
In line with cell migration, it is documented that under physiological and pathological 
conditions, MMPs work in coordination to facilitate cell invasion (Aoyagi et al., 1998). 
ECM breakdown, and perhaps other MMPs if secreted, would not help to increase 
invasion through collagen I or III coating. Furthermore, the exact mechanism 
underlying MMP activation that occurs either at the intracellular or extracellular levels 
is still unclear. Typically, activators cause a conformational change in the molecule 
that separates the Cys residue of pro-MMP from the zinc atom to generate a 
functionally active site. This might be through proteolytic activation by cellular 
endoproteases, oxidative stress, phosphorylation and via extracellular enzymes such 
as plasmin, thrombin or trypsin (Cha et al., 1996, Gaffney et al., 2015). Owing to the 
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lack of contact with other environmental cues that help in MMPs activation, thus, our 
study provided an incomplete picture of the ECM degradation and cell invasion.  
 
During vascular remodelling, various factors such as inflammatory mediators 
increase MMP secretion and steps to modulate cell migration appear to function as a 
network. Therefore, using in vitro SMC in culture fails to accurately recreate the 
precise environment which leads to MMP-1 secretion in vivo. Performing an in vivo 
study using intact SV could help to elucidate the signalling pathways and other 
mediators involved in the stimulation of cell invasion.  
  
It would have been interesting to measure TIMPs secretion, particularly TIMP1, 
TIMP2 and TIMP3 which are the main inhibitors of MMP-1 (Flannelly et al., 2002) in 
the CM collected. They can reduce MMP-1 activity, which in turn would affect SMC 
migration capacity through the coated membranes. Lastly, after 72 h of transfection, 
it may be too early to detect the functional effect of miR-21 overexpression on MMP-
1 protein activity and further time points might be studied to detect changes in SMC 
invasive phenotype. On the other hand, knockdown of miR-21 in SV-SMC did not 
change or reverse the invasive capacity of the cells through either collagen types. 
Taken together, understanding this previously mentioned scenario would help to give 
a broader overview of the condition and factors involved during SMC migration to 
conclude the role of miR-21 through MMP-1 expression in inducing SMC migration 
and invasion. 
 
This was followed by measuring pro-MMP-1, the precursor of MMP-1 which 
indicates the total amount of MMP-1 secreted in the CM of invaded SV-SMC. MMP-1 
is a member of a family of zinc-dependent proteases whose major function is the 
breakdown of ECM polymers (Newby, 2012). Given the ability of MMP-1 to affect the 
invasive capacity of the cells through collagen I and III, it was surprising that the 
secreted MMP-1 that we measured did not increase cell invasion in a discernible 
manner. There was a modest increase in total MMP-1 secretion in the premiR-21 
transfected cells which is consistent with the increased MMP-1 mRNA in the previous 
chapter, but it was not significant (Figure 5.6). This indicated that the MMP-1 secretion 
was not sufficient to induce an increase in cell invasion. Alternatively, other mediators 
that are regulated by miR-21 overexpression could have been secreted into the CM 
and antagonised the effect of miR-21 on MMP-1 upregulation. Likewise, there was no 
significant difference in total MMP-1 secreted by the antimiR-21 relative to antimiR-
negative transfected cells which migrated through collagen towards PDGF. An 
important study demonstrating the important role of miR-21 in cell migration was 
performed by Sarkar et al. (2010). They found that miR-21 was 3-fold increased when 
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the pulmonary SMC were exposed to hypoxia. Additionally, miR-21 targeted PDCD4 
and SPRY2 and knocking down miR-21 was able to reduce 50% of cell migration 
induced by hypoxia. Although they did not measure the secreted MMPs by hypoxic 
cells, it could be that the cells should be exposed to a pathological insult like a vascular 
injury to be triggered to simulate the clinical pathological situation. 
 
Although the secretion of MMP-1 is low in unstimulated cells, another set of 
experiments was carried out to assess the role of miR-21 manipulation on MMP1 
secretion in the absence of the chemoattractant PDGF. Total and active MMP-1 
secretion after premiR-21 or antimiR-21 transfection of SV-SMC showed that there 
was no significant difference in MMP-1 secretion in both groups. In the presence of 
an increased interstitial shear flow the increased cell migration correlated with the 
increased activity of MMP-1 (Shi et al., 2009). This indicates that the lack of the 
pathological stimuli would not trigger the static cells to secrete MMP-1 and also 
perhaps suggests that the inactive zymogen (MMP-1) remained in the latent stage 
due to the lack of sufficient trigger to activate the proteolytic activity in the unstimulated 
cells. It could be that miR-21 manipulation is unlikely to have an impact on active or 
pro-MMP-1 secretion at the tested time point (72 h). Lastly, there was no correlation 
between pro-MMP1 secretion and the number of migrated cells, through either 
collagen I or III in any of the transfected cells groups, indicating that other MMPs may 
be more important in mediating the migration of cells through collagen I and II than 
MMP-1. 
   
In summary, MMPs including MMP-1 play a crucial role in vascular remodelling and 
cell migration. The results of this study demonstrated the inability of miR-21 
overexpression to induce a further increase in cell migration; nevertheless, the 
secretion of pro-MMP-1 was moderately increased in the premiR-21 transfected cells.
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Chapter 6 
The role of miR-21 on SV-SMC proliferation and 
exploring downstream target genes 
 
 Introduction 
In the normal healthy vessel wall, SMC have an extremely low rate of proliferation, 
however following vascular injury, these cells display high plasticity and can adopt a 
dedifferentiated phenotype (proliferative and migratory). They remain susceptible to 
environmental factors; such as ECM components (laminin and collagens), reactive 
oxygen species, thrombin, TGF-β, shear stress and many other neuronal or 
mechanical mediators (Owens et al., 2004). PDGF-BB is a particularly important 
growth factor secreted by platelets, activated macrophages, vascular SMC and 
endothelial cells upon vascular injury. It is one of the major mitogenic factors which is 
also involved in SMC proliferation and motility by activating the MAPK signalling 
pathway in vascular physiological conditions (Kawai-Kowase and Owens, 2007).  
 
Recent reports have documented the important role miRs play controlling vascular 
SMC proliferation and differentiation in vascular diseases (Jamaluddin et al., 2011). 
In response to the wound healing process, proliferative and synthetic genes are also 
modulated by miRs. For example, suppression of the Smad1 protein by miR-24 
resulted in a synthetic human pulmonary SMC phenotype (Chan et al., 2010). MiR-
21 is involved in cell proliferation, migration, and invasion both in human and murine 
cancer and cardiovascular diseases (Rossi et al., 2007, Jazbutyte and Thum, 2010). 
Additionally, evidence suggests that the target proteins of miR-21 differ according to 
cell and tissue type (Bronnum et al., 2013).  
 
The most commonly reported target genes for miR-21 that showed a strong 
association with cell proliferation, migration, apoptosis and invasion are Phosphatase 
and Tensin Homolog (PTEN), Programmed Cell Death 4 (PDCD4), Sprouty-1 (Spry-
1) and Reversion-Inducing Cysteine-rich protein with Kazal motifs (RECK). Therefore, 
they were chosen to be investigated in this chapter in the context of SV-SMC 
remodelling. 
 
PTEN is known to regulate the cell cycle and inhibit phosphoinositide-3-kinase 
(PI3K). It is the most documented target gene affected by miR-21 in different cancer 
and cell types such as breast (Meng et al., 2006), hepatocellular cancer (Bao et al., 
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2013) and vascular SMC of rat carotid artery (Maegdefessel et al., 2015). In a key 
study, upregulation of miR-21 accelerated rat carotid artery SMC proliferation, whilst 
downregulation of the aberrantly overexpressed miR-21 in SMC inhibited neointimal 
formation following vascular injury, and this was through targeting PTEN (Ji et al., 
2007). Following vascular injury, it was reported that PTEN was downregulated by 
miR-21 leading to increased SMC proliferation (Horita et al., 2011). 
 
PDCD4 is a tumour suppressor protein, which inhibits cell proliferation, migration 
and invasion and has been shown to block protein synthesis by inhibiting translation 
(Zhen et al., 2013). MiR-21 induces translational inhibition of PDCD4 protein 
synthesis and targets PDCD4 mRNA post-transcriptionally (Asangani et al., 2008). 
Thus, the upregulated miR-21 in a variety of human cancers and inflammation have 
been associated with the loss of PDCD4 protein in these conditions (Lu et al., 2008b). 
Additionally, miR-21 mediated cell proliferation and migration through targeting 
PDCD4 in human pulmonary SMC (Sarkar et al., 2010). MiR-21 also protected cardiac 
myocytes in rats from ischaemia reperfusion injury through targeting PDCD4 (Cheng 
et al., 2010). 
 
Another gene known to be a target for the actions of miR-21 is SPRY-1, a member 
of a protein family that negatively regulate receptor tyrosine kinase signalling by 
suppression of the activation of MAPK/ERK (Jazbutyte and Thum, 2010). In a study 
by Thum et al. (2008), upregulated miR-21 inhibited Spry-1 resulting in activation of 
MAPK that led to cardiac fibrosis and dysfunction in mice. Finally, both PDCD4 and 
Spry-1 were found to be involved in miR-21 mediated rat cardiac fibrosis (Bronnum et 
al., 2013). 
 
RECK is a membrane-anchored glycoprotein and a novel regulator of MMPs. Its 
main function is to protect the ECM by negatively regulating expression and activity 
of MMP-2, MMP-9 and MT1-MMP (Oh et al., 2001, Takahashi et al., 1998). RECK is 
another tumour suppressor gene that prevents angiogenesis, invasion and metastasis 
and is documented to be a target of repression by miR-21 in different tissues including 
lung and gastric cancers, glioma cells and many others (Gabriely et al., 2008). Current 
studies have shown that the reduction or inactivation of RECK by miR-21 
overexpression is strongly associated with increased cell proliferation, invasion, and 
apoptosis (Wu et al., 2014). Although these four genes have a strong presence in the 
literature and their roles have been explored in various tissues, the regulation of these 
genes by miR-21 in SV-SMC has not been investigated. 
 
In addition to these four genes, miR-21 regulates several other genes in different 
human and animal tissues and these are listed in Table 1.4. 
156 
 
 
The aims of this chapter were therefore 
 To explore the role of miR-21 in human SV-SMC proliferation. 
 To identify the major targets of miR-21 and signalling pathways mediating 
its function in SV-SMC phenotypic changes, cell proliferation, and vascular 
remodelling. 
 
 Effect of PDGF-BB on SV-SMC proliferation 
Having previously observed the significant upregulation of miR-21 mediated by 
PDGF-BB (1 and 10 ng/ml) in chapter 4, we proceeded to investigate the link between 
the PDGF-induced changes in cell proliferation and miR-21 overexpression in SV-
SMC. To determine a suitable concentration of the mitogenic growth factor PDGF-BB 
for inducing cell proliferation, SV-SMC were seeded at a density of 1 x 104 cells per 
well in FGM in 24-well plates. Cells were incubated overnight at 37 °C in 5% CO2 to 
enable attachment, then quiesced in MGM for 72 h. At this point cell counts were 
performed on day 0 and the culture medium was replenished on the remaining cells 
with MGM containing either 1, 3, 5, or 10 ng/ml of PDGF. For each condition, cells 
were counted in triplicate and parallel wells of cells incubated in MGM or FGM acted 
as negative and positive controls, respectively. All culture medium was replenished 
with the same treatment at 48 h and cells were then counted 48 h later (Day 4). Cell 
proliferation showed a proportional increase in response to PDGF concentration from 
1-10 ng/ml (n= 2, Figure 6.1). The highest concentration of PDGF (10 ng/ml) showed 
an approximately equal proliferation rate to FGM which is the positive control. A 
concentration of 3 ng/ml was chosen as a suitable submaximal mitogenic 
concentration that showed approximately 50% increase in cell count relative to MGM 
and was used in the subsequent proliferation experiments. 
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 Effect of miR-21 overexpression/knockdown on SV-
SMC proliferation 
SMC proliferation is a key feature of neointimal hyperplasia and vascular 
remodelling, therefore the effect of miR-21 on cell proliferation was investigated. To 
examine the association of miR-21 with PDGF-related proliferation in ND SV-SMC, 
cells were transfected with premiR-21, antimiR-21 or their respective negative 
controls (premiR-ve and antimiR-ve) as described in Section 2.2.2. Briefly, 1 x104 cells 
were seeded in triplicate in MGM in 24-well plates after being transfected and 
quiesced for 48 h. Following 24 h, cells from the four groups were counted at day 0. 
The remaining wells were treated with 3 ng/ml PDGF in MGM to stimulate cell 
proliferation at a submaximal level, as the cell cycle is growth factor-dependent. The 
medium was replenished on day 2 and cells quantified on day 4.  
  
When data from five patients were pooled together, there was a trend of increased 
cell number at day 4 in the premiR-21 transfected cells relative to their controls, 
indicating an increase in cell proliferation (Figure 6.2A). However, knockdown of miR-
21 in SV-SMC did not induce changes in proliferation rate from day 0 to 4 relative to 
antimiR-negative transfected cells (n= 5, Figure 6.2B). Following measurement of the 
individual fold change in cell count for each group, the cells overexpressing miR-21 
in SV-SMC exhibited a significant 1.8 fold increase in cell number at day 4 relative to 
premiR-negative transfected cells (P< 0.01), whereas the antimiR-21 transfected cells 
were comparable to control (Figure 6.2C), suggesting that miR-21 knockdown was 
not sufficient to reverse the PDGF effect on cell proliferation. 
  
158 
 
 
 
M G M M G M 1 3 5 1 0 F G M
0
1 0
2 0
3 0
C
e
ll
 n
u
m
b
e
r
 (
t
h
o
u
s
a
n
d
s
)
D a y  4D a y  0
P D G F  ( n g / m l )
 
Figure 6.1: Concentration-dependent SV-SMC proliferation in response to 
PDGF-BB. 
SV-SMC proliferation in response to PDGF-BB stimulation (1-10 ng/ml) relative to 
MGM (negative) and FGM (positive) controls. Cells were quantified at day 0 and 4 
following PDGF treatment (n= 2). 
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Figure 6.2: Effect of miR-21 upregulation/knockdown on SV-SMC proliferation. 
Proliferation rate of SV-SMC transfected with (A) 30 nM premiR-negative (P-ve) or 
premiR-21 (P-21), (B) 100 nM antimiR-negative (A-ve) or antimiR-21 (A-21), from day 
0 - 4 in the presence of 3 ng/ml of PDGF. (C) Measurement of fold change in the 
transfected cell proliferation at day 4 relative to day 0 (**P< 0.01, ns = P> 0.05, paired 
t-test, n= 5). 
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 Exploration of potential target genes involved in 
SV-SMC proliferation following miR-21 manipulation 
Having observed a significant increase in cell number induced by miR-21 
overexpression in SV-SMC, we proceeded to examine the downstream signalling 
pathway involved in the functional effects mediated by miR-21; particularly on cell 
proliferation.  
Western blotting was conducted as described in Section 2.2.11 after miR-21 
manipulation as in Section 2.2.2 for the four different genes (PTEN, PDCD4, SPRY-
1 and RECK). These genes were chosen as they are the documented as potentially 
negatively regulated targets of miR-21 and highly associated with SMC proliferation 
and migration (detailed in 6.1).  
 
A. Effect of miR-21 modulation on PTEN, PDCD4, and SPRY-1 protein 
expression 
SV-SMC were transfected with premiR-21 or antimiR-21 for 6 h followed by 72 h 
incubation in MGM. Cell lysates were prepared and the effect of miR-21 manipulation 
on PTEN, PDCD4, and SPRY-1 proteins was measured using western blotting. 
Densitometry measurements for each patient lysate were normalised relative to β-
actin as a loading control.  
 
As shown in the representative blots there was no difference in PTEN (A), PDCD4 
(B) and SPRY-1 (C) protein levels between the premiR-21 and antimiR-21 transfected 
cells and their negative controls (Figure 6.5). The average densitometry of different 
patients samples also showed that PTEN (n= 6), PDCD4 (n= 4) and SPRY-1 (n= 3) 
protein expression was not affected by miR-21 manipulation in SV-SMC after 72 h of 
transfection (Figure 6.3).  
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Figure 6.3: Quantification of PTEN, PDCD4, and SPRY1 protein after 72 h of premiR-21 and antimiR-21 transfection in SV-SMC.  
SV-SMC were transfected with 30 nM premiR-ve (P-ve) control, premiR-21 (P-21) or 100 nM antimiR-negative (A-ve) control or antimiR-21 (A-
21). Representative immunoblots of PTEN (A, n= 6), PDCD4 (B, n= 4) and SPRY-1 (C, n= 3) protein levels 72 h following transfection are shown. 
All densitometry measurements were normalised to β-actin and the pooled densitometry data are displayed in the lower panel showing the 
average response of miR-21 overexpression or knockdown on the three proteins relative to their respective negative controls (all were non-
significant, One way ANOVA with Newman Keuls post-hoc test).
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B. Effect of miR-21 modulation on RECK mRNA expression and protein 
levels in SV-SMC 
 
Recent studies have shown that miR-21 modulates cell growth and invasion 
through downregulating RECK in many cancer cell types (Wu et al., 2014). To test 
the effect of miR-21 on RECK expression in SMC, miR-21 was overexpressed and 
knocked down in SV-SMC. Following 72 h of transfection, cell pellets were collected 
for RNA extraction and RT-PCR. MiR-21 overexpression led to approximately 50% 
reduction in RECK mRNA expression (P< 0.001, n= 8, Figure 6.4A). However, miR-
21 knockdown did not change RECK mRNA expression (n= 4, Figure 6.4B). 
   
As shown in the previous chapter in Figure 5.4, transfecting SV-SMC with premiR-
21 significantly maintained miR-21 overexpression up to 96 h following transfection. 
Having observed the inhibitory effect on RECK mRNA induced by the overexpression 
of miR-21, we next sought to examine the effect on RECK protein levels. Cell lysates 
of premiR-negative and premiR-21 transfected SV-SMC were collected for western 
blotting over a time course from 24 to 96 h. However, over this time interval, no 
significant changes in RECK protein were detected, as represented in the blot (Figure 
6.5A) and the quantitative measurement of RECK protein (n= 7, Figure 6.5B). This 
indicates that the effect of miR-21 overexpression on RECK might not reach the 
translational effect at this relatively early time point.  
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Figure 6.4: Effect of miR-21 overexpression/knockdown on RECK mRNA 
expression in SV-SMC 72 h following transfection. 
RT-PCR of RECK mRNA of SV-SMC transfected with 30 nM premiR-negative or 
premiR-21 (A, n= 8) or 100 nM antimiR-negative or antimiR-21 for 72 h (B, n= 4). 
(***P< 0.001, ns= not significant; ratio paired t-test). Gene expression was normalised 
to the endogenous control GAPDH and error bars denote SEM. 
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Figure 6.5: Time course of the effect of miR-21 overexpression on RECK 
protein levels in SV-SMC. 
A representative immunoblot of RECK protein expression in SV-SMC transfected with 
30 nM premiR-21 (+) or premiR-negative control (-) measured on day 1-4 post 
transfection (A). Protein levels were normalised to α-tubulin and densitometry 
measurement of RECK protein performed showing effect of miR-21 overexpression 
relative to premiR-ve at day 1 to 4 post transfection in cells from seven patients (B) 
(One way ANOVA with Newman Keuls post-hoc test). 
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Whilst RECK protein levels appeared unresponsive to miR-21 overexpression 
when measured over 24-96 h post transfection, this raises the possibility that the 
turnover rate of RECK is low and the response to miR-21 is delayed until a later time 
point. Therefore, we then sought to determine whether an effect on RECK protein 
expression in SV-SMC could be observed at the later time point of days 8 and 10 post 
miR-21 transfection.  
  
As shown in a representative immunoblot RECK protein was downregulated after 
day 8 in cells overexpressing miR-21 (Figure 6.6A). The quantitative measurement of 
RECK bands in five different samples consistently showed approximately a 40% 
reduction in RECK protein in the premiR-21 relative to premiR-negative transfected 
SV-SMC at day 8 (Figure 6.6B, P< 0.001) and to a lesser extent at day 10 (Figure 
6.6C, P< 0.05).   
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Figure 6.6: Quantification of RECK protein expression in SV-SMC following 
miR-21 overexpression at day 8 and 10. 
SV-SMC were transfected with 30 nM premiR-negative (P-ve) or premiR-21 (P-21). 
Representative blot shows the effect of miR-21 overexpression on RECK protein at 
day 8 and 10 (A). Pooled densitometry data of the effect of miR-21 overexpression 
on RECK protein level in SV-SMC at day 8 (B) and day 10 (C) (***P< 0.001 and *P< 
0.05, ratio paired t-test). Both n= 5, RECK bands were normalised to α-tubulin as a 
loading control.   
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 Discussion 
The present study demonstrated the role of miR-21 in significantly enhancing SV-
SMC proliferation. In addition to this, four target genes of miR-21 were investigated. 
Interestingly, whilst miR-21 overexpression in SV-SMC did not appear to modulate 
PTEN, PDCD4, and SPRY1, it did downregulate RECK mRNA and protein levels, 
although the protein changes were not evident until 8-10 days following transfection.  
    
The focus in this chapter was on SMC proliferation, which is a key cellular 
contributor of intimal hyperplasia. Vascular SMC are inherently stable in healthy 
vessels, however in response to injury, ECM degradation and mitogen secretion 
activate SMC phenotypic switching into a proliferative phenotype (Bennett et al., 
2016). Additionally, upon injury, platelet adhesion and PDGF secretion into the 
vascular wall also stimulate SMC proliferation and migration into the intima (Marx et 
al., 2011). The effect of the mitogenic agent PDGF-BB on SV-SMC is of particular 
interest as the SV graft is a widely used conduit in CABG. The data in this chapter 
further confirmed, as expected the mitogenic effect of PDGF-BB, whereby PDGF-BB-
induced SV-SMC proliferation in a concentration-dependent manner. 
  
MiR-21 plays a critical role in cardiovascular diseases, as discussed in the earlier 
chapters, and was found to be significantly upregulated in different proliferative CVDs 
(Ji et al., 2007). In the present study, we investigated the regulation of SV-SMC 
proliferative phenotype by miR-21 modulation. The proliferation assay was performed 
in the presence of PDGF-BB which is an important growth factor that triggers cell 
cycle transition from G0 into G1 phase. To determine the potential role of miR-21 in 
modulating SV-SMC proliferation, a submaximal concentration of PDGF-BB (3 ng/ml) 
was introduced into the premiR-21 and antimiR-21 transfected cells. In all five 
patients’ samples, there was a noticeable increase in cell proliferation in the premiR-
21 transfected cells at day 4 relative to premiR-negative control. However, the 
absolute cell count was variable and this was most likely due to the inherent 
differences in proliferation rate between cells from different donors. This inherent 
variation in SV-SMC function was demonstrated in Figure 3.4A and has been 
previously reported by our group (Madi et al., 2009). However, after normalising to 
fold change, cell proliferation at day 4 was found to be significantly increased in the 
premiR-21 transfected cells. 
  
Thus, the result of increased SMC proliferation by miR-21 overexpression in our 
study was consistent with previous work performed by Ji et al., 2007. They induced 
injury in rat carotid artery that resulted in miR-21 upregulation. They also 
demonstrated the proliferative effect of miR-21 on cultured SMC and knocking down 
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miR-21 significantly reduced SMC proliferation. This suggests the important role of 
miR-21 in promoting cell proliferation and perhaps involvement in the process of 
intimal hyperplasia. On the contrary, in our study, knockdown of miR-21 did not show 
a reversal or change in SV-SMC proliferation at day 4 relative to control. The results 
in our study may indicate that the premiR-21 pathway to facilitate cell proliferation is 
more sensitive to miR-21 overexpression. Whilst antimiR-21 transfection did not show 
a change in proliferation this suggests other miRs or transcription factors are more 
important and thus proliferation of the cells was persistent. As we showed previously 
that antimiR-21 transfection was able to knockdown the overexpressed miR-21 
(Figure 3.8), it would be useful to combine antimiR-21 with premiR-21 to test the effect 
of miR-21 knockdown after miR-21 overexpression on modulating cell proliferation. 
This would be consistent with the study performed by Ji et al., 2007 as they induced 
injury to the artery following angioplasty to induce miR-21 aberrant upregulation, then 
they knocked down miR-21 (Ji et al., 2007). This potentially models the clinical 
situation while our cultured cells were not exposed to the pathological insult that 
normally upregulates miR-21 in SMC. 
  
Overexpression of a single miR, such as miR-21 in our study, can repress more 
than 100 mRNAs, which then lead to a reduction in a large fraction of protein-coding 
genes (Miranda et al., 2006). Moreover, several miRs can act on the same target 
gene. The next logical step was therefore to identify the potential downstream target 
genes of miR-21 that may mediate the augmented response in SV-SMC proliferation. 
Four of the documented target genes (PTEN, PDCD4, SPRY1 and RECK) were 
studied at the protein level 72 h after overexpressing or knocking down miR-21. 
  
 
Several cancer studies have confirmed the negative regulation of PTEN by miR-21 
overexpression in a number of tissues such as liver (Meng et al., 2007a), breast (Han 
et al., 2012) and lung (Zhang et al., 2010). PTEN has consistently been demonstrated 
to be a target of repression by miR-21 leading to cell proliferation, migration and 
invasion in cancer cells, however, little is known about its role in vascular SMC 
(Jazbutyte and Thum, 2010). Additionally, the study performed by Ji et al. (2007) 
showed that miR-21 is involved in the neointimal formation and cell proliferation and 
the resultant in vitro reduction of proliferation in SMC treated with antimiR-21 was 
associated with an upregulation of PTEN protein expression. In contrast to this work, 
we were unable to detect an inverse relationship between miR-21 and PTEN protein 
levels after 72 h of premiR-21 transfection and instead found there to be no correlation 
between the premiR-21 or antimiR-21 transfection and PTEN protein levels relative 
to control. The discrepancy between the findings of Ji et al. (2007) and our recent data 
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is probably due to differences between species and tissues utilised. PTEN protein 
was measured in our present study at an early time-point (72 h post miR-21 
transfection) and perhaps the effect of miR-21 modulation on its translation process 
was not yet reached, whilst in the study by Ji et al (2007), their PTEN measurement 
was conducted 14 days after angioplasty. Finally, it could be that PTEN is not a 
downstream target for miR-21 in SV-SMC. Our unexpected result is also supported 
by recent work performed by Hermansen and colleagues who demonstrated no 
correlation between miR-21 and PTEN using human glioblastoma cells (Hermansen 
et al., 2016). They suggested that this could be down to an absence of miR-21 binding 
sites on PTEN mRNA.  
 
The other two documented target genes of miR-21 which are known to be involved 
in cell proliferation and migration were also tested by western blotting. PDCD4 is an 
important miR-21 target mediating an anti-apoptotic effect on vascular SMC and rat 
cardiac myocytes (Cheng and Zhang, 2010, Cheng et al., 2009b). Additionally, miR-
21 downregulated Spry-1 in mouse model which is known to regulate cardiac 
fibroblast growth (Thum et al., 2008). In our study, both PDCD4 and SPRY-1 protein 
levels were measured 72 h after SV-SMC transfection with premiR-21 and antimiR-
21. The result showed no significant difference between premiR-21 and antimiR-21 
relative to their negative controls for both genes. This is perhaps due to the previously 
mentioned reasons about the lack of changes to miR-21 modulation obtained with 
PTEN, including the early time of measurement or these genes are not targets of miR-
21 in SV-SMC.  
  
RECK is an important negative regulator of MMPs (particularly, MMP-2 and MMP-
9) that degrade ECM and are involved in regulation of several human physiological 
and pathological conditions. Different studies documented that RECK is negatively 
regulated by miR-21 in glioma cells (Gabriely et al., 2008), lung and gastric cancers 
(Zhang et al., 2008, Wu et al., 2014). Various studies have also shown that RECK 
plays a crucial role in cell proliferation (Li et al., 2012, Wu et al., 2014). RECK was 
also a target of repression by miR-21 in different types of cancer-mediated cell 
proliferation such as in oesophagal squamous cell carcinoma (Wang et al., 2013a), 
keratinised oral cancer (Jung et al., 2012) and prostate cancer (Reis et al., 2012).  
  
Studies have demonstrated that factors stimulating vascular SMC proliferation, for 
example, growth factors, act through activation of the Rac1-Skp2-P27Kip signaling 
pathway (Matozaki et al., 2000). Additionally, the normal cell cycle is regulated by 
cyclin-dependent kinases, which are inactivated by P27KiP (Wu et al., 2008). SKP2 (S-
phase kinase-associated protein 2) is important for P27KiP degradation resulting in 
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increased cell proliferation. The effect of RECK on suppressing cell proliferation is 
mainly mediated by inhibiting SKP2 (Pan et al., 2015) as illustrated in Figure 6.7. 
Thus, this suggests that the suppression of RECK by miR-21 can facilitate cell 
proliferation by removing the suppressive effect on cell progression mediated by 
RECK as illustrated in Figure 6.8.  
 
 
Figure 6.7: Schematic diagram shows the effect of RECK on cell cycle. 
Cell cycle progression is dependent on the regulated expression and activation of a 
set of kinases (cyclin-dependent kinases (CDK) and cyclins which phosphorylate 
proteins that regulate cell growth. CDK inhibitors P21Cip1 and P27Kip1 delay cell cycle 
progression by inhibiting CDK activity. RECK can suppress cell cycle by 
downregulation of SKP2 and consequent upregulation of P27Kip1. 
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Figure 6.8 Diagram demonstrating the mechanism of action of RECK and its 
relation to miR-21 and SV-SMC proliferation. 
A model for RECK targeted by miR-21 in relation to cell cycle regulating factors and 
SMC proliferation. Overexpression of miR-21 negatively regulates RECK expression, 
consequently triggering SKP2 activation and P27KiP1 degradation. This will remove 
the repression effect on cell cycle progression and eventually increase cell 
proliferation. SKP2 (S-phase kinase-associated protein 2) and P27Kip1 (also known as 
cyclin-dependent kinase inhibitor 1B).  
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In the present study, using RNA samples of SV-SMC from eight different donors, 
overexpressing miR-21 induced a significant reduction in RECK mRNA 72 h after 
transfection. In contrast, the antimiR-21 transfected cells did not show any significant 
difference in RECK mRNA expression relative to control, indicating that the impact of 
miR-21 on RECK expression was most apparent when levels of miR-21 were 
increased by premiR-21. The SV-SMC that were utilised in all the functional assays 
were not compromised by the pathological stimulus which aberrantly upregulates 
miR-21 as would occur in pathological conditions to be able to knock it down. 
Therefore, this probably makes it difficult to detect any effect in antimiR-21 
experiments. Moreover, whilst miR-21 is knocked down, other miRs are still active 
and can modulate cell proliferation through other target genes. 
   
MiRs downregulate their target mRNA levels, mediating degradation and 
repression of protein synthesis (Dangwal et al., 2012). Therefore, it was important to 
validate that the achieved reduction in RECK mRNA was translated into a reduction 
in RECK protein. The effect of miR-21 overexpression on RECK protein was analysed 
by western blotting. However, unexpectedly, changes in RECK protein were not 
detectable at any time points up to 96 h. Different proteins have different turnover 
rates and the lack of response to miR-21 overexpression at earlier time points 
suggested that the turnover rate of RECK is relatively slow.  
 
To check whether this was the case, RECK protein measurement was performed 
at day 8 and 10 following miR-21 overexpression. The result showed that miR-21 
overexpression significantly reduced RECK protein levels in the SV-SMC of five 
different donors at both time points. This also confirms that the turnover rate of RECK 
protein is low and thus the changes in its level are not detectable shortly after 
transfection.  
  
Finally, the effect of miR-21 upregulation on increasing SV-SMC proliferation was 
a key finding in this study. Therefore, it is important to follow up this observation and 
map the expression of RECK mRNA and protein levels for miR-21 functional effects, 
particularly in cell proliferation. Following up future work would identify whether miR-
21 is involved in mediating functional or phenotypic changes through RECK gene 
repression.  
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Chapter 7  
General discussion and conclusions 
 
Coronary artery disease is a chronic disorder which remains the major cause of 
death worldwide. When coronary blood flow is compromised, CABG surgery using 
the IMA and SV is mandatory to re-route the coronary circulation. However, neointimal 
hyperplasia and graft restenosis remain important clinical problems and are 
considered a major limitation following the use of SV in CABG surgery. T2DM is one 
of the major metabolic disorders which increases the patients’ susceptibility to 
cardiovascular diseases. Moreover, T2DM patients are prone to higher rates of CABG 
surgery and associated with worse consequences following SV graft surgery (Berry 
et al., 2007). Although a large amount of research is directed to targeting intimal 
hyperplasia and prolonging graft patency, none of the available therapies treat the 
original factor(s) involved in this process and robust therapeutics are lacking. 
Therefore, further investigation of the molecular mechanisms of intimal hyperplasia is 
mandatory to improve the patency of SV after CABG.  
 
 
Recent research highlighted the important role of miRs in epigenetic regulation of 
the vasculature (Alexander and Owens, 2012) and in particular, vascular remodelling 
(Albinsson and Sessa, 2011). The aberrant expression of miRs is highly associated 
with cardiovascular abnormalities and therefore, these miRs could be possible novel 
therapeutic targets in regulating vascular remodelling. Distinct miRs are also 
implicated in T2DM and its related cardiovascular diseases including neointimal lesion 
formation following vein grafting (Alexandru et al., 2016, Riches et al., 2014). 
 
  
MiR-21 is one of the most highly expressed miRs in the vasculature and is strongly 
associated with increased cell migration and proliferation (Wang et al., 2015a). 
However, relatively few studies have linked miR-21 to vascular remodelling and SV 
graft failure. Vascular SMC play a vital role in neointima formation and vascular 
remodelling following SV grafting owing to their plasticity and phenotypic switching 
into a synthetic and migratory phenotype (Alexander and Owens, 2012). Neointima 
formation is highly associated with excessive SMC proliferation and migration; 
therefore we decided to explore the role of miR-21 in vascular remodelling, particularly 
with respect to human SV-SMC phenotypic changes.  
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SV-SMC from T2DM patients exhibited a distinct phenotype that was previously 
reported by our group (Madi et al., 2009). The diabetic SV-SMC were characterised 
by their rhomboidal shape and slower proliferation rate in comparison to cells from 
non-diabetic counterparts. Therefore, the central research question was whether miR-
21 was aberrantly expressed in native T2DM SV-SMC and was responsible for 
cellular dysfunction that conceivably contributes to the poor outcomes of SV grafting 
in T2DM patients. Whilst the results of this study emphasised that SV-SMC from 
T2DM patients exhibited distinct morphological and functional characteristics from ND 
counterparts, the level of miR-21 was comparable between T2DM and ND SV-SMC. 
Therefore, we proceeded to investigate the role of miR-21 expression levels in 
regulating SV-SMC phenotype and function independent of T2DM. 
 
  
SMC are the principal cellular component of the vascular wall and their plasticity is 
very important for both normal adaptation to the arterial circulation and vein 
remodelling. When this remodelling becomes abnormally excessive in the conduit, 
adverse remodelling subsequently leads to intimal hyperplasia. Thus, miR-21 was 
artificially overexpressed or knocked down in native SV-SMC to ascertain which 
phenotypic and functional changes were mediated by miR-21 modulation. SV-SMC 
were treated with ‘diabetic factors’ and various mediators involved in vascular 
remodelling to identify which physiological and pathological factor(s) could modulate 
miR-21 expression. Whilst “diabetic” stimuli had no significant effect on miR-21 
expression, PDGF-BB demonstrated a robust miR-21 overexpression in SV-SMC and 
therefore, it was utilised in the subsequent functional assays. A broad range of 
downstream target genes of miR-21 that are related to vascular remodelling were 
investigated using a focussed ‘atherosclerosis’ RT-PCR array. Out of the 84 array 
candidate genes, a follow up RT-PCR showed significant changes induced by miR-
21 overexpression on MMP-1 and IL-1A mRNA expression. 
 
 
To address our research question and to further achieve the goals of the research, 
MMP-1 was followed up to test the effect of miR-21 in inducing SV-SMC invasion 
through MMP-1 modulation. The regulation of miR-21 on SV-SMC proliferation, the 
second principal factor of intimal hyperplasia, was also explored. Finally, the findings 
obtained in this thesis indicate that miR-21 undoubtedly plays an important role in the 
regulation of the SMC phenotype and hence can be implicated in intimal hyperplasia 
and vascular remodelling. The main findings of this study are summarised in the 
following section. 
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7.1. Principal findings 
  Distinct phenotypic differences between T2DM and ND SV-SMC 
that were not associated with miR-21 overexpression 
Both SV-SMC obtained from T2DM and ND patients co-expressed the 
characteristic SMC marker genes α-SMA and SM-MHC, identifying them as SMC. 
Consistent with previous studies obtained by our group (Riches et al., 2014), SV-SMC 
cultured from T2DM exhibited a predominantly rhomboidal phenotype, increased 
average cell area, and slower proliferation rate. In contrast, the ND SV-SMC exhibited 
mainly classical spindle-shaped elongated SMC morphology, with higher proliferation 
rate. These distinct phenotypes probably play an important role in increasing the 
prevalence of cardiovascular diseases and impaired vascular remodelling in T2DM 
compared to ND counterparts. Owing to their slow proliferation rate, this may underlie 
an impaired adaptation of diabetic cells within SV grafts used to bypass the arterial 
circulation. A rhomboidal dedifferentiated SMC phenotype was also reported to be a 
prevalent phenotype in atherosclerotic lesions and intimal hyperplasia (Hao et al., 
2003). The characteristic larger cell area could predispose the diabetic SV graft to 
earlier neointimal lesion formation. Perhaps with poor glycaemic control, loss of the 
associated intercellular interaction or a higher apoptotic propensity of the expanded 
cell size results in accelerated intimal occlusion in diabetic patients. This can therefore 
explain, at least in part, the higher tendency to graft failure in diabetic patients 
following SV graft surgery (Gao et al., 2015). 
 
 
 
Whilst miR-21 expression was elevated in SV-SMC of a small number of five T2DM 
patients relative to non-diabetic counterparts, this difference was not reproducible 
when the number of samples was increased to 16. A subsequent power calculation 
revealed that a sample number of 11 was required for each group to obtain 80% 
power of detecting a 50% difference between the two groups. Therefore, the initial 
assumption that was built on the elevated miR-21 in five diabetic samples was 
underpowered to make robust conclusions. In contrast, the comparable level of miR-
21 expression obtained from the 16 different samples was powered enough to draw 
the conclusion that miR-21 levels were not associated with diabetic status and thus 
subsequent experiments of the project were carried out on SV-SMC of non-diabetic 
patients. 
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 PDGF-BB significantly upregulated miR-21 in SV-SMC through 
activation of Akt and ERK pathways 
The results of our study clearly showed a significant upregulation of miR-21 
expression by 1-10 ng/ml PDGF in SV-SMC (Figure 7.1A). We also showed that 
blocking either one of the two main signalling pathways of PDGF (Akt or ERK) 
abrogated the PDGF-induced miR-21 overexpression, indicating that both pathways 
are linked to each other and both pathways are involved in miR-21 upregulation as 
inhibiting either pathway abolished miR-21 upregulation. 
 
 
PDGF-BB is an important chemoattractant and mitogenic factor known to be 
activated in response to vascular injury. PDGF-BB exerts its biological action through 
binding and phosphorylation of protein tyrosine kinase receptors (PDGFRα and 
PDGFRβ). Dimerisation of the activated PDGF receptors mediates activation of 
several downstream intracellular pathways through PI3K, Src, Ras, Raf and PIP2  
pathways which eventually lead to phosphorylation of ERK/MAP kinase and Akt 
pathways within the target cell (Farooqi and Siddik, 2015, Lopatina et al., 2014).  
The genomic location of pri-miR-21 is reported to be on chromosome 17q23.2., in 
the 10th intron where miR-21 overlaps with the protein-coding gene, TMEM49 (Patel 
and Noureddine, 2012). Regulation of miR-21 expression is conserved and controlled 
by its own promoter sequence (Fujita et al., 2008). The promoter of miR-21 can be 
controlled independently of the overlapping gene. MiR-21 transcription can be 
activated by activation protein 1 (AP-1) and by other multiple transcription factors and 
hormones including signal transducer and activator of transcription 3 (STAT3), 
oestrogen and the androgen receptor (Jazbutyte and Thum, 2010). 
 
The transcription factor AP-1 complex is composed of Fos (c-fos, FosB, Fra1 and 
Fra2) and Jun (c-jun, JunB and JunD) proteins (Eferl and Wagner, 2003). ERK is 
reported to be an upstream regulator of Fra2 and JunB (Reich et al., 2010, Cevik et 
al., 2008). Additionally, phosphorylation of PI3K/Akt by PDGF is reported to induce 
selective modulation of c-jun and Fra1 which are major components of AP-1 
(Ramachandran et al., 2010). Therefore, the underlying mechanism of miR-21 
overexpression could be a dual activation of Fra2/JunB by ERK and c-jun/Fra1 by Akt 
signalling pathways.  
 
 
 
PDGF has previously been shown to modulate the expression of several other 
miRs, mediating an increase in cell proliferation and migration (Yu and Li, 2014). 
Overexpression of miR-31 accompanied by increased SMC proliferation was reported 
in rat carotid artery treated with 20 ng/ml of PDGF. Interestingly, the selective 
MAPK/ERK pathway inhibitor PD98059 significantly reduced miR-31 expression in 
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SMC (Liu et al., 2011). PDGF also induced miR-221 expression alongside the PDGF-
BB-mediated increase in pulmonary artery SMC proliferation and migration (Davis et 
al., 2009). Knocking down these two miRs (miR-31 and miR-221) partially reduced 
PDGF-mediated SMC dedifferentiation. Conversely, other miRs were downregulated 
by PDGF-BB including miR-30, miR-198 and miR-216 in different types of cancer cells 
(Shao et al., 2011).  
 
A relatively recent study has shown that treating human hepatic stellate cells with 
5 ng/ml PDGF significantly upregulated miR-21 and collagen α1 expression (Wei et 
al., 2013) resulting in increased liver cell fibrosis. The positive association between 
PDGF-BB and miR-21 in SV-SMC suggests that the regulatory effect of PDGF on 
SMC proliferation and migration could possibly be mediated through miR-21 
upregulation. 
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Figure 7.1: Schematic illustration showing the effect of PDGF-BB on miR-21 and 
the upregulation of miR-21 on SV-SMC function. 
Diagram illustrating PDGF-BB-induced activation of PDGF-Rs and upregulation of 
miR-21 and MMP-1 expression in SV-SMC (A). Overexpression of miR-21 
downregulated RECK that could be responsible for the increased SMC proliferation 
via inhibiting SKP2 and migration through inhibiting MMPs (B). Solid lines represent 
experimental results and dashed lines indicate an unconfirmed mechanism. 
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 Overexpression of miR-21 induced MMP-1 mRNA expression  
MiR-21 is reportedly elevated 4.6-fold in human atherosclerotic plaque (Raitoharju 
et al., 2011). For the first time to be documented, our human ‘atherosclerosis’ 
microarray and RT-PCR data showed that miR-21 overexpression induced 
upregulation of MMP-1 mRNA expression. Owing to the natural negative effect of 
miRs on gene expression, the upregulation of MMP-1 by miR-21 is almost certainly 
indirect, which makes this relationship challenging to uncover. This indicates that miR-
21 may inhibit a gene that normally acts as a negative regulator for MMP-1 such as 
TGF-β1 (Uria et al., 1998). The response of MMP-1 to different miRs is variable, as 
one would expect. Overexpression of miR-155 reduced the expression of MMP-1 
whereas miR-203 overexpression showed an indirect increase of MMP-1 expression 
in rheumatoid arthritis synovial fibroblasts and this was highly correlated with chronic 
inflammation of the disease (Stanczyk et al., 2008).  
 
Our study also showed that the upregulation of MMP-1 expression was observed 
in PDGF-treated SV-SMC, indicating a positive relationship between PDGF, miR-21, 
and MMP-1 (Figure 7.1). As described earlier the activation of PDGF receptors by 
PDGF leads to Akt and ERK phosphorylation which further stimulate downstream 
intracellular signalling pathways. Studies also reported that AP-1, which is an 
activating transcription factor for miR-21, directly activates MMP-1 transcription 
(Wang et al., 2012). Therefore, the precise signalling mechanism behind MMP-1 
upregulation by PDGF, and whether miR-21 upregulation is involved in this pathway, 
would be interesting to delineate. It is reported that PDGF can upregulate MMP1 
expression through activation of the ERK1/2 signalling pathway (Ito et al., 2009), 
therefore it would be pertinent to block the ERK pathway in the PDGF-treated SV-
SMC and measure whether MMP1 and miR-21 are regulated. 
Both PDGF and MMP-1 are important mediators involved in SMC phenotypic 
switching and vascular injury (Metz et al., 2012). MMP-1 is a collagenase that 
preferentially degrades type I and III collagen; facilitating SMC migration and invasion 
in the vessel wall. MMP-1 plays an important role in vascular remodelling and clinical 
studies have also reported that high serum levels of MMP-1 are a useful predictor of 
human atherosclerosis (Lehrke et al., 2009). In an experimental mouse model, 
blocking MMP-1 with FN-439 (a selective MMP-1 inhibitor) following carotid injury 
significantly attenuated neointima formation inside the artery (Austin et al., 2013a). 
Therefore, by further understanding the mechanistic link between miR-21 and MMP-
1 upregulation, antimiR-21 therapy could potentially provide a protective therapeutic 
strategy for human intimal hyperplasia. 
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 Overexpression of miR-21 increased SV-SMC area and 
proliferation 
A number of studies reported that miR-21 expression was dysregulated in various 
proliferative and migratory cancer and cardiovascular diseases (reviewed in Bonci 
(2010)). In our study, overexpression of miR-21 in SV-SMC altered the typical spindle 
SMC morphology, resulting in increased average cell area. Therefore, miR-21 was 
able to drive phenotypic changes in SMC that are characteristic of those observed in 
both native T2DM and dedifferentiated SMC phenotypes in general. These 
dedifferentiated phenotypes that are also reported to be involved in atherosclerotic 
lesion may cause enzymatic changes and enhanced fibrosis inside the intima (Hao et 
al., 2003, Campos et al., 2016) and thus, the upregulation of miR-21 in SV-SMC can 
be implicated in atherosclerosis and neointimal occlusion. 
 
 
A key finding in our study was that overexpression of miR-21 significantly increased 
SV-SMC proliferation. Whilst my project was in progress, an important study was 
published by McDonald et al. (2013). They reported a significant upregulation of miR-
21 expression in ex vivo models of porcine, mouse and human SV graft models, 
mediating neointima formation in comparison to the ungrafted SV. When they blocked 
miR-21 in the human ex vivo SV graft with 5000 nM antimiR-21 or using miR-21 
ablated mice, the neointima was significantly reduced in the engrafted SV. Therefore, 
the increased miR-21 was implicated in increasing SMC and fibroblast proliferation 
and thus increased neointima formation.  
 
Our finding is highly important as increased SMC proliferation is an important risk 
factor for proliferative cardiovascular diseases. The characteristic dedifferentiated and 
proliferative phenotype of SMC is positively correlated with neointima formation 
following SV graft surgery (Sur et al., 2014). Numerous other studies have 
documented increased tumour growth induced by miR-21 via inhibition of tumour 
suppressor genes including PTEN and PDCD4 (Luo et al., 2015, Bao et al., 2013). 
Moreover, RECK has an anti-proliferative effect by suppressing cell cycle progression 
as illustrated in Figure 6.7. RECK was validated as a target of repression by miR-21 
that induced lung cancer cell line growth and proliferation (Xu et al., 2014). However, 
the target genes by which miR-21 regulates SV-SMC proliferation are not yet 
identified and this is a worthy area for further investigation (Figure 7.1).  
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 RECK was identified as a novel target of miR-21 overexpression 
Various studies have demonstrated the vital role of RECK in relation to 
angiogenesis and cell migration (Takahashi et al., 1998, Yoon et al., 2003). RECK 
was shown to be a target of repression by miR-21 in different types of cancer cells. 
For example, miR-21 was reported to increase proliferation and invasion of gastric 
cancer (Zhang et al., 2008), glioma (Gabriely et al., 2008) and lung cancer cell lines 
through direct inhibition of RECK (Xu et al., 2014). However, to the best of our 
knowledge, RECK expression and its modulation by miR-21 has not been 
investigated with respect to neointima formation and vein graft failure.  
Our preliminary finding demonstrated a novel finding by identifying RECK as a 
target gene of miR-21 in SV-SMC (Figure 7.1B). Overexpression of miR-21 
significantly downregulated RECK mRNA at the earlier time point (at day 3) and a 
subsequent reduction of protein levels was detected at a later time point (day 8-10). 
Therefore, targeting RECK by miR-21 would be implicated in the phenotypic changes 
mediated by miR-21 overexpression.  
 
 
RECK is a membrane-anchored protein that protects ECM and regulates basement 
membrane remodelling; mainly by suppressing MMP-2, MMP-7, MMP-9 and MT1-
MMP (Oh et al., 2001, Miki et al., 2007). It suppresses MMP secretion from the cell 
and competitively inhibits MMP protease enzymatic activity (Welm et al., 2002). In 
addition to its anti-migratory effect, RECK has an anti-proliferative effect that is mainly 
mediated by inhibiting SKP2. SKP2 is an important stimulus for cell proliferation by 
mediating P27KiP degradation which usually blocks cyclin-dependent kinases (Figure 
6.7) (Pan et al., 2015). This therefore suggests that the suppression of RECK by miR-
21 can facilitate cell proliferation by removing the negative effect on cell progression 
mediated by RECK as illustrated in Figure 7.1B.   
 
7.2. Strengths and limitations  
Owing to the high propensity of SV graft failure, the use of SMC from human SV 
samples which are harvested for CABG surgery strongly links the findings to the 
clinical problem. Therefore, a major strength of this thesis is the use of SMC explanted 
from different patients allowing us to study the effect of miR-21 on this specific cell 
type. Another strength of this study was the use of multiple patients’ samples in each 
experiment to reflect inter-individual variation from a wider population. In this study, 
SV-SMC were cultured from a total of 136 patients recruited between August 2012 
and January 2016. Although the majority of CABG patients are T2DM patients (Riches 
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et al., 2014), we deliberately selected ND patients in chapters 4-6, therefore the 
majority of SV-SMC were from ND patients (78%). The mean ± S.E.M. age of the 
patients was 64 years ± 0.9. Most of them were males (88%), reflecting the high 
prevalence of coronary artery disease and CABG in male patients. 
 
The walls of blood vessels normally experience a dynamic environment that is 
subjected to forces mediated by pressure variations and haemodynamic factors such 
as shear stress and the vasoactive property of the wall itself. It is worth mentioning 
that all of the functional experimental studies in this thesis were conducted by using 
in vitro SMC under static culture conditions and importantly in the absence of a 
defined vascular injury. The lack of an interaction with the haemodynamic 
environment and the contribution of other cell types and matrix molecules in our cell 
culture models are obvious limitations. In addition there was a high degree of 
variability in the response of cells obtained from different patient’s samples and a 
large number of samples were needed to achieve sufficient statistical power. 
 
7.3. Future directions: 
 Investigate the role of miR-1260 and miR-1280 
An initial screening was performed to identify the levels of miR expression in SV-
SMC between 6 T2DM samples relative to 6 ND samples. The results obtained from 
a High Throughput Sequencing approach (Vertis Biotechnologie AG) were presented 
in Table 3.1. Relatively more is known about miR-145 and miR-21 which have been 
studied widely in cancer and cardiovascular fields, indicating their important roles in 
physiological and pathological conditions. Although there was a high fold increase of 
miR-1260 and miR-1280 in T2DM relative to ND, there are only two studies implicating 
miR-1280 in metastasis of bladder and pancreatic cancer cells (Majid et al., 2012, 
Piepoli et al., 2012), but nothing in the cardiovascular field. Similarly there are no 
existing studies suggesting high expression of miR-1260 in cardiovascular diseases 
or involvement of this miR in any other type of human disease which make them 
challenging to undertake in this thesis. Studying miR-1280 and miR-1260 as an 
extension to the current project might be attractive to investigate their role in 
cardiovascular diseases. 
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 Silencing RECK gene and test the effect of miR-21 modulation 
on SV-SMC function 
It is known that increased SMC proliferation and migration from the media into the 
intima plays a major role in neointimal hyperplasia and vein graft occlusion. Having 
obtained a significant increase in SV-SMC proliferation induced by miR-21 and given 
that miR-21 overexpression suppressed the RECK gene, it would be a worthwhile aim 
to investigate and confirm whether the effect of miR-21 on SMC migration and 
proliferation is mediated through RECK inhibition (Figure 7.1).  
 
The increased SV-SMC proliferation induced by miR-21 was observed 7 days 
following transfection which is equivalent to the time at which miR-21 overexpression 
showed a significant suppression of RECK protein levels. As an extension of the 
increased SMC proliferation effect induced by miR-21, it would be an attractive 
strategy to use siRNA to knock down RECK, then the effect of miR-21 on SMC 
proliferation could be measured in the presence and absence of RECK gene 
silencing. If silencing RECK showed a reduction in cell proliferation in the cells 
overexpressing miR-21, this would provide novel evidence for RECK in miR-21-
induced SMC proliferation. RECK has been reported to antagonise cell proliferation 
by inhibiting SKP2 (Figure 6.8), which activates cyclin-dependent kinase in the G1 
phase of the cell cycle and therefore its suppression promoted cancer cell proliferation 
(Pan et al., 2015).  
 
 
 
Flow cytometry, or fluorescence-activated cell sorting (FACS), is a widely used 
method to stain DNA and assess cell cycle progression. FACS analysis could be used 
to test the effect of RECK modulation on cell cycle progression. The FACS technique 
is able to identify and quantify each phase of the cell cycle affected by miR-21-induced 
RECK modulation, namely G0 (resting phase), G1 (metabolic changes), S (DNA 
synthesis), G2 (protein synthesis) and M (cell division) (Kim et al., 2012). SMC would 
be seeded in a 6-well plate, transfected with premiR-21 or antimiR-21 and incubated 
for 7-8 days. Cells could then be harvested and the effect of RECK on cell cycle 
progression measured by FACS.  
 
 
 
Another important property of RECK that could regulate SV-SMC function is its role 
in inhibiting cell migration. MMP-2 and MMP-9 are the two most affected proteases 
inhibited by RECK, so these MMPs could be measured to test their contribution in 
SMC migration and invasion. Conditioned media could be collected from miR-21 
transfected migrated cells and gelatin zymography and/or ELISA used to measure the 
proteolytic activity of MMPs. Using this approach we could measure the secreted 
MMP-2 and MMP-9 and determine whether their activity is enhanced by suppressing 
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their negative modulator (RECK) by miR-21 overexpression. Similarly, RECK siRNA 
could be utilised to investigate the effect of miR-21 on regulating MMP-2 and MMP-9 
activity and SMC migration in the presence and absence of RECK gene silencing. 
 
The unexpected negative result obtained in chapter 5 (when miR-21 
overexpression did not increase SV-SMC invasion through collagen-coated 
chambers) does not rule out an enhanced migratory effect of miR-21 per se, as miR-
21 overexpression has been implicated in increasing cell migration and tumour cell 
metastasis by direct suppression of PTEN, PDCD4 and RECK (Zhou et al., 2013). It 
would be relevant to confirm the positive effect of miR-21 on SMC migration by 
repeating the Boyden chamber assay in the absence of collagen coating and loading 
premiR-21 and antimiR-21 transfected SV-SMC in the upper chamber. This assay 
would allow us to test the effect of miR-21 on cell migration (i.e. motility) without the 
need for matrix degradation, and at the same time all of the MMPs and TIMPs 
secreted in the conditioned media could be quantified using ELISA. 
 
 Identify the effect of miR-21 on intact SV neointima thickness 
Intimal hyperplasia has important clinical implications in SV graft failure following 
CABG surgery. To test the effect of miR-21 on neointimal hyperplasia, an intact ex 
vivo human SV organ culture system has previously been validated as a promising 
model that partially mimics the clinical situation of in vivo SV responses to 
environmental changes.  
 
Whilst under normal conditions the level of miR-21 is expected not to be elevated, 
it would therefore be important to induce vascular injury to increase miR-21 
overexpression and measure the subsequent effect of miR-21 knockdown on the 
regulation of SV remodelling. To investigate the effect of miR-21 on neointimal 
thickness and vascular remodelling, a high concentration of antimiR-21 could be 
added to the culture media to knock down miR-21 in the SV; a method utilised by 
McDonald et al 2013. Alternatively, the delivery of a modified antimiR-21 to the target 
cells could be performed using a viral vector such as lentivirus or adenovirus (Chen 
et al., 2015). Other studies have demonstrated the efficacy of using exosome 
nanoparticles to encapsulate the target miR-21 and deliver it into the target cells 
(Zomer et al., 2010). At the end of the experimental period, neointimal thickness would 
be measured and SMC isolated by collagenase digestion to test the identified target 
genes of miR-21 (such as RECK) and this could be measured by RT-PCR.  
Additionally, serial sectioning of SV across various time points could be performed 
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followed by immunohistochemistry for visualising the vascular SMC marker genes α-
SMA and SM-MHC to test the differentiation state of SMC. 
 
  
A drawback of the organ culture model is lack of flow and pressure, however using 
a suitable bioreactor machine can mimic normal arterial blood flow. This model would 
provide clinical relevance as it maintains the cell-cell and cell-matrix interactions of 
different vascular cell types (e.g. endothelial cells and adventitial fibroblasts) in wound 
healing, following vascular injury. An isolated sample of SV could be maintained in 
tissue culture under optimised flow conditions and the level of miR-21 could be 
measured in different sections of SV at different time intervals, before and after 
introducing a catheter which induces tissue injury. Where elevated levels of miR-21 
are observed, the intimal thickness could be evaluated by performing cross-sectioning 
of the SV segment and making micromorphometric measurements. 
 
 
Haematoxylin and Eosin stains are utilised to visualise the vein sections for 
photomicrographs (imaging) and morphometric (shape) analysis of the injured SV 
segment and compared with a healthy uninjured SV. The size of the intimal thickness 
of the vascular wall can be quantified by tracing the stained sections and drawing out 
the boundaries around the cells. Additionally, SMC proliferation towards the intima 
can be quantified using Bromodeoxyuridine (BrdU), a useful assay to label replicating 
DNA and measure cell proliferation (Uemura et al., 2015, Porter et al., 1996) or 
immunostaining with proliferation cell nuclear antigen (PCNA). The proliferation rate 
is measured by counting BrdU/PCNA-positive cells that selectively highlight nuclei 
within S-phase (Castronuovo et al., 2002). 
  
 
A well-known approach for gene delivery is the use of adenovirus vectors, however, 
an efficient delivery of gene therapy remains to be identified for the human SV organ 
culture model. The local and direct administration of gene therapy into the vein would 
also retain the therapy at the area of administration and minimise the risk of it reaching 
the systemic circulation (Southerland et al., 2013). The time period of miR knockdown 
should be temporary to stabilise the initial secretion of mediators and suppress genes 
involved in graft failure, at least until the SV graft adapts to the new arterial circulation 
to prevent early vascular remodelling. In an ex vivo porcine SV model experiment, an 
isolated SV was treated with adenovirus gene therapy of TIMP3 and grafted into the 
arterial circulation. A maintained reduction in neointima formation was effectively 
obtained up to 9 weeks following the surgery (George et al., 2011). A relatively recent 
study has shown a protective effect by using adenovirus-mediated delivery of 
sarco/endoplasmic reticulum calcium ATPase (SERCA) 2a isoform gene. This gene 
is important for normalising calcium levels and it has an important role for normal 
187 
 
 
cardiac function and an inhibitory effect on SMC proliferation. Transforming this gene 
into a human IMA ex vivo organ culture model antagonised neointima formation and 
in-stent restenosis that occurred following coronary intervention (Lipskaia et al., 
2013). Clinically, targeting the selected gene in SV is easily accessible during 
harvesting the SV and before implanting into coronary circulation and this potentially 
minimises the risks of systemic effects. Therefore, utilising an in vivo model of 
vascular injury and targeting miR-21 in SV would provide a potentially challenging, 
yet useful therapeutic tool to prevent vital aspects of vascular remodelling caused by 
SMC proliferation.  
 
 
Using an intact SV in the ex vivo model would also permit the study of changes in 
all of the 3 main parts of the blood vessel; the endothelial injury level, the media and 
the adventitia. The adventitial layer plays an important role in controlling blood vessel 
homeostasis and it also contains fibroblasts and collagen to provide structural support 
to the wall (Stenmark et al., 2013). The accumulation and migration of the adventitial 
cell components into the media and the intimal layer also contribute to intimal 
hyperplasia (Chen et al., 2013b). Therefore, this would also give a broader overview 
of the involvement of each vascular layer together with their cellular content in the 
development of neointimal hyperplasia. 
 
 Measuring circulating miR-21 in plasma of patients before and 
after CABG and precision medicine 
Recent studies are highlighting the important role of miRs as critical biomarkers for 
different pathological diseases and survival rate. MiRs can be secreted into biological 
fluid and blood in microparticles or exosomes to resist degradation by RNAse 
(Beltrami et al., 2015). Therefore, measuring the aberrantly expressed miRs in blood 
could reveal competent biomarkers for early detection of cardiovascular diseases and 
many other life-threatening conditions. The significantly high level of miR-21 in blood 
was measured as an indication of disease prognosis and survival rate of patients with 
late-stage pancreatic cancer (Bauer et al., 2012), hepatocellular carcinoma 
(Tomimaru et al., 2012), colon cancer (Li et al., 2013), gastric cancer (Wu et al., 2015), 
prostatic cancer (Huang et al., 2015) and breast cancer (Yang et al., 2015). Measuring 
miR-21 along with HbA1c in plasma of CAD patients undergoing CABG surgery might 
provide a useful tool as a biomarker of CVDs and SV graft failure. To our knowledge, 
no studies in the literature have reported miR-21 measurement in body fluid as a 
biomarker for cardiovascular diseases or T2DM. This could be a novel area of 
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research if miR-21 was measured as a marker to investigate the SV graft status 
following CABG. 
 
As cardiovascular and diabetic patients exhibit a broad degree of heterogeneity, a 
future promising approach will be that of personalised medicine. Patients would first 
be stratified into diabetic and non-diabetic groups. Their future treatment could then 
be tailored according to the phenotypic characteristics of the individual. This is what 
is called ‘precision medicine’ which takes into account every individual’s variability 
(Coote and Joyner, 2015). This includes analysing a patient’s inherited genomic 
characterisation (such as proteomics, metabolomics and genomics) together with 
studying the epigenetic status of each individual which results from the interaction 
with environmental cues. As 50% of SV grafts fail within 10 years in the UK (Deb et 
al., 2012), research exploring the epigenetic factors involved in genetic regulation and 
disease pathogenesis could be a future therapeutic strategy. Therefore, it is worth 
classifying the patients and studying their epigenetic characteristics to try to determine 
the similarities and variabilities between each individual and to implement 
personalised therapy that helps prolong graft patency and prevent pathological 
vascular remodelling. 
 
7.4. Conclusion 
In summary, the results presented in this thesis suggest that miR-21 plays a vital 
role in modulating SMC function that leads to the development of intimal hyperplasia. 
This was concluded after demonstrating the ability of miR-21 overexpression to 
significantly increase SV-SMC area and cell proliferation. A focused array and follow-
up TaqMan RT-PCR data showed that overexpression of miR-21 in SV-SMC 
upregulated MMP-1 expression. PDGF-BB, as one of the important factors 
upregulated in response to vascular injury, was positively correlated with the increase 
of miR-21 and MMP-1 expression. Moreover, this is the first study to reveal that the 
overexpression of miR-21 significantly increased SV-SMC proliferation and reduced 
RECK mRNA and protein levels. Further understanding of miR-21’s downstream 
signalling and mechanistic effects would determine the promising role of miR-21 on 
SV-SMC function and provide a novel therapeutic target for the prevention of vein 
graft failure. 
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